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Yasmin Kate Hilliam – October 2015 
Abstract 
Non-cystic fibrosis bronchiectasis (NCFBr) is a chronic, progressive respiratory 
disease characterised by irreversible widening of the airways and thickening of the 
bronchial walls. There have been large amounts of research into cystic fibrosis (CF) and 
very little into NCFBr, despite its prevalence in the UK having been predicted to be >10 
times that of CF. The leading cause of mortality in CF is chronic bacterial lung infection, 
particularly with Pseudomonas aeruginosa. Transmissible strains of P. aeruginosa are 
associated with increased morbidity and mortality in CF. Chronic P. aeruginosa infections 
are also known to adversely affect the health of NCFBr patients although very little in-
depth research has been performed. This work aims to investigate the diversity of 
populations of P. aeruginosa in NCFBr patients attending bronchiectasis services 
throughout England and Wales. The maintenance of P. aeruginosa strains in long-term 
infections in the lungs of NCFBr patients were investigated using an array tube 
genotyping system. The majority (15) of the 20 patients studied were found to maintain 
the same strain of P. aeruginosa throughout the course of infection. The population 
structure of P. aeruginosa isolates from NCFBr patients was investigated using both the 
array tube system and whole genome sequencing. The population of isolates from NCFBr 
patients was found to be distributed evenly throughout the general population of P. 
aeruginosa. Whole genome sequencing was also used to investigate the diversity of P. 
aeruginosa isolates from 23 individual patients and it was shown that in the majority of 
these (16) that all isolates were the same strain and closely related to one another. Only 
one of the 157 NCFBr patients was found to harbour a transmissible strain of P. 
aeruginosa which is a significantly lower prevalence than in CF. There is still a large 
disparity between our knowledge regarding CF and NCFBr and so further research into 
P. aeruginosa infections in NCFBr is required.
ii 
 
Acknowledgements 
I am incredibly grateful to have been given the chance to continue with my 
studies and especially to have been able to do so with the support of a fantastic group 
of people. The guidance offered by Jo Fothergill and Craig Winstanley throughout my 
time in the laboratory and whilst writing this thesis has been invaluable and greatly 
appreciated. In particular, I am thankful for Jo’s patience in teaching me a wide variety 
of practical techniques in the time I have been under her supervision and her unfaltering 
support, without which I would not have come away from my education with skills and 
knowledge that I have today.  
I am indebted (literally and figuratively) to my parents who have supported me 
throughout the duration of my time at university and without whom none of this would 
have been possible. Finally, my thanks go to Josh who has endured hours of travel on 
British public transport systems to keep me company throughout my studies and who 
suffered the majority of my whinging whilst writing this thesis without any complaint of 
his own.  
iii 
 
Contributions 
Provision of Pseudomonas aeruginosa isolates from England and Wales 
 Dr Juliet Foweraker, Papworth Hospital 
 
Provisions of Pseudomonas aeruginosa isolates from Liverpool centre 
 Paul Roberts, Royal Liverpool and Broadgreen University Hospitals 
 
Storage of Pseudomonas aeruginosa isolates 
 Yasmin Hilliam, University of Liverpool 
 
Polymerase chain reaction assays 
 Yasmin Hilliam, University of Liverpool 
 
Gel electrophoresis 
 Yasmin Hilliam, University of Liverpool  
 
Array tube genotyping 
 Yasmin Hilliam, University of Liverpool 
 
Construction of eBURST diagrams 
 Yasmin Hilliam, University of Liverpool  
 
Genomic DNA extraction 
 Yasmin Hilliam, University of Liverpool  
 
Genomic DNA quantification and quality testing 
 Yasmin Hilliam, University of Liverpool  
 
Sequencing library preparation 
 Dr Margaret Hughes and Dr Lisa Olohan, Centre for Genomic Research 
 
Illumina sequencing 
 Dr Anita Lucaci, Centre for Genomic Research 
 
Bioinformatics analysis of sequencing data 
 Dr Richard Gregory and Dr Luca Lenzi, Centre for Genomic Research 
 
Genome assembly 
 Matthew Moore, University of Liverpool 
 
Core genome extraction 
 Matthew Moore, University of Liverpool  
iv 
 
Construction of phylogenetic tree 
 Matthew Moore, University of Liverpool 
  
Variant calling 
 Matthew Moore, University of Liverpool   
v 
 
Abbreviations 
AES  Australian epidemic strain 
ART  antiretroviral therapy 
AT  Array Tube 
ATS   American Thoracic Society 
BCC  Burkholderia cepacia complex 
BCOS  COPD-bronchiectasis overlap syndrome 
BMI  body mass index 
bp  base pair 
BSI  bronchiectasis severity index 
BTS  British Thoracic Society 
CAP  community-acquired pneumonia 
CF  cystic fibrosis 
CFTR  cystic fibrosis transmembrane conductance regulator 
COPD  chronic obstructive pulmonary disease 
CRK  CT10 regulator of kinase 
CT  computed tomography  
DNA  deoxyribonucleic acid 
dsDNA  double-stranded DNA 
EDTA  ethylenediaminetetraacetic acid 
ERS  European Respiratory Society 
FEV1  forced expiratory volume in 1 second 
GATK  Genome Analysis Toolkit 
gDNA  genomic DNA 
vi 
 
GER  gastro-oesophageal reflux 
HIV  human immunodeficiency virus 
HRCT  high resolution computed tomography 
HSL  homoserine lactone 
IPC  International Pseudomonas aeruginosa Consortium 
LB  Luria broth 
LES  Liverpool epidemic strain 
MES  Manchester epidemic strain 
MGEs  mobile genetic elements 
MIC  minimum inhibitory concentration 
MLST  multilocus sequence typing 
MLVA  multiple-locus variable number tandem repeat analysis 
MRC  Medical Research Council 
MRCA  most recent common ancestor 
MRSA  methicillin-resistant Staphylococcus aureus 
NCFBr  non-cystic fibrosis bronchiectasis 
NDK  nucleoside diphosphate kinase 
NGS  next generation sequencing  
NTHi  nontypable Haemophilus influenzae 
NTM  non-tuberculosis mycobacterium 
PCR  polymerase chain reaction 
PES  Prairie Epidemic Strain 
PFGE  pulsed-field gel electrophoresis 
QS  quorum sensing 
RAPD-PCR random amplified polymorphic DNA fingerprinting-PCR 
vii 
 
RGP  regions of genomic plasticity 
ST  sequence type 
T1SS  type I secretion system 
T2SS  type II secretion system 
T3SS  type III secretion system 
TB  tuberculosis 
TLR  toll-like receptor 
UV  ultraviolet 
VAP  ventilator associated pneumonia  
VNTR  variable number tandem repeat 
1 
 
Chapter One 
Introduction 
1.1 Bronchiectasis 
Bronchiectasis is a chronic and progressive respiratory disease with which 
patients often suffer from a persistent cough, sputum production, and recurrent 
microbial infections leading to exacerbations and further lung damage. 
Bronchiectasis is defined by the British Thoracic Society (BTS) by the irreversible 
dilation and damage to  the bronchi (Pasteur et al. 2010) and is often also 
characterised by thickening of the bronchial walls. Disease progression can occur 
through damage to the lungs and airways which most often occurs during chronic 
bacterial infection when the airways are constantly inflamed, but can occur due to 
other factors such as smoking and particle inhalation. The causes of bronchiectasis 
are wide ranging, including genetic disorders and environmental factors. The most 
well characterised and intensively studied cause of bronchiectasis is cystic fibrosis 
(CF). Other chronic conditions are also associated with bronchiectasis including 
rheumatoid arthritis, inflammatory bowel disease, and gastro-oesophageal reflux 
(GER) (De Soyza et al. 2013) however the effects of these conditions on the health of 
bronchiectasis patients is little known due to lack of research into the condition.  
Bronchiectasis is perceived by many, since the further development of antibiotic 
treatments, to be a rare and easily managed disease, of little clinical importance (De 
Soyza et al. 2013) although in recent times it is becoming clearer that this is not the 
case. It is possible that research into bronchiectasis has been neglected due to belief 
that the disease would disappear in developing countries alongside the decline of 
diseases such as tuberculosis (Chalmers 2015). Accurate data on the numbers of 
patients currently undergoing regular treatment for bronchiectasis are sparse; in the 
USA the prevalence of adult bronchiectasis has been estimated at 52 in 100 000 
people, with higher prevalence among women and older individuals (Weycker et al. 
2005); however in the UK, in just nine centres, there are 5000 patients receiving 
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regular follow-up treatment for bronchiectasis (De Soyza et al. 2013) suggesting that 
the true prevalence among adult populations may be even higher. 
1.1.1 Cystic fibrosis  
CF is perhaps the most well-known and best-understood cause of 
bronchiectasis and is the most common life-threatening hereditary genetic disorder 
among Caucasians. In 1990 the median survival age for CF patients was 31.9 years 
but improvements in patient care and treatment have led to an increased median 
survival age of 49.7 years in the most current five year period (ending in 2012) 
(Stephenson et al. 2015). CF is an autosomal recessive condition in which a mutation 
in the cystic fibrosis transmembrane conductance regulator (CFTR) gene leads to 
improper transport of chloride ions. The most prevalent causative mutation is a 
deletion of three base pairs in the CFTR gene which leads to the loss of a 
phenylalanine residue at amino acid position 508, known as ΔF508 (Kerem et al. 
1989; Riordan et al. 1989; Rommens et al. 1989). Despite chronic airway infections 
being a hallmark of the condition, CF is defined as a multi-organ disease, affecting 
the gastrointestinal tract, pancreas, and the reproductive tract as well as the 
respiratory tract (Pauwels et al. 2012). Due to abnormal CFTR protein produced as a 
result of the mutation in the CFTR gene, the airway mucus becomes thick and sticky 
and is not easily cleared by cilial beating. Clearing of the mucus is crucial in preventing 
airway infections and so build-up of mucus provides an ideal environment for 
microbial pathogens to colonise. Antibiotics are often unable to properly diffuse in 
the viscous mucus and so these infections are difficult to clear, leading to prolonged 
inflammatory response by the immune system. This extended immune response 
leads to damage and widening of the airways, leading to bronchiectasis.  
1.1.2 Non-cystic fibrosis bronchiectasis 
There are a range of underlying causes that can lead to development of non-
cystic fibrosis bronchiectasis (NCFBr), although it is estimated that in 25 – 50% of 
cases a cause is not identified (http://www.blf.org.uk/page/bronchiectasis); this is 
known as idiopathic bronchiectasis. Advances in diagnostics mean that patients with 
CF are often diagnosed shortly after birth and healthcare regimens can be 
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implemented early on to extend life expectancy. Symptoms of NCFBr often do not 
manifest until much later in life and are more difficult to definitively diagnose with 
the average age of many NCFBr cohorts being between 60 and 70 years (Chalmers 
2015). Post-infective bronchiectasis is often caused by severe childhood respiratory 
infections such as pneumonia, whooping cough, and measles; however, vaccination 
against childhood illnesses is expected to reduce post-infective bronchiectasis in 
adults in the future (NHS Choices 2015). Immunodeficiency can also leave the lungs 
vulnerable to damage by the inflammatory response. In the past, there was high 
mortality in HIV-infected patients who presented with acute pulmonary infections 
such as bacterial pneumonia, tuberculosis, and acute bronchitis but  the arrival of 
early antiretroviral therapy (ART), widespread prophylactic antibiotic treatment and 
improvements in life expectancy have seen a significant reduction in the incidence of 
life-threatening opportunistic infections, resulting in an increase in non-infectious 
chronic respiratory disease among HIV-positive individuals, including chronic 
obstructive pulmonary disease (COPD) and NCFBr (Calligaro & Gray 2015). There is 
also evidence that aspiration of gastric reflux products may play a role in the 
development on bronchiectasis, although the links between GER and CF have been 
more extensively studied than the links between NCFBr and GER (Pauwels et al. 
2012). 
Problems often arise in epidemiological studies of NCFBr with acquiring 
definitive diagnoses of the condition. NCFBr is most commonly diagnosed by the 
presence of dilated bronchi apparent on a computed tomography (CT) scan, and this 
is known as radiological bronchiectasis, but studies have shown that dilated bronchi 
are commonplace among the healthy elderly population. A UK study of patients aged 
>75 years vs. patients under the age of 55 identified bronchial dilation in 60% of the 
patients aged 75 and over compared with presence in only 6% of the younger group 
(Copley et al. 2009). This study included both smokers and non-smokers but revealed 
no relationship between smoking status or history and bronchial dilation (Copley et 
al. 2009). A further study examining CT scans of the lungs of elderly never-smokers 
with no respiratory disease revealed that 19.1% of over 75’s had radiological 
bronchiectasis (Winter et al. 2015). These data have led to the speculation that 
4 
 
bronchiectasis may, in part, be a sign of aging in the lungs; however other symptoms 
generally expressed by NCFBr patients include chronic cough, sputum production 
and respiratory tract infections. This has led to some clinicians to use the term 
“clinically significant bronchiectasis” to refer to patients who present with the 
symptoms listed above alongside radiological bronchiectasis (Chalmers 2015). 
Similarities and overlap between similar pulmonary diseases also hinder 
conclusive diagnosis of NCFBr. The overlap between bronchiectasis and COPD has 
not been extensively studied and work carried out so far does not present a 
conclusive assessment of risk of bronchiectasis and COPD comorbidity (Chalmers 
2015). COPD is diagnosed on the basis of mostly-irreversible airflow obstruction 
which is measured by spirometry and is therefore a physiological diagnosis. 
Bronchiectasis is diagnosed by imaging (usually CT) which shows permanent airway 
dilation and thickening of the airway walls which results in a structural diagnosis 
(Hurst et al. 2015). Increasingly, COPD patients are given a CT scan as a part of 
diagnosis or follow-up care and consequently there is an impact on the detection of 
structural changes in the airways of COPD patients. The presence of symptoms of 
both conditions (figure 1.1) has been given the name COPD-bronchiectasis overlap 
syndrome (BCOS) and recommendations for the treatment of BCOS and 
improvements in research have recently been made (Hurst et al. 2015). A small study 
previously reported high frequencies of bronchiectasis among those diagnosed with 
COPD. In a cohort of 201 patients with COPD the frequency of bronchiectasis was 
reported at 57.6%, with higher mortality among those with bronchiectasis and COPD 
(Martínez-García et al. 2013). However, this high frequency of bronchiectasis has not 
been corroborated by larger-scale studies. In one study the frequency of 
bronchiectasis among COPD patients was found to be no higher than that which 
would be expected among the general population of otherwise-healthy individuals 
due to the background frequency of bronchiectasis among the elderly (Agusti et al. 
2010) and this was echoed by later research which found no higher incidence of 
bronchiectasis in those with COPD than in those with no reported COPD diagnosis; 
bronchiectasis was reported in 26% of patients with no known diagnosis of 
pulmonary disease (Jairam et al. 2015). Research from the COPDGene study, which 
5 
 
investigated a large cohort of 3636 patients, reported the frequency of 
bronchiectasis among COPD patients at 20.8% (Stewart et al. 2012). A more recent 
study which focused on patients with high levels of exacerbation found only five 
cases of bronchiectasis among 96 COPD patients (Uzun et al. 2014). These variations 
in frequencies indicate that the research carried out into BCOS thus far is not robust 
enough to allow predictions to be made about the frequency of bronchiectasis 
among COPD patients, although it is probably that it occurs in a maximum of 20% 
patients (Chalmers 2015). 
In the US a research registry was founded in 2008 to give a centralised 
database of NCFBr patients from clinical institutions across the country. The aim of 
the registry is to encourage research collaborations and multi-centre clinical trials for 
the treatment of NCFBr. The demographics of the registry are typical of NCFBr 
patients; predominantly female (79%), white (91%), with an average age of 65 years 
(Aksamit et al. 2012).  
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Figure 1.1: Venn diagram illustrating key symptoms and diagnoses of bronchiectasis and COPD, and those found in BCOS. 
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1.1.3 Lack of research into non-cystic fibrosis bronchiectasis  
In the UK prevalence of NCFBr is much higher than that of CF with data 
suggesting that, of the estimated 150 000 patients living with bronchiectasis (Quint 
et al. 2012), only around 10 000 are due to CF. Despite this, there has been very 
limited NCFBr research and there are currently no specific licenced drug therapies for 
the condition (Pasteur et al. 2010). The world’s first national guidelines for NCFBr 
diagnosis and treatment were developed in the UK in 2010 by the BTS. Research into 
NCFBr has been limited partly by lack of funding but also by lack of carefully 
phenotyped patients. With such a wide range of causes and severities of symptoms, 
along with other conditions with similar symptoms (e.g. COPD), it can be difficult to 
strictly categorise NCBFr patients. The BTS Guideline for NCFBr makes 
recommendations for the diagnosis and treatment of NCFBr in both adults and 
children (Pasteur et al. 2010). The report provides rigorous and detailed testing 
guidelines for patients exhibiting symptoms of bronchiectasis. The report also 
identified significant gaps in evidence at discovery (first translational gap) and clinical 
interfaces (second translational gap) (Pasteur et al. 2010). In 2012 the BTS Quality 
Standards for clinically significant bronchiectasis was published and is recommended 
to be read alongside the Guideline for NCFBr. The Quality Standards report aims to 
allow healthcare professionals to make the best decisions regarding diagnosis and 
treatment based on the latest evidence and best practices. The document also aims 
to help NCBFr patients and carers understand what services they should expect from 
their healthcare provider (British Thoracic Society 2012). 
In CF patients chronic bacterial infections in the lungs, particularly with 
Pseudomonas aeruginosa, are significant contributors to morbidity and mortality 
(Fothergill et al. 2010a). It has been demonstrated in many studies that there is an 
association between P. aeruginosa infection and mortality, lowered lung function, 
and worsening quality of life in NCFBr patients (Evans et al. 1996; Davies et al. 2006; 
King et al. 2007; Loebinger et al. 2009). A more rapid decline in lung function 
associated with P. aeruginosa infection was suggested by Evans et al. (1996) and 
Davies et al. (2006) although this is not universally acknowledged. None of these 
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studies have proven, however, that the prognostic effect of P. aeruginosa infection 
is as a direct consequence of infection rather than as a marker of existing disease 
severity (Chalmers 2015).  
1.1.4 Prevalent microbial pathogens 
Due to the permanent inflammation and dilation of the airways of NCFBr 
patients and the associated reduction in host defences, 64 – 79% of NCFBr patients 
have chronic bacterial airway infections even when the patients are apparently 
clinically stable (Pasteur et al. 2000; Angrill et al. 2002; King et al. 2007). Haemophilus 
influenzae and P. aeruginosa are the most common pathogens affecting NCFBr 
patients. Moraxella catarrhalis, Streptococcus pneumoniae and Staphylococcus 
aureus are also often isolated from sputum samples, although Pasteur et al. (2000) 
suggested that the presence of S. aureus among the lung microbiota may be 
indicative of undiagnosed CF and advised that clinicians should follow S. aureus 
isolation with genetic and sweat tests. Alongside bacterial pathogens, viruses and 
fungi also play a pathogenic role in NCFBr patients. Common respiratory viruses (e.g. 
human rhinovirus, respiratory syncytial virus, and influenza A and B) are detected 
more frequently in patients suffering chronic respiratory diseases, such as COPD and 
NCFBr, compared to healthy individuals (Mitchell et al. 2015) and that the prevalence 
of viral infections in cases of NCFBr exacerbations is higher than in clinically stable 
bronchiectasis (Gao et al. 2015). It has been shown that patients experiencing 
exacerbations who tested positive for respiratory viruses by PCR assay also 
experienced a greater increase in markers of systemic and airway inflammation when 
compared with virus-negative patients experiencing exacerbations (Gao et al. 2015). 
Research into the prevalence and effects of fungal infection in NCFBr has been 
extremely limited and so much of our understanding of the role of fungi in chronic 
lung conditions is based on work undertaken in the context of CF. Aspergillus spp. 
and Candida albicans are known to persist frequently in the lungs of CF patients and 
so recently the prevalence of these organisms has also been investigated in NCFBr. 
In work undertaken by Máiz et al. (2015) it was shown that there is indeed a high 
prevalence of persistence of both Aspergillus spp. and C. albicans in clinically stable 
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NCFBr patients. The persistence of Aspergillus spp. and C. albicans were shown to be 
associated with daily sputum purulence and the administration of long-term 
antibiotic treatment respectively. Long-term antibiotic treatment is generally only 
utilised to treat chronic P. aeruginosa infection, as opposed to H. influenzae, and so 
persistence of C. albicans is found to be associated with P. aeruginosa colonisation 
in NCFBr patients (Máiz et al. 2015). P. aeruginosa has been shown to form dense 
biofilms on the hyphae of C. albicans without binding to or killing the fungi (Hogan & 
Kolter 2002). It is likely that the presence of bacteria, fungi, and viruses play a 
combinatorial role in pathogenesis in NCFBr and so further research into microbial 
pathogens is necessary. 
H. influenzae strains can be categorised into one of two groups: typable and 
nontypable. Typable isolates have a capsule and generally cause systemic infections, 
such as bacteraemia and meningitis. Nontypable H. influenzae (NTHi) is 
unencapsulated and often causes non-invasive mucosal infections, such as otitis 
media, sinusitis, and conjunctivitis (Garmendia et al. 2014). In COPD colonisation with 
NTHi is a marker of disease progression and of severe airflow obstruction and it is for 
this reason that much of the research carried out into lower airway infections by NHTi 
has been undertaken with regards to COPD (Garmendia et al. 2014). In a study by 
McDonnell et al. (2015) H. influenzae was isolated from 89 (57.4%) of 155 COPD 
patients, although only 51 (32.9%) met colonisation criteria. Of these 51, 14 patients 
were still colonised at the data capture point. This data suggests that 37 patients 
(74.5%) had cleared H. influenzae, opposed to the 34.0% of patients who cleared P. 
aeruginosa (McDonnell et al. 2015). 
NCFBr patients are frequently diagnosed with community-acquired 
pneumonia (CAP), although there are currently no specific clinical recommendations 
available (Polverino et al. 2015). It was found that S. pneumoniae was the most 
common causative pathogen of CAP both among NCFBr patients and among other 
CAP patients. Whilst these pneumococcal infections usually cause acute disease, they 
can also be accompanied by chronic infection with P. aeruginosa and this was shown 
to be common among NCFBr patients (Polverino et al. 2015). 
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Comprehensive taxonomic studies have defined several distinct, closely 
related species of bacteria among those previously designated as “B. cepacia” on the 
basis of phenotype alone (Vandamme et al. 1997). These seven distinct organisms (B. 
cepacia genomovars I – VII) are collectively known as the B. cepacia complex. 
Members of the Burkholderia cepacia complex (BCC) have been recognised as 
important opportunistic pathogen among CF patients for many years, with a 
significant proportion of infected patients succumbing rapidly to progressive 
necrotising pneumonia (LiPuma et al. 2001). In many cases, BCC infection is 
associated with poor outcomes following lung transplant and so many centres 
consider BCC infection an absolute contraindication to receive transplant lungs. 
However many CF patients are either transiently infected with BCC or can remain 
colonised for years with no apparent adverse clinical effects (LiPuma et al. 2001). 
Although infection with the BCC has been reported in patients with NCFBr (Ledson et 
al. 1998) it is relatively uncommon. In a study by Carraro et al. (2014) the BCC was 
identified in 14 patients of 47 (20 with bronchiectasis and 27 with CF). Of these 14 
patients, 13 had CF showing that the BCC is more common among patients with CF 
than in those with NCFBr (Carraro et al. 2014). 
1.2 Pseudomonas aeruginosa 
P. aeruginosa is a versatile Gram-negative bacterium that can live in a wide 
range of niche environments and can opportunistically colonise susceptible 
individuals to cause disease (Winsor et al. 2011). As well as being the most prevalent 
life-threatening pathogen in CF patients (Govan et al. 2007), P. aeruginosa frequently 
affects other immunocompromised individuals such as cancer and severe burn 
patients and is a major cause of bacterial keratitis which can lead to blindness if 
untreated (Winsor et al. 2011). It is notable that infection with P. aeruginosa is rare 
among otherwise healthy individuals and is most likely encountered and rebuffed by 
the body’s immune system on a regular basis due to its abundance in the natural 
environment (Lyczak et al. 2000). P. aeruginosa is also a major cause of nosocomial 
infections worldwide, and is responsible for ~10% of such infection in the European 
Union (de Bentzmann & Plésiat 2011). The majority of these nosocomial infections 
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take the form of acute lung infections (pneumonia) in patients in intensive care units 
(Lyczak et al. 2000). The ability of the organism to colonise such a wide variety of 
environments and to cause a range of human diseases is now widely believed to be 
due to a multitude of virulence factors which act in a combinatorial fashion to cause 
injury to the host (Lee et al. 2006). 
P. aeruginosa can cause both acute and chronic infections and has a wide 
range of virulence factors which are important in pathogenicity in acute infections 
and also in establishing chronic infections. Table 1.1 shows some of the most 
important virulence factors of P. aeruginosa and how they act upon host cells to 
cause damage.   Generally, only a small selection of bacterial species are recovered 
from the wounds of burns victims, including: S. aureus, Klebsiella spp., P. aeruginosa, 
and Enterobacter spp. (Bowen-Jones et al. 1990). Despite increasing awareness of 
the dangers posed by bacterial infection and therefore the necessity for sterility in 
healthcare environments, P. aeruginosa has been found to contaminate floors, bed 
rails, and sinks in hospitals and this, along with the prevalence of P. aeruginosa in the 
general environment, makes it a threat to the health of burns patients recovering in 
hospitals (Chitkara & Feierabend 1981). It is quickly apparent that the external 
defences of the immune system are compromised at the site of a burn wound but 
due to the limited number of bacterial species which are recovered from infected 
wounds it is likely that it is necessary for the bacteria to be able to adapt to take 
advantage of the concerted impairment of many of the host defence mechanisms to 
colonise a burn, as opposed to the presence of one or a few specific virulence factors 
(Lyczak et al. 2000). P. aeruginosa is also one of the leading causes of ulcerative 
keratitis of the cornea and is associated with users of extended-wear contact lenses. 
The exact links between contact lens use and bacterial pathogenesis have not been 
fully elucidated, though work has shown that the ocular mucus, which usually binds 
bacterial cells and prevents adhesion to the corneal surface, can be altered by the 
use of contact lenses and may therefore facilitate bacterial adhesion, along with 
other virulence factors (Versura et al. 1987). 
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Table 1.1: Important virulence factors associated with acute P. aeruginosa infections, and establishment of chronic infections. 
Virulence 
factor 
Secretion 
system 
Host target Role in pathogenicity 
Type IV pili - Cell surface 
Major surface adhesin; signal transduction mechanism requires attachment of type IV pili to solid surface, 
retraction of pilus, and signal transduction through the Chp chemo-sensory system (activates cAMP production 
and transcription of hundreds of genes, including key virulence factors) (Persat et al. 2015). 
Type III 
secretion 
system 
(T3SS) 
- Cell surface 
Creates a proteinaceous channel through which toxins are transported directly into the host cell cytoplasm; 
PopB, PopD, and PcrV are required for pore formation but PopB also plays a role in P. aeruginosa pathogenicity 
independently from effector proteins (Galle et al. 2012). 
 ExoS T3SS Cell structure 
Bifunctional toxin; GTP-ase activating protein activity and ADP ribosyl transferase activity; actin cytoskeleton 
disruption (associated with cell-rounding) and inhibition of DNA synthesis, vesicular trafficking, and endocytosis; 
causes irreversible damage to host cell cytoskeletal structure (Galle et al. 2012). 
 ExoT T3SS Cell structure 
Bifunctional toxin; GTP-ase activation protein activity and ADP ribosyl transferase activity; ribosylates CT10 
regulator of kinase (CRK) I and CRKII adaptor proteins (Galle et al. 2012).  
 ExoU T3SS Cell structure Potent phospholipase; causes rapid cell death (Galle et al. 2012). 
 ExoY T3SS Cell structure  
 Secreted adenylyl cyclase; increases concentration of intracellular cAMP in host cell, leads to disruption of actin 
cytoskeleton and increased endothelial permeability (Galle et al. 2012); the role of ExoY in P. aeruginosa 
pathogenicity is unclear. 
Nucleoside 
diphosphate 
kinase (NDK) 
T3SS/ 
unknown 
Macrophages  
T3SS may not be involved in NDK secretion, role is unclear; cytotoxicity in host macrophages achieved by 
disrupting extracellular ATP concentrations; cytotoxicity is not kinase-dependent (Neeld et al. 2014). 
Flagella  - Cell surface  
Major surface adhesion; elicits strong NFκB-mediated inflammatory response via signalling through toll-like 
receptor (TLR) 5 and a caspase-1-mediated response through Nod-like receptor, Ipaf; provides bacterium with 
swimming motility in liquid (Miao et al. 2007). 
Alkaline 
protease  
T1SS 
Complement 
proteins 
Zinc metalloprotease; causes degradation of host complement proteins and fibronectin (Laarman et al. 2012); 
helps interfere with flagellin signalling through host TLR5 by degrading free flagellin monomers and thereby 
helping P. aeruginosa avoid host immune detection (Bardoel et al. 2011). 
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Table 1.1 continued 
Virulence 
factor 
Secretion 
system 
Host target Role in pathogenicity 
LasA  T2SS 
Matrix 
proteins 
Serine protease; reduced elastolytic properties when compared with LasB but thought to enhance proteolytic 
activity of LasB (Matsumoto 2004). 
LasB  T2SS 
Matrix 
proteins 
Major extracellular protease;  degrades matrix proteins such as elastin, fibronectin, and vitronectin, as well as 
a small number of cell receptors (Golovkine et al. 2014). 
Protease IV  T2SS 
Complement 
proteins 
Serine protease; degrades complement proteins, immunoglobulins, and fibrinogen (Gellatly & Hancock 2013); 
inhibits association of P. aeruginosa with alveolar macrophages (Malloy et al. 2005). 
    
Pyocyanin - 
Widespread 
toxicity 
Redox-active phenazine; inhibition of host cell respiration, ciliary function, and epidermal cell growth; disrupts 
calcium homeostasis; induces apoptosis in neutrophils; production partly controlled by oxidative stress 
response regulator, OxyR, and is thought to play a protective role against phagocytic cells (Lau et al. 2004). 
Rhamnolipid - - 
Surfactant; participate in the maintenance of uninhabited channels surrounding biofilm communities which 
serve to provide nutrients and oxygen to the colonies of bacteria (Davey et al. 2003); biofilms can form on 
implants and on dead or living tissue and are inherently difficult to eradicate with antibiotics due to the inability 
of antibiotics to penetrate the extracellular matrix. 
Alginate - - 
Extracellular polysaccharide; overproduced in mucoid strains often isolated from chronic CF infections; 
participates in the production of biofilms; thought to protect bacteria from host response in CF lungs (Gellatly 
& Hancock 2013); treatment with imipenem induces expression of alginate and leads to thickening of biofilms 
(Bagge et al. 2004). 
Pyoverdine - Cellular iron 
Siderophore; little free iron available in host environment so pyoverdine acts to sequester iron from host depots 
(Gellatly & Hancock 2013); iron-bound pyoverdine acts as a signalling molecule and interacts with Pseudomonas 
cell receptor FpvA, causing upregulation of exotoxin A, endoprotease, and pyoverdine itself (Jimenez et al. 
2012). 
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Whilst presenting the greatest threat in terms of morbidity and mortality to 
CF patients, P. aeruginosa can also cause acute infections within the lungs of patients 
generally in intensive care units in hospitals. Many of the virulence factors associated 
with burn wound infections and keratitis are also implicated in acute infections of 
the lungs. More specifically, the type III secretion system (T3SS), which delivers ExoS, 
ExoT, and ExoU in mammalian cells, appears to play a major role in acute 
pathogenicity in the lungs. It has been shown that immunisation against the type III 
secretion-associated Pseudomonas V antigen protects animals from lung damage 
during acute P. aeruginosa infection (Sawa et al. 1999). 
When chronically infecting the lungs of CF patients P. aeruginosa presents 
with a particular set of phenotypes: alterations in the secretion of mucoid 
exopolysaccharide, exotoxins, proteases, and siderophores; conversion of 
lipopolysaccharide from smooth to rough; and a loss of motility (Mahenthiralingam 
et al. 1996). Often isolates from chronic lung infections are found to not produce O 
antigen, pili, and flagella which are common virulence determinants (Jain et al. 2004). 
These changes are thought to allow the bacterium to thrive in the CF lung 
environment which is vastly different to the environmental conditions from which 
unique strains of P. aeruginosa often originate.  
P. aeruginosa has a large and versatile genome (6 – 7 Mbp) which allows the 
bacteria to adapt quickly to a wide range of growth conditions. The pangenome of P. 
aeruginosa is made up of a well conserved core genome and a highly variable 
accessory genome and the organism’s ability to thrive in such a wide range of 
environments is attributed to this adaptable accessory genome. The core genome is 
defined as the genes always present in strains of P. aeruginosa, regardless of origin 
(laboratory, clinical, or environmental) and that encode metabolic and pathogenic 
factors observed in all strains of P. aeruginosa (Kung et al. 2010). Work by Wolfgang 
et al. (2003) showed that between 96.1% and 97.7% of PAO1 genes were detected in 
18 strains tested and that 93.4% of the 5549 nonredundant genes making up the 
PAO1 genome were present in all 18 strains tested. The segments of accessory 
genome that vary by strain are not randomly scattered throughout the genome and 
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often cluster around certain loci, which Mathee et al. (2008) described as regions of 
genomic plasticity (RGP). The sequences present in these RGPs are commonly 
referred to as genomic islets (<10 kbp) or islands (>10 kbp). The definition of what 
constitutes a genomic island changes as new information comes to light but it is most 
commonly used to refer to horizontally acquired genetic elements, present in the 
chromosomes of some strains but absent from others (Kung et al. 2010). Analysis 
also suggests that the genome lacks large amounts of gene replication, with many 
more distinct gene families than other large bacterial genomes, and therefore that 
selection for environmental versatility has enabled the expansion of the genome and 
development of small paralogous gene families which encode specific, discrete 
functions (Stover et al. 2000). 
1.2.1 Pathogenicity in chronic lung infections 
The morbidity of chronic lung infections is generally measured by recording 
the decline in lung function of patients at each clinic visit. Lung function is measured 
frequently by forced expiratory volume in 1 s (FEV1) according to European 
Respiratory Society (ERS) and American Thoracic Society (ATS) standards (Brusasco 
et al. 2005). The Medical Research Council (MRC) dyspnoea or breathlessness scale 
is also used to assess patients’ health. The breathlessness scale does not quantify 
breathlessness itself; it is a short questionnaire answered by the patient which 
assigns a numerical value (between 1 and 5) to the disability caused by 
breathlessness experienced. The dyspnoea scale correlates well with other 
breathlessness scales, lung function measurements (such as FEV1), and direct 
measurements of disability (such as walking distance) and is thus regularly used by 
physicians assessing severity in conditions such as NCFBr and COPD (Stenton 2008). 
Furthermore, the bronchiectasis severity index (BSI) specifically informs the status of 
bronchiectasis patients and consists of 8 commonly measured clinical parameters 
that reflect the age, body mass index (BMI), FEV1, MRC dyspnoea score, exacerbation 
frequency, prior hospitalisations, chronic bacterial colonisation status, and the 
presence of cystic bronchiectasis on high resolution CT (HRCT) (Chalmers et al. 2014). 
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Studies into the effects of P. aeruginosa infections in NCFBr patients have 
been somewhat limited. It has been shown that patients who have, at some point, 
cultured P. aeruginosa from a sputum sample have significantly worse predicted 
FEV1% and increased hospital admission rates, although there has been shown to be 
no significant associated increase in exacerbations or MRC dyspnoea scores 
(McDonnell et al. 2015). Patients colonised with P. aeruginosa were up to 4 times 
more likely to have reduced FEV1%, up to 10 times more likely to suffer from 
polymicrobial colonisation, and experienced up to 12 times higher risk of mortality 
compared to patients who had never cultured P. aeruginosa from a sputum sample. 
Average decline in lung function, measured by FEV1, for patients with NCFBr is 
currently understood to be ~50 ml per year (Nicotra et al. 1995; King et al. 2005; 
Martínez-García et al. 2007) but colonisation with P. aeruginosa is shown to be 
independently associated with accelerated decline in lung function, with an FEV1 loss 
of 123.3 ml per year (Martínez-García et al. 2007). It was also noted that the levels 
of antibiotic resistance among isolates were lower in NCFBr patients in comparison 
to CF patients. From the patients in this study there were no panresistant strains 
identified and only very few multiresistant strains, furthering support for the 
separate and distinct disease classification of NCFBr from CF (McDonnell et al. 2015). 
Previously it has been suggested that colonisation of NCFBr patients by P. aeruginosa 
could act as an identifier for patients with an increased decline in lung function, since 
P. aeruginosa selectively colonises those patients with poor lung function (Evans et 
al. 1996) and it was shown by Davies et al. (2006) that P. aeruginosa colonisation of 
NCFBr patients was in fact a marker of more severe airflow obstruction. However, 
McDonnell et al. (2015) showed that as well as ~50% of patients with moderate 
airflow obstruction suffering from P. aeruginosa colonisation, there were around 
10% of patients with normal FEV1 volumes who were also colonised, which indicates 
that P. aeruginosa may be an important pathogen across all stages of airflow 
obstruction and requires careful observation. 
17 
 
1.2.2 Epidemic (transmissible) strains of Pseudomonas aeruginosa 
Chronic infection with P. aeruginosa is well-documented as the leading cause 
of morbidity and mortality in CF patients and in the past it was widely accepted that 
the most common source of infection for these patients was by uniquely acquired 
environmental strains (Fothergill et al. 2012). It has been known for some time that 
CF siblings often share strains of P. aeruginosa that are directly related to one 
another and are not a strain that is abundant in the environment that had been 
acquired independently (Speert & Campbell 1987; Grothues et al. 1988; Renders et 
al. 1997). A wider role for transmissible strains of P. aeruginosa among CF patients 
emerged after a multi-resistant strain of P. aeruginosa was identified in a Danish CF 
centre and was found to be harboured by a number of patients in this centre 
(Pedersen et al. 1986). The number of patients colonised with this particular strain 
of P. aeruginosa continued increasing after its initial identification until a segregation 
policy, and stricter personal hygiene guidelines, were introduced to the hospital. 
Thus, this strain of P. aeruginosa was identified as an epidemic strain. Further to this, 
another antibiotic resistant strain of P. aeruginosa was found to be highly prevalent 
among children with CF at a paediatric centre in Liverpool, UK (Cheng et al. 1996). 
This strain was named as the Liverpool Epidemic Strain (LES) and was also later 
identified among large numbers of patients at an adult CF centre also in Liverpool 
(Panagea et al. 2003). In response to growing concern about the prevalence of 
transmissible strains of P. aeruginosa among CF patients and the increased morbidity 
and mortality experienced by patients colonised by an epidemic strain (Jones et al. 
2002; Armstrong et al. 2003; Al-Aloul et al. 2003) a large scale study was carried out 
across England and Wales to more fully characterise the epidemic strains present 
among CF patients (Scott & Pitt 2004). 
A nationwide study was carried out analysing 1225 isolates from CF patients 
at 31 centres across the UK. A total of 849 individual patient isolates were analysed 
by pulsed-field gel electrophoresis (PFGE) and initially compared against isolates 
from the same centre in order to ascertain levels of transmission within centres. The 
number of isolates sharing similar DNA patterns (≥80% similarity) compared with the 
number of isolates with unique patterns was used to give a ratio which was, in turn, 
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used as a crude measure of diversity of patient strain populations within each centre. 
The number of clustered isolates varied greatly between the 31 centres involved in 
the study. Some hospitals showed a roughly equal number of strains in each category 
(clustered vs. unique) but in five centres the clustered isolates outnumbered the 
unique isolates, which indicated a higher occurrence of cross-infection between 
patients in these centres (Scott & Pitt 2004). All 849 individual patient isolates were 
compared to investigate transmission of strains between centres. Six clusters 
containing 233 isolates were identified. The DNA patterns of these clusters were 
compared with the representatives from previous published outbreaks: Liverpool, 
Manchester, Melbourne, and clone C. A total of 93 isolates from 15 centres clustered 
with the representatives of the LES; 11 isolates from three centres clustered with the 
Manchester epidemic strain (MES); and 15 isolates from eight centres clustered with 
the clone C genotype (Scott & Pitt 2004). The high incidence and widespread 
frequency of these epidemic strains of P. aeruginosa was not expected, although this 
and other data has since informed treatment and segregation of patients attending 
CF clinics in the UK (The UK Cystic Fibrosis Trust Infection Control Group 2004).
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Figure 1.2: Timeline showing key events in the discovery of various transmissible strains of P. aeruginosa from the late-1980s to the modern day. Highlighted 
are key discoveries such as the earliest known strain of LES, work by Scott & Pitt (2004) revealing the presence of multiple epidemic strains present in CF 
centres in the UK, and the discovery of an Australian epidemic strain (AES). Figure adapted from Fothergill et al. (2012).
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Three novel clusters were also identified. One of these was named Midlands 
1 and contained 86 isolates; 66 of these came from one hospital (in the Midlands) 
and isolates with this genotype were also found in 8 other centres. Another novel 
cluster, named cluster 4, contained 12 isolates from four geographically distinct 
centre. The final novel cluster was formed of ten isolates from one hospital (Trent) 
and was named Trent. It was found that none of the UK CF P. aeruginosa isolates 
clustered with the Melbourne genotype, now known as the Australian Epidemic 
Strain-1 (AES-1) (Scott & Pitt 2004). Although a majority of CF patients were found to 
harbour unique strains of P. aeruginosa, around one in five of those sampled were 
infected by one of two transmissible genotypes. The LES accounted for 11% of the 
isolates analysed in this study and was found in 48% of the 31 centres. The Midlands 
1 strain was found to be the second most common genotype, accounting for 10% of 
isolates sampled and present in 29% of centres. Despite being found in 14% of 154 
patients in the Manchester CF centre (Jones et al. 2001) the Manchester genotype 
was found in only 1% of patients in this study, and clone C was represented by 2% of 
isolates (Scott & Pitt 2004). The most probable explanation for this distribution of 
these genotypes among the isolates sampled is cross-infection with P. aeruginosa 
among CF patients both within and between centres. This was an unexpected result, 
as transmission between CF centres had not previously been reported. The antibiotic 
susceptibilities of epidemic isolates were also investigated in this study and it was 
found that there was considerable variation among isolates of the LES genotype: 
some isolates showed susceptibility to all nine agents (amikacin, ceftazidime, 
ciprofloxacin, gentamicin, imipenem, meropenem, piperacillin, tazobactam, and 
colistin) whilst others exhibited resistance to all agents but colistin (Scott & Pitt 
2004). There was also variation found among the antibiotic resistance profiles for the 
Manchester and Midlands 1 strains, one of which showed resistance to colistin (Scott 
& Pitt 2004).  A more recent study has confirmed the LES as the most common clone 
isolated from UK CF patients (Martin et al. 2013). 
Outside of the UK there have been numerous reports of other epidemic 
strains of P. aeruginosa. Several distinct epidemic strains have been found in both 
adult and paediatric CF centres across Australia (figure 1.2). A strain now known as 
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the Australian epidemic strain-1 (AES-1), previously known as the Melbourne 
genotype, was initially identified in a paediatric clinic in Melbourne (Armstrong et al. 
2002). A survey of patients in Sydney found that a large number of patients were 
infected with the same strain, which was initially named pulsotype-1 (Anthony et al. 
2002) but was later discovered to also be AES-1 (Armstrong et al. 2003). AES-1 was 
also found to be present in both adult and paediatric CF centres in Brisbane (O’Carroll 
et al. 2004) although a second transmissible strain (AES-2) was found to be more 
highly prevalent in the Brisbane centres (Syrmis et al. 2004). AES-2 is associated with 
younger CF patients and with lowered spirometry scores and increased antibiotic 
resistance when compared with other P. aeruginosa strains (O’Carroll et al. 2004). 
Another transmissible strains, AES-3, was found to be most common among patients 
in Tasmania and is associated with increased virulence in patients over 15 years of 
age (Bradbury et al. 2008). 
Denmark was the first country to report the presence of an epidemic strain 
of P. aeruginosa among CF patients (Pedersen et al. 1986) and there has been further 
work carried out into prevalent strains present among the population. Genetic 
analysis of the dominant DK2 clone showed very little diversity among isolates 
despite the highly variable conditions faced by the bacteria in the CF lung 
environment (Yang et al. 2011), however only a small number of isolates underwent 
analysis for this work and so further study is almost certainly required to begin to 
fully understand the changes that occur in populations of P. aeruginosa during 
infection in the CF lung. Evidence for epidemic strains of P. aeruginosa in the context 
of summer camps for CF patients has been provided from Denmark, the Netherlands, 
and Norway (Hoogkamp-Korstanje et al. 1995; Ojeniyi et al. 2000; Fluge et al. 2001). 
Indeed, work by Ojeniyi et al. (2000) showed a cross-infection rate of 100% when 27 
CF patients of mixed infection status attended a one-week winter holiday camp. 
The LES was found to be present in patients attending CF clinics in Ontario, 
Canada along with another, less–prevalent, previously-undescribed epidemic strain 
of P. aeruginosa (Aaron et al. 2010). This study was the first to highlight the presence 
of epidemic strains of P. aeruginosa being shared across continents, although there 
have not been studies into the prevalence of LES, or other epidemic strains, in the 
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US. It is not possible to determine whether the LES originated in the UK or in Canada, 
although there is previous evidence of international transmission of bacterial 
pathogens between CF patients. More recently in Canada a novel clone, named the 
Prairie Epidemic Strain (PES), with increased antibiotic resistance was found in 31 
(29%) of 107 patients attending an adult CF centre in Alberta (Parkins et al. 2014). Of 
these 107 patients there were 66 who had matched isolates from initial and final 
centre visits. In 90% of these patients (60) a stable infection was maintained for a 
mean period of 10.8 years, but five patients experienced strain displacement of their 
unique P. aeruginosa strain by the PES within two years of transferring to the adult 
CF centre (Parkins et al. 2014). The PES has been present in this cohort of patients 
since at least 1987 and is unique to CF patients, having not been isolated from any of 
the patients in a NCFBr control group. The strain also appears to cause chronic 
infection during childhood and was not found in any patients who were diagnosed 
with CF in adulthood (Parkins et al. 2014). 
Transmissible strains have also been reported for other CF pathogens. 
Epidemiological studies of B. cenocepacia isolates from CF patients in Edinburgh, 
Scotland; Manchester; and Toronto, Canada in the early 1990s revealed the same 
infecting strain of B. cenocepacia in patients from all 3 centres (LiPuma et al. 1990; 
Govan et al. 1993). It was suspected that the index case was a patient from 
Edinburgh, who acquired the infection in the late 1980s and travelled to Canada for 
a summer camp with 12 other children from the UK in 1990. Subsequently, 11 of the 
children from the UK and a number of Canadian children also in attendance at the 
camp became infected with the same clonal strain of B. cenocepacia (Govan et al. 
1993). Although CF summer camps have since been widely abandoned, it is possible 
that the LES was transmitted between Canadian and UK patients at one such camp 
in the late-1980s or early-1990s before the camps were shunned due to infection 
control concerns. Conversely, a study by Speert et al. (2002) undertaken in CF centres 
in British Columbia, Canada showed that the risk of cross-infection in these centres 
was very low, and did not warrant segregation of patients beyond the Pseudomonas-
status based scheme already in place. Ontario and British Columbia are, however, 
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geographically distinct regions of a large country and what is typical for CF patients 
in one province is by no means representative of the other. 
Transmissibility is also an important issue with regards to infection control in 
other bacterial species affecting CF patients. A study into non-tuberculosis 
mycobacterium (NTM) Mycobacterium abscessus was prompted by increasing 
numbers of CF patients becoming infected with the bacterium and concern that 
person-to-person transmission may occur. Whole genome sequencing and antibiotic 
susceptibility testing of 168 consecutive isolates from 31 patients attending a UK 
adult CF centre was undertaken by Bryant et al. (2013). It was revealed that there 
were two clustered outbreaks of near-identical isolates of M. abscessus subspecies 
massiliense which differed by fewer than 10 bp. All patients had been exposed to 
opportunities for interpatient transmission within the hospital and environmental 
sampling was unable to identify a possible source of environmental acquisition 
(Bryant et al. 2013). Isolates were found to have constitutive resistance to amikacin 
and clarithromycin and the apparent transmissible nature of the strains means that 
patients with no previous exposure to long-term macrolides or aminoglycosides were 
also infected with resistant strains which has serious implications for treatment and 
future healthcare (Bryant et al. 2013). 
1.2.2.1 Antibiotic resistance among epidemic strains of Pseudomonas aeruginosa 
The prevalence of epidemic strains among CF patients in centres across the 
UK, especially that of the LES, has necessitated further investigation into the levels of 
antibiotic resistance present in these populations. The LES is particularly aggressive 
and well-adapted to the CF lung environment and it was hypothesised that these 
features were likely due to changes in gene expression in LES isolates. This was tested 
by comparison of two LES isolates (associated with chronic and acute infections) to 
each other and to PAO1 under two different growth conditions (Salunkhe et al. 2005). 
This study investigated the changes in gene expression for several groups of genes 
associated with various functions of the cell. In both LES isolates the majority of 
upregulated genes when grown in Luria broth (LB), compared to PAO1, were found 
to be those previously reported to be regulated by quorum sensing (QS). The LES 
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isolate associated with the acute infection of a non-CF parent of a CF patient (LES431) 
was found to express substantially elevated levels of mRNA transcripts associated 
with known P. aeruginosa virulence genes including those encoding alkaline 
protease, elastase, LasA protease, pyocyanin and others (Salunkhe et al. 2005). 
Among the genes up-regulated in both LES431 and the chronic CF infection-
associated LES (LES400) compared to PAO1 were those associated with antimicrobial 
susceptibility. Those genes affected included the ampC β-lactamase gene, the 
MexAB-OprM and MexXY efflux pumps, and the pyochelin biosynthesis genes 
(Salunkhe et al. 2005). Both LES400 and LES431 were less sensitive to β-lactams, 
aminoglycosides, and quinolones although LES431 was more resistant to the β-
lactams piperacillin (in combination with the β-lactamase inhibitor tazocin) and 
imipenem (Salunkhe et al. 2005). Table 1.2 summarises the changes to genes and 
proteins in both LES isolates which were identified through the sequencing of genes 
of interest. 
It is clear from this work that LES isolates have a wide range of defences 
against antimicrobial agents which, when considered alongside the significantly 
worse prognosis for LES-positive CF patients (Al-Aloul et al. 2003), further 
necessitates the segregation of patients by LES status as opposed to Pseudomonas 
status only. 
To examine the wider effects of antibiotic resistance of LES, the antibiotic 
resistance profiles of LES and non-LES isolates from an adult CF centre in Liverpool, 
UK were tested over a period of five years using the disc diffusion method which 
incorporated tazobactam/piperacillin, meropenem, tobramycin, ciprofloxacin, 
ceftazidime, and colistin (Ashish et al. 2012). Overall, the mean antibiotic resistance 
of both groups of P. aeruginosa was shown to increase between 2004 and 2008 but 
LES isolates had increased resistance to all antibiotics except colistin when compared 
to the non-LES group. The non-LES group exhibited increased mean resistance to 
ciprofloxacin, tobramycin, and colistin but the LES group showed increased mean 
resistance to all six antibiotics. The relative numbers of resistant and panresistant 
strains were also found to be significantly higher in the LES group (Ashish et al. 2012). 
Many LES isolates (such as LES431) have been shown to exhibit an unusual QS 
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phenotype which is characterised by a dysfunctional QS system, leading to 
overproduction of QS-related factors early in the growth phase, and is termed 
hypervirulence (Winstanley & Fothergill 2009). The hypervirulence phenotype has 
been linked in some strains to increased resistance to some antibiotics. Although the 
mechanism is unknown, this increase may be linked to up-regulation of QS-regulated 
efflux pumps (Fothergill et al. 2007). The hypervirulence phenotype has not been 
identified in non-LES P. aeruginosa isolates and so it is feasible that the change in QS 
regulation may play a role in the success of LES and the greater morbidity and 
antibiotic resistance associated with it (Ashish et al. 2012). 
Table 1.2:  Summary of mutations found in LES isolates vs. PAO1 which may impact on 
antibiotic resistance profiles of clinical isolates (Salunkhe et al. 2005). 
Protein, gene, 
 or region 
Mutation in 
LES400 and 
LES431 vs. PAO1 
Implications 
AmpR 
One amino acid 
change (D135 → G) 
Similar to a previously described mutation which 
inferred increased β-lactamase activity (Bagge et al. 
2002). 
AmpD 
Two amino  
acid changes 
Inactivation of AmpD associated with increased 
levels of AmpC β-lactamase production (Langaee et 
al. 2000; Bagge et al. 2002) but identical mutations 
also found in isolates with low level basal and 
inducible AmpC. 
MexR 
One amino acid  
change 
May affect MexAB-OprM efflux pump but this pump 
only contributes marginally to β-lactam and 
fluoroquinolone resistance (Hocquet et al. 2003). 
mexR - mexA 
intergenic 
region 
Single 
nucleotide  
change 
May affect MexAB-OprM efflux pump but this pump 
only contributes marginally to β-lactam and 
fluoroquinolone resistance (Hocquet et al. 2003). 
oprD 
Expression  
downregulated 
Carbapenem resistance associated with lowered 
levels of OprD in isolates with MexAB-OprM efflux 
pump (Pai et al. 2001). 
mexZ 
Stop codon, 
MexZ protein 
truncated 
Similar truncations have been linked to stable  
aminoglcoside resistance in clinical CF isolates 
(Vogne et al. 2004). 
 
1.2.3 Hypermutable strains of Pseudomonas aeruginosa 
Hypermutable strains are most commonly produced by alterations in DNA 
mismatch repair genes, leaving the bacteria unable to avoid errors in genome 
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replication and therefore greatly increasing the occurrence of mutations (Miller 
1996). In isolates taken from both CF patients and from environmental sources it was 
found that the most frequently affected gene is mutS (Oliver et al. 2002). Many 
mutations acquired by hypermutators prove to be synonymous, offering little or no 
selective advantage to the organism, or detrimental nonsynonymous mutations 
which reduce fitness and lead to the death of organisms carrying the mutation. The 
advantages held by hypermutators are that the increased rate of mutations increases 
the chance of the organism acquiring a beneficial mutation which allows it to better 
survive in its current environment. The heterogenous and often-changing 
environment of the CF lung is therefore ideal for the selection of hypermutator 
strains. Once adapted to an environment, a hypermutator strain is expected to revert 
to a nonmutator type to prevent the accumulation of deleterious mutations in the 
population; however, this is not always observed in CF patients (Oliver 2000). Of 30 
CF patients, 11 were shown to harbour mutator strains of P. aeruginosa and in most 
cases the same RAPD-PCR type strain was recovered from each patient over the 
period of the study, indicating that the mutator strains evolved within the patients 
(Oliver 2000). 
Maciá et al. (2005) carried out research into hypermutator strains present in 
both NCFBr and COPD patients, finding that the prevalence of these strains was high 
among these patients. Of the isolates collected 53% were found to be hypermutable, 
and hypermutable strains were found in 17 (57%) of the 30 patients. Eleven of these 
patients harboured hypermutable strains with a defective mutS gene. There was 
shown to be no evidence of interpatient transmission events; 32 different P. 
aeruginosa clones were identified by PFGE, each present in individual patients. In 28 
of the 30 patients a single clone was identified, however the remaining 2 patients 
were found to be colonised with two different clones. In 10 patients two or more 
morphologically distinct isolates were recovered but were proven to be of a single 
clonal type by PFGE analysis. The presence of hypermutable strains in such a high 
proportion of patients indicates that clonal strains of P. aeruginosa are likely to be 
maintained in NCFBr patients for a number of years once established, as the 
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increased rate of spontaneous mutation allows near constant adaptation to the 
variable environment within the lungs of NCFBr patients. 
1.2.4 Genomic polymorphism in chronic Pseudomonas aeruginosa strains 
There are many common mutations that have been shown to occur when P. 
aeruginosa establishes a chronic infection within the lungs of patients with 
suppurative lung conditions. Much work has been undertaken to investigate the role 
of mutations in the QS systems of P. aeruginosa and their role in chronic infection, 
particularly in the context of CF patients. QS circuits are complex and rely on 
multicomponent communication to regulate a network of interactions which affect 
the destiny of the cell. Communication among a population of bacterial cells occurs 
via the secretion of the signalling molecules, homoserine lactones (HSLs), into the 
external environment and, upon reaching a critical concentration, are detected by 
surrounding bacterial cells which triggers a series of intracellular responses 
(Winstanley & Fothergill 2009). The QS network of P. aeruginosa is of particular 
interest due to its complexity, involving two interdependent LuxIR-type QS systems: 
LasIR and RhlIR which interact with a quinolone signal along with numerous 
regulators and sigma factors. QS regulation provides a method by which bacterial 
pathogens are able to reduce early detection by the host by delaying the production 
of virulence factors until the bacterial population reaches such a concentration so as 
to be able to have a significant effect (Girard & Bloemberg 2008). However other 
purposes for HSLs have been discovered: 3-O-C12-HSL produced by P. aeruginosa can 
inhibit the filamentation of the fungus Candida albicans which can coinfect with P. 
aeruginosa as an opportunistic pathogen (Hogan et al. 2004). 3-O-C12-HSL has also 
been found to act as an antimicrobial agent against Gram-positive organisms 
(Kaufmann et al. 2005) and long-chain HSLs have been found to function as 
biosurfactants influencing bacterial swarming (Daniels et al. 2006). The QS systems 
have been implicated in many of the classical features of chronic P. aeruginosa 
infection, including that of biofilm formation. The formation of biolfilms is known to 
contribute significantly to P. aeruginosa resistance to even the most aggressive 
antibiotic therapies (Stewart & Costerton 2001). The direct involvement of the QS 
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system in biolfilm development has been a contentious issue for some time and 
studies using las or rhl mutants do suggest a role for QS in the formation of biofilms 
but variation between strains, changes in gene expression due to environment, and 
putative interactions at any of the stages in biofilm formation have all hindered in 
the definition of a clear role for QS mutations in chronic infection (Winstanley & 
Fothergill 2009).  
As well as common mutations that occur among isolates causing chronic lung 
infections, there are also “fixed” mutations present in the genomes of many 
transmissible strains of P. aeruginosa that generally offer some competitive 
advantage to the bacterium in causing long-term lung infections. Whole genome 
sequencing of seven clinical LES isolates was undertaken by Jeukens et al. (2014) in 
order to compare the genomic variations between transmissible strains of P. 
aeruginosa. Approximately 1/6 of the polymorphisms identified in the genomes of 
the seven LES isolates were found in regulatory genes, and 29% of them were 
predicted to have a high functional impact (Jeukens et al. 2014). Both exsA and fleR 
were identified as frequently variable regulatory genes. ExsA is a transcriptional 
regulator of the type III secretion system and was found to differ from LESB58 in four 
isolates, each with a different amino acid substitution (LES431, LESB65, LESlike1, and 
LESlike4). The LES is notably non-motile with no visible flagellum and so the 
redundancy of the fleR gene, responsible for the expression of flagellum in motile 
strains, allows for the occurrence of nonsynonymous deleterious mutations which 
can become fixed in the genome. A nonsense mutation in fleR was shared by the 
three UK LES isolates (LES400, LES431, and LESB65).. These UK isolates also shared a 
14 bp deletion in the gltR regulatory gene which is necessary for glucose 
transportation. Fixed mutations have also previously been identified in regulatory 
genes in the DK2 transmissible lineage of P. aeruginosa (Yang et al. 2011). Mutations 
in lasR, rpoN, and mucA (implicated in the mucoid phenotype) were identified in 
these LES isolates and although they were not fixed mutations they are still likely to 
have a functional effect on the proteins produced. 
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1.2.5 Genotyping of Pseudomonas aeruginosa 
There are a large number of ways to genotype bacterial species, all with 
varying discriminatory powers (table 1.3). Due to the plasticity of the P. aeruginosa 
accessory genome, which includes prophages and genomic islands, the genomes of 
individual strains can range between 5.2 and 7 Mbp in size (Tümmler 2006) and this 
variation means that methods of varying degrees of discrimination need to be utilised 
to correctly genotype P. aeruginosa isolates. Different methods are selected based 
on the needs of the researcher but some of the most commonly used genotyping 
methods for P. aeruginosa are: variable number tandem repeat (VNTR), PFGE, 
random amplified polymorphic DNA PCR (RAPD-PCR), multilocus sequence typing 
(MLST), and the Array Tube (AT). 
PFGE was developed by Schwartz & Cantor (1984) as a method of 
fractionating chromosomal DNA of Saccharomyces cerevisiae to produce a molecular 
karyotype to facilitate the assignment of genes to yeast chromosomes. PFGE has 
been considered the “gold standard” of identification for many bacterial species and 
has a high resolution for distinction between strains but cannot be compared 
between laboratories (Larché et al. 2012). RAPD-PCR  was developed by Williams et 
al. (1990) as a method by which genetic maps of inheritance could be constructed. 
RAPD-PCR, as implied by the name, requires no specific knowledge of the sequences 
to be amplified; the assay is based on the amplification of random DNA segments 
with single primers with an arbitrary nucleotide sequence (Williams et al. 1990). In 
some cases, multiple genotyping techniques are needed in order to confirm the 
validity of results, or simply to achieve a greater depth of information. Both RAPD-
PCR and PFGE were used to investigate the relationship between the unusual 
phenotype and genotype of chronic P. aeruginosa isolates, collected sequentially 
from patients. A panel of eight 10-mer primer sequences chosen specifically to 
identify P. aeruginosa were found to give reproducible polymorphisms suitable for 
strain identification. A small selection of isolates from this study were also subjected 
to analysis by PFGE after digestion with SpeI. This study systematically investigated 
the relationship between the genotype of an infecting strain of P. aeruginosa and the 
subsequent phenotypic changes observed during chronic infection in CF patients. In 
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general, the RAPD-PCR profiles of the sequential isolates remained stable, indicating 
that the phenotypic changes were due to adaptation of the infecting strain to unique 
conditions of the CF lung, as opposed to strain replacement (Mahenthiralingam et al. 
1996). Similar work was carried out by Fothergill et al. (2010) in an attempt to identify 
genuine LES isolates. The standard diagnostic PCR for LES consists of two multiplexed 
sets of primers, PS21 and LESF9 (table 2.1), although there have been several cases 
in which false positives and negatives have been identified which necessitated the 
testing of these anomalous isolates. However, Fothergill et al. (2010) discovered that 
PFGE, RAPD-, and BOX-PCR fingerprinting methods were unable to unequivocally 
resolve which isolates were and which were not genuine LES. The nature of chronic 
lung infections in CF patients may be partly responsible for the inability of these 
techniques to fully resolve the identity of isolates. Guidelines on how to interpret 
PFGE restriction patterns and thus infer relationships between isolates were put 
forward by Tenover et al. (1995) but this method was suggested for use in analysing 
sets of isolates for epidemiological studies of relatively short-term outbreaks (1 – 3 
months) in community or hospital settings. Because of the genomic instability of P. 
aeruginosa in the CF lung, it may be, therefore, that PFGE is not a suitable method 
for examining relatedness in the context of long-term chronic infections that are 
typical in CF patients. Further to this, the AT genotyping method was also 
investigated for its efficacy in discriminating between strains of P. aeruginosa. The 
AT system was developed by Wiehlmann et al. (2007) and relies on the amplification 
of 58 targets for hybridisation with a chip embedded in the base of a 1.5 ml tube. The 
markers are either single nucleotide polymorphisms (SNPs) or variable genes, the 
former being used to form a hybridisation profile which is converted into a 
hexadecimal code and can be directly compared against databases of other P. 
aeruginosa strains. The variable gene markers can be used to investigate the 
accessory genome of P. aeruginosa as the targets include virulence factors and 
previously reported genomic islands. It has been previously reported that the AT 
genotyping system is 99.9% accurate in discriminating between strains of P. 
aeruginosa (Morales et al. 2004) and it was found by Fothergill et al. (2010) to be 
very useful in resolving anomalous results from other genotyping methods.  
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VNTR analysis was initially developed by Jeffreys et al. (1985) as a method of 
genetically “fingerprinting” human DNA using minisatellite genetic markers (or 
VNTRs). Minisatellites were also shown to be present in bacterial genomes and so 
assays were developed for VNTR typing of bacterial populations. Multiple-locus VNTR 
analysis (MLVA) is based on a set of polymorphic tandem repeat loci and has been 
developed for a number of bacterial species (Le Fleche et al. 2001; Le Fleche et al. 
2002). A MLVA scheme was developed for typing of P. aeruginosa by Onteniente et 
al. (2003) using seven polymorphic loci identified in the sequenced genome of PAO1. 
MLVA typing of P. aeruginosa was further developed by Vu-Thien et al. (2007) to 
include a further eight loci. The aim of developing MLVA for P. aeruginosa was to be 
able to assign a code to each strain that represented its genetic profile which would 
allow for the creation of an inter-laboratory database for easy strain comparison. 
From the 15 alleles selected for MLVA typing there were found to occasionally be 
problems with amplification of some minisatellites, although amplification of all 15 
alleles was reported in most cases (Vu-Thien et al. 2007). It was also noted that it was 
possible to remove certain markers, reducing the number to 14 or even as few as 10, 
to make an easier and more robust MLVA scheme and still maintain discriminatory 
powers.  
MLST was developed as a portable approach to identifying clones within 
populations of pathogenic microorganisms by Maiden et al. (1998). To develop MLST 
evaluation for a bacterial species, sequences are determined for fragments of 
housekeeping genes within the genome and each distinct allele within a locus is 
assigned an arbitrary number. A major advantage of MLST is that the data is truly 
transferable between laboratories meaning that data can be easily shared and 
compared through an online database per species analysed. MLST typing was 
developed for P. aeruginosa by Curran et al. (2004) and consists of seven genes 
identified through the use of the P. aeruginosa PAO1 genome database 
(http://www.pseudomonas.com) (Stover et al. 2000) and selected based on a 
number of factors including biological role, location, and suitability for nested primer 
design. This work showed that MLST was an effective and suitably discriminatory 
method for typing P. aeruginosa isolates from a wide range of clinical and  
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environmental sources (Curran et al. 2004). It was shown that some isolates 
with identical sequence types (STs) possessed different serotypes and toxA types, 
although this weak association between MLST STs and serotypes and toxA types is 
likely as a result of the effect of recombination in P. aeruginosa (Curran et al. 2004). 
Although a large database of MLSTs for P. aeruginosa now exists to allow comparison 
Table 1.3: Pros and cons of various genotyping methods commonly used in epidemiological studies 
of bacterial pathogens.  
Genotyping 
method 
Pros Cons 
PFGE 
High resolution and 
discriminatory power 
Cannot be readily compared between 
laboratories 
Can be developed for a wide 
range of organisms 
Time consuming 
Global chromosomal monitoring 
Results can be rendered unusable by uneven 
gel, faulty electrodes, or uneven buffer 
heights 
RAPD-PCR 
No prior knowledge of sequences 
required  
Results can vary greatly due to differences in 
PCR protocol and so cannot accurately be 
compared between laboratories Can be developed for a wide 
range of organisms 
Fast and inexpensive 
Low resolution; does not provide sequence  
information  
MLVA 
Codes assigned to strains can be 
readily shared between 
laboratories 
High-variable VNTRs not available in all 
organisms 
High resolution and 
discriminatory power Developed protocols may only work to 
identify specific species and serovars 
Fast and inexpensive 
MLST 
Codes assigned to strains can be 
readily shared between 
laboratories 
Expensive 
Schemes can developed for a 
wide variety of microbial 
organisms 
Sequence conservation in housekeeping genes 
can sometimes prevent discrimination 
between strains 
Large databases of MLST codes 
available for many organisms 
(http://pubmlst.org) 
AT 
Rapid genotyping 
Analysis of hybridisation pattern is largely  
qualitative 
Provides limited information 
regarding accessory genome 
Some cases of poor hybridisation at markers 
Codes assigned to strains can be 
readily shared between 
laboratories 
Accessory genome information limited to 
presence or absence of mobile genetic 
elements 
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of isolates from around the world (http://pubmlst.org/paeruginosa/) MLST is often 
too costly to be carried out, especially in small laboratories, on a regular basis (Curran 
et al. 2004). 
1.2.6 Whole genome sequencing of Pseudomonas aeruginosa  
The large and diverse genomes of Pseudomonas spp. play a role in the 
difficulties experienced when genotyping P. aeruginosa isolates and so as the cost, 
both monetary and timely, of whole genome sequencing has reduced with 
improvements in accuracy and depth it has become an increasingly common method 
to investigate aspects of bacterial life. Early sequence-based studies of P. aeruginosa, 
following on from the sequencing of the whole genome of PAO1 (Stover et al. 2000), 
supported the idea of a conserved backbone of sequences interspersed with 
numerous strain-specific regions in a manner similar to Escherichia coli (Kiewitz & 
Tummler 2000; Spencer et al. 2003). It has since been confirmed that mobile genetic 
elements (MGEs) are commonplace within Pseudomonas spp. and have been 
identified in all Pseudomonas species in which they have been sought (Silby et al. 
2011). It has previously been noted that recombination is a source of genetic diversity 
among isolates of P. aeruginosa. Plasmids are particularly common among the 
genomes of many Pseudomonas species. They are often large and can have a broad 
host range, even beyond Pseudomonas spp. Plasmids frequently encode entire 
pathways, often virulence related (i.e. antibiotic resistance), and the associated 
regulatory machinery (Spiers et al. 2000). More recently it has been shown that 
recombination among P. aeruginosa populations in chronically infected CF patients 
acts as a driver of genetic and phenotypic diversity (Darch et al. 2015). Comparison 
of P. aeruginosa genomes often involves measuring the amount of genetic material 
in the genome that is different from the core genome of P. aeruginosa. The core 
genome is defined as the conserved sequences of the P. aeruginosa genome with the 
remaining genes comprising the accessory genome, which is defined as the set of 
genes not present in one or more strain (Mathee et al. 2008). Thus, the defined core 
genome changes and reduces in size every time a new genome sequence is 
published. Advances in genome sequencing technologies have allowed for the 
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sequencing of genomes of multiple P. aeruginosa isolates for the investigation of 
virulence mechanisms, including resistance genes and virulence factors (Lee et al. 
2006; Boyle et al. 2012); relatedness of isolates and tracing of transmission events 
(Snyder et al. 2013; Jeukens et al. 2014; Quick et al. 2014); and evolution of bacterial 
strains (Wong et al. 2012; Dettman et al. 2013; Marvig et al. 2014). It has been shown 
that, based on core genome SNP phylogeny, the wider population of P. aeruginosa 
can be separated into two major groups (Stewart et al. 2014). The International 
Pseudomonas aeruginosa Consortium (IPC) is aiming to sequence over 1000 
genomes and build an analysis pipeline for the comprehensive study of the evolution 
of the P. aeruginosa genome and antibiotic resistance and virulence genes (Freschi 
et al. 2015). The ambition of the IPC is to assemble a large and representative strain 
collection, with associated genomic data, which will aid research into identification 
of resistance markers and data mining for new therapeutic targets. The IPC also aims 
to make improvements in patient care by developing platforms and pipelines to link 
genomic and clinical data which will allow the identification of prognostic markers by 
clinicians. Given the importance of P. aeruginosa in CF, it is also hoped that the IPC 
will be able to transform CF diagnostic microbiology and develop tools to enable CF 
clinicians to better interpret genomic data and thus make informed decisions 
regarding cross-infection (Freschi et al. 2015). Work has also been undertaken to 
investigate the possibility of next generation sequencing (NGS) of bacterial genomes 
to provide genotypic information regarding antibiotic resistance to better define 
nonsusceptible isolates from patient samples. The growing number of novel 
resistance mechanisms known to exist in various bacterial species has rendered 
many of the PCR-based methods insufficient (Kos et al. 2015). Analysis of the 
genomes and antibiotic resistance profiles of 390 P. aeruginosa isolates from diverse 
locations and clinical infections was used to resolve the ability of identification of 
resistance genes to predict phenotypic changes in antibiotic resistance. In the case 
of meropenem and levofloxacin it was shown that the genome-based resistome was 
in good agreement with the susceptibility data, which suggested that the 
identification of some resistance mechanisms can be readily achieved through 
sequence analysis (Kos et al. 2015). Difficulty was experienced reconciling the 
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susceptibility data for amikacin with resistome data and this may be due to the role 
played by efflux pumps and their relative expression in aminoglycoside resistance. 
One of the downfalls of whole genome sequencing in this context is its inability to 
measure gene expression which is known to play a large role in antibiotic resistance 
(Kos et al. 2015). Nonetheless this research highlights one of the many potential uses 
of whole genome sequencing and could, in the future, be combined with techniques 
such as transcriptome sequencing (RNA-Seq) to better predict resistance profiles 
from genetic information (Kos et al. 2015).   
Alongside the potential  uses of whole genome sequencing in investigating 
bacterial isolates in depth it has also been suggested that it could be used in future 
as a diagnostic tool, allowing the rapid and accurate identification of bacterial species 
and associated risk factors (i.e. antibiotic resistance) to allow the best possible 
decision to be made with regards to patient health. As technological advances are 
made and sequencing platforms become more compact and user-friendly it is likely 
that increasing number of diagnostic laboratories will have access to sequencing 
platforms, and that the technical requirements for their use will become comparable 
to those required for diagnostic PCR (Török & Peacock 2012). At present, the depth 
of information provided by whole genome sequencing is not warranted for use in the 
majority of work undertaken in diagnostic microbiology, although there have already 
been cases in which the benefits of sequencing could be beneficial to public health; 
in particular, the outbreak of E. coli 0104:H4 in Germany in 2011. Investigators 
sequenced four outbreak strains and two historical reference strains to create optical 
maps of the strains within 62 h, demonstrating real-time use of diagnostic 
sequencing to investigate an ongoing outbreak of disease (Mellmann et al. 2011). In 
this context, sequencing may be useful for the rapid identification of multidrug-
resistant Gram-negative bacteria, such as P. aeruginosa, in nosocomial outbreaks. 
Sequence data would allow diagnostic laboratories to identify an outbreak strain and 
analyse the presence of antibiotic resistance genes present in the genome in order 
to present the patient with an effective treatment for infection (Török & Peacock 
2012). At present the greatest obstacle to rapid diagnostic sequencing is the lack of 
automated interpretation software that can accurately translate sequence data to 
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provide the required information in a format that is accessible to microbiologists, as 
opposed to bioinformaticians, and can be applied rapidly to a clinical situation (Török 
& Peacock 2012). 
1.3 Aims  
The overall aim of this work is to further understanding of the importance of P. 
aeruginosa infection in patients with NCFBr. The disease itself is grossly understudied 
and it is only in recent years that the burden of NCFBr both on patients and on 
healthcare systems has been fully realised. Research into P. aeruginosa infection in 
CF patients has been extensive, though is by no means complete, and by comparison 
the available information regarding chronic P. aeruginosa infections in NCFBr 
patients is incredibly sparse. Very little is known about the retention of strains or the 
presence of transmissible strains of P. aeruginosa among NCFBr patient populations 
and this work aims to begin to resolve this. An understanding of the prevalence of 
transmissible strains of P. aeruginosa among NCFBr patients is important in terms of 
healthcare standards and is necessary to inform segregation policies in 
bronchiectasis centres. It is also hoped that this work will act as a foundation for 
others to continue research into P. aeruginosa infections in NCFBr patients, 
particularly with regards to the long-term effects of chronic infection on both 
patients and bacterial populations. It has been shown that antibiotic resistance 
among P. aeruginosa isolates increases over the course of chronic infection in CF 
patients (Ashish et al. 2012) and so future research into similar outcomes from NCFBr 
patients should be undertaken given the current burden placed upon public 
healthcare providers by increasing levels of antibiotic resistance.The specific aims of 
this work are to: 
1. Use AT genotyping to investigate the maintenance of P. aeruginosa 
strains in chronic lung infections in NCFBr patients over an extended 
period of time; 
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2. Compare the four digit AT codes to those in databases from previous 
studies to place NCFBr P. aeruginosa isolates in the context of the 
wider P. aeruginosa population; 
3. Use whole genome sequencing to investigate the diversity and 
population structure of P. aeruginosa isolates from NCFBr patients; 
4. Use whole genome sequencing to investigate the heterogeneity of 
P. aeruginosa populations within chronically infected individuals 
with NCFBr. 
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Chapter Two 
Methods and Materials 
2.1 Collection and storage of isolates 
The collection of UK-wide isolates were provided by Dr Juliet Foweraker 
(Papworth Hospital) and isolates from Liverpool were provided by Paul Roberts 
(Royal Liverpool University Hospital). A total of 408 isolates (appendix, table A1) were 
collected from 16 adult bronchiectasis centres in the UK. The patients were adults 
with confirmed bronchiectasis, with no known cystic fibrosis (CF), who regularly 
attend clinics at the centres. Isolates were catalogued with the information provided 
by the centre and stored at -80°C in 1 ml 5% (V/V) glycerol Luria broth (LB) (table 2.2). 
In preparation for storage, isolates provided from frozen bead stocks at Royal 
Liverpool and Broadgreen University Hospitals (RLBUHT) and from slopes from other 
centres were plated on to Columbia agar (Oxoid) (table 2.2) and grown overnight at 
37°C. Following overnight growth a sweep of each organism was taken with a 5 μl 
inoculation loop and resuspended in 1 ml 5% (V/V) glycerol LB in a 1.5 ml Eppendorf 
tube. Each tube was vortexed to homogenize the mixture before being labelled and 
stored at -80°C. 
2.2 PCR amplification screening  
Polymerase chain reaction (PCR) screening was performed on all isolates in 
order to confirm their identity as P. aeruginosa; screen for Liverpool Epidemic Strain 
(LES), Midlands 1 and Manchester Epidemic Strain (MES) (Fothergill et al. 2008). To 
prepare a crude DNA extract a sweep of colonies from overnight growth on Columbia 
agar (Oxoid) at 37°C was suspended in 100 µl sterile distilled water and heated at 
99°C for 5 min. Following centrifugation, 1 μl of supernatant was used in 25 μl 
volumes containing 5 μl GoTaq buffer, 0.5 μl dNTPs (10 mM), 300 nM forward primer 
per primer set, 300 nM reverse primer per primer set, 2 μl MgCl2 (25 mM), 0.1 μl 
GoTaq 2G polymerase (5 u μl-1), and sterile distilled water to final volume of 25 μl. 
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Following initial denaturation by heating at 94°C for 2 min, amplification was 
performed for 30 cycles consisting of 20 s at 94°C, 20 s at annealing temperature 
(table 2.1) and 40 s at 72°C, with a 2 min extension time of 72°C following completion 
of the cycles. 5 μl of PCR product was loaded into a 1% (W/V) agarose gel (0.5 x TBE 
buffer (W/V); table 2.2) and subjected to electrophoresis at 100 V for approximately 
40 min. The products were visualised under UV light using GeneSnap software with 
a 1 kb+ DNA ladder (Invitrogen) for size comparison. 
Table 2.1: Oligonucleotide primers used in this study. 
Primer Target Oligonucleotide sequence 
(5´ - 3´) 
Annealing 
temp. (°C) 
Product 
size (bp) 
Reference 
PA-SS F 16S rRNA 
P. aeruginosa 
GGGGGATCTTCGGACCTCA 58 956 (Spilker et al. 
2004) PA-SS R TCCTTAGAGTGCCCACCCG 
PAL-1 oprL 
P. aeruginosa 
ATGGAAATGCTGAAATTCGGC 57 504 (De Vos et al. 
1997) PAL-2 CTTCTTCAGCTCGACGCGACG 
LESF9 F 
LESF9 (LES) 
AACACTTGCTCCATCTGC 56 431 (Fothergill et 
al. 2008) LESF9 R CACGATATCCAGCAAGAC 
PS21 F 
PS21 (LES) 
AAGCAGGCCAGCGTGTCTA 56 364 (Fothergill et 
al. 2008) PS21 R AAAACGTAGCAAGCAGTG 
MID1 F 
Midlands 1 
TTGCGCTCCATCGTTTGA 56 649 (Smart et al. 
2006) MID1 R CTCCAGATGCCTACGAAA 
MA15 F Manchester  
epidemic strain 
GTCGGCAGATAGCCTTTGTC 56 308 (Lewis et al. 
2005) MA15 R CGACTAATACCCGTCGCTTC 
EXOU F 
exoU 
CCGTTGTGGTGCCGTTGAAG 58 134 (Ajayi et al. 
2003) EXOU R CCAGATGTTCACCGACTCGC 
EXOS F 
exoS 
GCGAGGTCAGCAGAGTATCG 58 118 (Ajayi et al. 
2003) EXOS R TTCGGCGTCACTGTGGATGC 
FpvAI-1F Pyoverdine 
receptor type I 
CGAAGGCCAGAACTACGAGA 55 326 (de Chial et al. 
2003) FpvAI-1R TGTAGCTGGTGTAGAGGCTCAA 
FpvAII-2F Pyoverdine 
receptor type II 
TACCTCGACGGCCTGCACAT 55 897 (de Chial et al. 
2003) FpvAII-2R GAAGGTGAATGGCTTGCCGTA 
FpvAIII-3F Pyoverdine 
receptor type III 
ACTGGGACAAGATCCAAGAGAC 55 506 (de Chial et al. 
2003) FpvAIII-3R CTTCTTCAGCTCGACGCGACG 
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2.3 Clondiag/Alere Array Tube genotyping 
Bacterial samples isolated as from single colonies were grown overnight at 
37°C on Columbia agar (Oxoid) and a sweep of the organism collected using a 5 μl 
inoculating loop and suspended in 1 ml sterile distilled water. Following 
centrifugation at 13 000 rpm for 2 min the supernatant was removed and the pellet 
resuspended in 200 μl sterile distilled water. The suspension was transferred to a 0.5 
ml Eppendorf tube and heated at 99°C for 5 min. Following further 2 min 
centrifugation at 13 000 rpm, 5 μl supernatant was added to a 5 μl Master Mix 
containing 4.9 μl Labelling buffer and 0.1 μl biotin-dUTP Labelling enzyme. 
Amplification was then carried out in a linear PCR programme which consisted of 
initial denaturation at 96°C for 5 min and then 50 cycles of 62°C for 20 s, 72°C for 40 
s and 60°C for 1 min. The linear PCR uses only one primer per target, instead of a pair, 
which produces only single stranded products and thus limits the amount of 
amplification and controls cross-contamination. The primers are all of a similar length 
and the sequences and melting temperatures are shown in the appendix, table A2.  
Before proceeding with hybridisation, the array tubes were washed twice in 
hybridisation buffer for 5 min at 550 rpm. Amplified single stranded DNA (ssDNA) 
was transferred to the AT and hybridisation completed by the addition of 90 μl 
hybridisation buffer and incubation at 60°C for 1 h. The ssDNA/hybridisation buffer 
mix was then carefully removed from the AT by pipetting. Care was taken to avoid 
any contact between the pipette tip and the AT chip as any contact could damage 
the probes. 
The tubes were then washed 3 times with 500 μl AT wash buffer 1 to limit 
non-specific hybridisation; once without mixing or incubation and twice incubated at 
30°C for 5 min at 550 rpm. Following washing, 100 μl horseradish streptavidin-
peroxidase (HRP) solution was added to allow conjugation. Tetramethylbenzidine 
(TMB) was then added to allow precipitation staining and complete the process. AT 
images were acquired using an ATR 03 Colorimetric reader and AT-Iconclust software 
(Alere Technologies, Jena). Figure 2.2 shows a simplified step-by-step protocol for AT 
genotyping; a more detailed protocol can be obtained from the manufacturer (Alere 
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Technologies, Jena). Six control spots are present on the AT chip that bind directly to 
HRP which allow indication of a correct test performance and aid in orientating the 
image for analysis (figure 2.3).  
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Table 2.2: Table of buffers and solutions used in gel electrophoresis, extraction of genomic DNA, and 
AT genotyping.  
Buffer/Solution/Media Ingredients Instructions 
Columbia agar (Oxoid) 
Special peptone (23 g) All components were added to 1 l 
distilled water and boiled to 
dissolve completely. Media was 
then sterilised by autoclaving at 
121°C for 15 mins. Media was 
allowed to cool to 50°C before 
being poured into plates, allowed 
to set, and then stored at 4°C 
until use. 
Starch (1 g) 
NaCl (5 g) 
Agar (10 g) 
Luria broth (LB) 
Tryptone (10 g) All components dissolved in 1 l 
distilled water and sterilised by 
autoclaving at 121°C for 15 mins. 
Media was then cooled and 
stored at room temperature.  
Yeast extract (5 g) 
NaCl (10 g) 
Glycerol LB (5% V/V) 
LB (475 ml) All components combined and 
mixed well. Media sterilised by 
autoclaving at 121°C for 15 mins. 
Media was then cooled and 
stored at room temperature. 
Glycerol (25 ml) 
TBE buffer (0.5 x W/V) 
Tris (162 g) All components were added to 
2.5 l distilled water and then 
mixed on a stirring plate until 
completely dissolved. Volume was 
then made up to 3 l with distilled 
water 
EDTA (11.16 g) 
Boric acid (83.5 g) 
Nuclei lysis solution 
(Promega) 
2-Amino-2-(hydroxymethyl)-1,3-
propanediol   
Sodium dodecyl sulphate (60% W/V) 
1 kb+ DNA ladder 
(Invitrogen) 
1 Kb Plus DNA Ladder™ (1 µg µl-1) All components combined to give 
a final concentration of 1 µg µl-1 1 
Kb Plus DNA Ladder ™. For 
loading into gel the solution was 
diluted 1:6 with 6X DNA loading 
dye (Thermo Scientific). 
Tris-HCl (10 mM, pH 7.5) 
NaCl (50 mM) 
EDTA (1 mM) 
AT wash buffer 1 (2 x 
SSC/0.01% Triton X100) 
NaCl (175.3 g) NaCl and sodium citrate were 
dissolved in 800 ml sterile distilled 
water. The pH was adjusted to 7.0 
and the volume made up to 1 l 
with sterile distilled water. The 
solution was then diluted 1:10 in 
H2O and Triton X100 was added 
to a final concentration of 0.01% 
V/V. 
Sodium citrate (88.2 g) 
  
AT wash buffer 2 (0.2 x SSC) AT wash buffer 1 diluted 1:100   
Hybridisation buffer Formamide 60 - 100% (125 ml)   
HRP conjugation solution 
Luminol (3-aminophthalhydrazide) (125 
ml) 
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Figure 2.1: 1 kb+ DNA ladder (Invitrogen) (table 2.2) The 1kb plus DNA ladder is composed of 
20 double-stranded DNA bands ranging from 100 bp to 12,000 bp, with a quick orientation 
band at 1,650 bp that forms a distinct doublet with the 2 kb band, and seven bands of round 
sizes below 1 kb. 
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Figure 2.2: Stages of the Clondiag Array Tube system adapted from Alere Technologies: hybridisation, streptavidin-horseradish peroxidase (HRP) conjugation, 
tetramethylbenzidine (TMB) precipitation and colorimetric analysis (http://alere-technologies.com/en/products/lab-solutions/platforms/arraytube-at.html). 
PCR (50 cycles) 
Ubiotin labelling 
Colorimetric analysis 
DNA 
HRP conjugation and 
TMB precipitation 
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2.3.1 Layout of the AT chip 
The AT system was developed in 2007 and consists of 77 oligonucleotides 
immobilised and embedded in a microchip in the base of a tube (Wiehlmann et al. 
2007). The layout is divided in to 3 sections (figure 2.3): genomic islands, variable 
genes, and SNPs. The chip contains 29 markers for a range of genomic islands and 
islets, 15 markers for variable genes, a LES PS21 marker, and 16 markers relation to 
SNP loci. The markers for the genomic islands, variable genes, and the LES PS21 
marker are represented by two spots on the chip, and the SNPs by four spots.  
2.3.2 Interpretation of the AT chip 
Analysis of the 13 SNP patterns at 7 conserved loci (ampC, citS, alkB2, fliCa, 
oprI, oprL, and oriC) and the presence or absences of 3 variable genes encoding the 
type III secretion virulence proteins ExoU and ExoS and the flagellin protein FliC 
provides a genetic profile, initially read as a 16 digit binary code, and then translated 
into a 4 digit hex code. The genomic islands and variable genes are represented by 
two oligonucleotides and the presence of the spots on the chip following 
hybridisation indicates whether the target is present. If the gene is present the isolate 
is assigned a “1” for that locus; if the gene is not present it is assigned a “0”. Each SNP 
is represented by four oligonucleotides: two on the left which have sequences 
matching with PAO1 and two on the right with sequences that do not match with 
PAO1 (these are considered a “mutant strain”). If the hybridisation spots are stronger 
on the left (PAO1 sequence) the isolate is assigned a “0” for that locus. If the 
hybridisation spots are stronger on the right (“mutant” sequence) the isolate is 
assigned a “1” for that locus. Figure 2.4 shows examples of binding for both wild type 
(PAO1) and non-PAO1 (mutant) variants of the hybridisation spots to act as a guide 
when reading the AT image (figure 2.4). Interpretation of the AT chip is carried out 
manually and so the interpreted results can be somewhat subjective. 
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2.3.3 Hexadecimal code conversion 
The resulting hexadecimal binary code can then be converted to a 4 digit code 
as shown in figure 2.5 and a genetic fingerprint is produced and assigned to the 
strain. This code can then be compared to isolate information from several large, 
previously described databases (Wiehlmann et al. 2007; Cramer et al. 2012; Shankar 
et al. 2012; Hall et al. 2014; De Soyza et al. 2014). A combined dataset was created 
including information from all 761 isolates from the previous databases. The 
comparison allows for further information to be acquired about the strain in 
question, in particular if it has previously been assigned a clone type and 
environments from which isolates of the same strain type have been previously 
collected.  
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Figure 2.3: Positions of SNPs, genomic islands, and variable genes on the AT chip (Wiehlmann 
et al. 2007). 
C45, C46, C47 – gene island in Clone C , PAGI – Pathogenicity Island, pKLC – pKLC102 plasmid 
in Clone C,  pyov.rec 1,2a,2b,3 – pyoverdine type receptors I,II and III fpvA, pyov.rec B – 
pyoverdine type I receptor fpvB, LES PS21 marker, PA0636, PA0722, PA0728, PA2185, 
PA2221, PA3835 – PAO1 sequences, TB –C47-1, TB- C47-2 - TB, pKLC102 related gene island 
integrated in tRNA(Lys), fla-islands 1,2 orfA, orfI and orfJ – flagellin glycosylation islands. , 
fliCa, fliCb – Flagellin proteins, ExoU/ExoS – Type III secreted virulence factors, ampC – 
βlactamase, oprL – outer membrane lipoprotein, citS – citrate synthase, oprI – outer 
membrane lipoprotein, alkB2 – alkaline hydroxylase alkB2 
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Figure 2.4: Predetermined table for comparison of hybridisation patterns for the seven 
conserved loci used for AT chip interpretation (Wiehlmann et al. 2007) 
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Figure 2.5: Conversion of the hexadecimal binary code, adapted from Wiehlmann et al. (2007). 
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2.4 Genomic DNA extraction for Illumina sequencing 
A total of 191 isolates, isolated from single bacterial colonies, were selected 
to undergo whole genome sequencing. Genomic DNA (gDNA) was extracted from 
these isolates using a Promega Wizard Genomic DNA Purification Kit. The basic 
protocol was followed, with some minor adjustments to improve yield and purity. 
Asterisks indicate where the method used deviates from that provided by the 
manufacturer. 
A single colony was picked and grown overnight in 5 ml LB broth in a shaking 
incubator at 37°C and 180 rpm. To pellet the cells, 1 ml overnight culture was 
centrifuged for 2 min at 14 000 rpm and the supernatant discarded. Cells were lysed 
by adding 600 μl Nuclei Lysis Solution and mixing gently. The tubes were then 
incubated at 80°C for 5 min and then cooled on ice for a further 5 min*. Once cool 3 
μl RNase A Solution (Promega) was added and gently mixed. The tubes were then 
incubated at 37°C for 1 h and then cooled on ice for 5 min*. Protein was precipitated 
by adding 400 μl Protein Precipitation Solution* and vortexing immediately. The 
tubes were kept on ice for 5 min and then centrifuged at 14 000 rpm for 5 min*. The 
supernatant was then transferred to a tube containing 600 μl room temperature 
isopropanol and mixed by inverting the tube several times. Following centrifugation 
at 14 000 rpm for 15 min* the supernatant was removed. Once dry, 600 μl room 
temperature 70% ethanol (V/V) was added to each tube and the samples were 
centrifuged at 14 000 rpm for 15 min*. The supernatant was then removed and the 
tubes left to air dry completely. The DNA pellet was then rehydrated by adding 100 
μl DEPC-treated water and storing overnight at 4°C. 
2.4.1 Quantification of genomic DNA by Qubit fluorometer  
Quantification of gDNA in samples was carried out using a Qubit 3.0 
fluorometer and Qubit dsDNA broad range assay kit (Life Technologies). A working 
solution was made using concentrated assay reagent and dilution buffer in a 1:200 
dilution. 190 μl working solution was added to 10 μl of each of the two pre-diluted 
standards for a total reaction volume of 200 μl. 2 μl sample was used per reaction, 
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and made up to a final volume of 200 μl with working solution. The tubes were 
vortexed for 2 – 3 seconds and then incubated at room temperature for 2 min before 
being inserted into the Qubit fluorometer to measure fluorescence. Samples were 
required to contain >20 ng μl-1 gDNA in order to be sent for sequencing.  
2.4.2 Quantification and purity testing of genomic DNA by NanoDrop 
spectrophotometer  
Further quantification and purity testing of gDNA in samples was carried out 
using a NanoDrop 1000 spectrophotometer (Thermo Scientific). Extracted DNA had 
previously been eluted in DEPC-treated water and so the same was used as a blank 
for NanoDrop measurements. 2 μl DEPC-treated water was carefully pipetted on to 
the lower measurement pedestal of the spectrophotometer and the sampling arm 
then closed to form a liquid column to allow the machine to make a blank 
measurement. 2 μl sample was pipetted in the same manner on to the lower 
measurement pedestal of the machine and measurements made. Both the upper and 
lower measurement pedestals were wiped clean with a soft clean tissue between 
sample measurements.  
NanoDrop measurements provide a wide range of information on the 
absorbance of the sample but the measurements most highly relating to the purity 
of the sample are the ratios of sample absorbance at 260/280 nm and 260/230 nm. 
260/280 ratio of absorbance assesses purity of DNA present in the sample. A ratio of 
~1.8 is generally accepted as “pure” for DNA samples. If the ratio is much lower than 
1.8 it may indicate the presence of protein or other contaminants that absorb 
strongly at 280 nm. 260/230 ratio of absorbance is a secondary measure of DNA 
purity and 260/230 ratios for “pure” samples are often higher than the respective 
260/280 ratios, often in the range of 1.8 – 2.2. A much lower ratio may indicate the 
presence of co-purified contaminants. 
52 
 
2.5 Whole genome sequencing 
2.5.1 Data acquisition 
Following gDNA extraction and quantification, samples were sequenced and 
analysed at the Centre for Genomic Research at the University of Liverpool. Shotgun 
libraries were prepared from the normalised samples using TruSeq Nano library 
preparation kit. Following library preparation, paired-end sequencing (2 x 100 bp) 
was performed by multiplexing into one lane of the Illumina HiSeq platform and 
sequenced with SBS V4 chemistry. 
Following processing, the raw Fastq files were trimmed for the presence of 
Illumina adapter sequences using Cutadapt version 1.2.1 (Martin 2011). The option 
–O 3 was used to that the 3ʹ end of any reads which match the adapter sequence for 
3 bp or more were trimmed. The reads were further trimmed using Sickle 
(https://github.com/najoshi/sickle) version 1.200 with a minimum window quality 
score of 20. Reads shorter than 10 bp after trimming were removed. If only one read 
of a pair passed this filter, it was included in the R0 file, with files R1 and R2 containing 
corresponding paired-end sequences. 
2.5.2 Genome assembly 
Genome assembly, core genome extraction, phylogenetic analysis, and 
variant calling were performed by Matthew Moore (University of Liverpool). Quality 
filtered and adapter trimmed short reads were de novo assembled and scaffolded 
using SPAdes-3.5.0 (Bankevich et al. 2012). Genome assembly quality metrics such as 
N50, largest contig, and overall number of contigs were produced using QUAST 
(Gurevich et al. 2013). Pairwise comparisons between assembled genomes were 
performed using progressiveMauve (Darling et al. 2004). 
2.5.3 Core genome extraction 
The core genome was extracted using Panseq (Laing et al. 2010) and was 
defined as 500 bp fragments of all genomes in this study which matched with at least 
85% similarity. 
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2.5.4 Phylogeny 
A phylogenetic tree was approximated from core genome polymorphic sites, 
not including gaps or ambiguous bases by maximum likelihood with inner node 
bootstrap (n = 100) and 10 discrete gamma categories. All phylogenetic analyses 
were performed using MEGA6 (Tamura et al. 2013) and visualised using the iTOL 
software (Letunic & Bork 2007; Letunic & Bork 2011). Long branches were reduced 
for clarity. 
2.5.5 Variant calling 
Short reads were mapped to a reference genome PAO1 (Stover et al. 2000) 
using bwa-0.7.5 (Li & Durbin 2009) (-mem). Resulting sequence alignment map (.sam) 
files were ordered, converted to binary alignment map (.bam) format, and duplicates 
marked. The .bam files were de-duplicated using picardtools-1.8.5 
(http://sourceforge.net/p/picard/wiki/Main_Page/) and variants called using GATK-
3.3 (McKenna et al. 2010) HaplotypeCaller module. All variants were filtered using 
vcffilter (https://github.com/ekg/vcflib) and annotated using snpEff 
(http://snpeff.sourceforge.net/SnpEff_manual.html).  
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Figure 2.6: Flow diagram illustrating the processes undertaken in the computational analysis 
of genomic data from this study. All processes described in more detail in sections 2.5.1 – 
2.5.5.  
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2.6 eBURST algorithm  
The eBURST algorithm (http://eburst.mlst.net) was originally devised and 
developed by Ed Feil from the University of Bath (Feil et al. 2004). An enhanced 
version was later developed and integrated into the MLST websites (Spratt et al. 
2004) and the latest version (eBURSTv3) has been developed with funding from the 
Wellcome Trust, and is hosted by Imperial College London. The algorithm displays 
the relationships between closely-related isolates within a bacterial population using 
a simple model of bacterial evolution based on a founding or ancestral genotype that 
diversifies to produce a cluster of related genotypes. The algorithm predicts descent 
of genotypes from the ancestor and displays the output as a radial diagram. The 
eBURST algorithm has mainly been applied to MLST data though in this case it has 
been used to display the relationships between genotypes identified through AT 
genotyping. For use with the AT genotypes, the profiles were converted to a tab 
delineated text file and uploaded to the eBURST site. For analysis, the programme 
was set to estimate the relatedness based on 16 loci, with a minimum of one identical 
loci for group definition, a single locus variant (SLV) count of 0 for subgroup 
definition, and number of re-samplings for bootstrap support set to 1000. 
The data is divided into groups of sequence types (STs) that have a level of 
similarity in their SNP profiles. Within a single group all STs must be an SLV of at least 
one other ST in the group. The primary founder of any group is defined as the ST that 
differs from the largest number of other STs at only a single locus. In the case of two 
STs having the same number of SLVs, the one with the greater number of double 
locus variants (DLVs) is selected as the founding member. More than one group can 
be displayed, appearing as a cluster, in a single eBURST diagram along with any 
unlinked STs. The eBURST diagram shows the patterns of descent within a group in a 
radial fashion with lines connecting the founder to each of its SLVs, and lines 
connecting these STs to other STs varying from them at only one locus. The size of 
the node representing an ST indicates the relative abundance of that ST within the 
population.  
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Chapter Three 
Longitudinal study of chronic 
Pseudomonas aeruginosa infections in 
non-cystic fibrosis bronchiectasis 
patients 
 
3.1 Introduction 
3.1.1 Maintenance of Pseudomonas aeruginosa strains in cystic fibrosis patients 
Pulmonary infections are the biggest cause of morbidity and mortality in 
cystic fibrosis (CF) patients. Throughout childhood patients may be infected with a 
wide range of microbial pathogens, although colonisation by the most prevalent 
pathogens tends to be age-related (figure 3.1): Staphylococcus aureus is acquired 
during infancy, Haemophilus influenzae in the early years of development, and P. 
aeruginosa in adolescence (Govan & Deretic 1996). Unless detected early and rapidly 
treated with an aggressive course of antibiotics, P. aeruginosa infections persist 
within CF patient lungs often for the rest of their life. Longitudinal studies of both 
adult and paediatric CF patients have been previously carried out by many authors 
(Şener et al. 2001; Leone et al. 2008; Burns et al. 2001; Jelsbak et al. 2007; 
Mahenthiralingam et al. 1996) and have provided insights into transmission and 
maintenance of P. aeruginosa strains between and within patients.  
A study carried out by Jelsbak et al. (2007) using array tube (AT) genotyping 
in a Danish CF clinic investigated diversity of 45 P. aeruginosa isolates taken from 7 
patients diagnosed as chronically infected (defined as being infected for a period of 
>12 years) over a period of 1 year. Amongst these 45 isolates only 5 different 
genotypes were identified, with considerable clonal overlap between patients. The 
group also carried out a long-term longitudinal study on 6 of the 7 patients which 
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revealed chronic infection as a dynamic process in which genotypes carried by 
patients are periodically replaced by different clones. Two genotypes were found to 
be particularly dominant, with one genotype found to have infected all six patients 
at some point during the period of the study. The results of this study demonstrated 
clearly that the two dominant clones among these patients were capable of inter-
patient transmission, and so it is likely that the clones have a strong selective 
advantage in colonising the CF airway. 
Leone et al. (2008) used pulsed-field gel electrophoresis (PFGE) and O 
serotyping to analyse the genotypic characteristics of isolates from 55 adult CF 
patients over a 5 year period. The discriminatory powers of PFGE and O serotyping 
were determined to be too low to define the relationships between phenotypic and 
genotypic characteristics of the isolates or to elucidate any possible transmission 
events between patients in the centre; however the results of the study did suggest 
long-term persistence of strains of P. aeruginosa in some patients. Hypermutable 
strains, defined by an increase in frequency of spontaneous mutations (Oliver 2000), 
were also revealed to be present in some instances, with variations in PFGE profiles 
and antibiotic susceptibility. 
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Figure 3.1:  Data  from CF Registry Annual data report (Cystic Fibrosis Trust 2014) indicating the percentage of patients affected by bacterial infection by 
common pathogens at different ages.  Chronic infection with S. aureus or P. aeruginosa were identified at annual review. Data on Burkholderia cepacia, H. 
influenzae, and methicillin-resistant S. aureus (MRSA) were collected from culture results at annual review. 
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Analysis of P. aeruginosa isolates from 20 CF patients over a period of 10 years 
by Şener et al. (2001) used random amplified polymorphic DNA fingerprinting-PCR 
(RAPD-PCR) in combination with phenotypic tests to further understand the 
dynamics of P. aeruginosa populations in CF lung infections. The study revealed that 
many patients were colonised with strains of varying phenotypes but sharing a 
consistent genotype, although other patients were colonised with strains of varying 
genotypes. From the 20 patients, 24 unique RAPD types were identified from RAPD-
PCR. Seven patients shared the same genotype, which Şener et al. (2001) speculated 
may have originated in one of the patients, with the earliest strain being isolated in 
May 1992, and spread to the others through close contact in CF clinic sessions. Of 
these seven, six patients consistently harboured this same genotype during repeated 
sampling over a 12 month period and one patient was also found to harbour a second 
genotype in one sample. Of the 20 patients, 13 harboured a single persistent 
colonising genotype; defined as the same genotype isolated from all specimens (at 
least 5) from a patient collected over the study period. Nine patients also showed 
transient colonisation with genotypes other than the persistent coloniser genotype. 
Genotyping of sequential isolates from these patients revealed that each of the 
patients was colonised with strains of a predominant RAPD type which remained 
stable over a period of up to 6 years.  
3.1.2 Transmissible strains of Pseudomonas aeruginosa in CF patients 
Generally, it has been accepted that CF patients with chronic lung infections 
acquire a strain of P. aeruginosa from the environment  that, over time, becomes 
adapted to living in the niche environments within the CF lung and that these strains 
are usually unique to the patient in question (Fothergill et al. 2012). Phenotypic 
typing systems have previously suggested that CF siblings in close contact with one 
another often harbour the same P. aeruginosa strain, and it has been repeatedly 
confirmed that a single strain cross-infects in these cases (Speert & Campbell 1987; 
Grothues et al. 1988; Renders et al. 1997), as opposed to independent acquisition of 
a clonal strain. Independent acquisition of strains can occur when certain strains are 
naturally more abundant within the environment, hence increasing the likelihood 
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that multiple patients will acquire the same strain. Clone C, for example, is 
distributed worldwide and clone C strains are highly prone to infecting CF patients in 
several countries including the UK, Canada, and Germany (Römling et al. 2005) 
although the mechanisms of acquisition of the strain are unclear, and may vary 
completely from patient to patient. 
Since the 1980s studies have suggested that unique environmental 
acquisition may not exclusively be the method by which chronic P. aeruginosa 
infections are acquired by CF patients. A strain of P. aeruginosa caused an epidemic 
among patients attending a Danish CF centre early in 1983 and was described by 
Pedersen et al. (1986). Later, Cheng et al. (1996) reported that a high proportion of 
children in a single CF centre in Liverpool were colonised with a β-lactam resistant 
epidemic strain of P. aeruginosa. It was determined by use of PFGE and flagellin 
genotyping that 55 patients were infected with the same strain of P. aeruginosa, now 
known as the Liverpool Epidemic Strain (LES). Several years later a study conducted 
in an adult CF centre in Liverpool indicated that 63 out of 80 P. aeruginosa-positive 
patients were infected with the LES (Panagea et al. 2003).  
A nationwide study into the prevalence of transmissible strains of P. 
aeruginosa was undertaken by (Scott & Pitt 2004). Strains with unique genotypes 
were found to be harboured by at least 72% of all patients, although small clusters 
of related strains were found to be present in some centres, indicating limited 
transmission of local strains. The most prevalent strain was one indistinguishable 
from the previously described LES which accounted for approximately 11% of patient 
isolates from CF centres in England and Wales (Scott & Pitt 2004). The Midlands 1 
strain was found to be harboured by 86 patients in 9 centres, and the Manchester 
Epidemic Strain (MES) was found in 3 centres. Inter-patient transmission and 
superinfection by strains of P. aeruginosa are now accepted as common methods of 
infection among CF patients, yet lack of funding has impeded research into similar 
transmission events in non-CF bronchiectasis (NCFBr) patients. 
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3.1.2 Maintenance and transmission of Pseudomonas aeruginosa strains in non-
cystic fibrosis bronchiectasis patients 
Lack of research into the maintenance and transmission of P. aeruginosa 
strains among NCFBr patients has meant that many key issues regarding patient care 
that are addressed in CF guidelines, in particular the issue of segregation, have been 
ignored in the British Thoracic Society (BTS) guidelines for NCFBr patients (Pasteur et 
al. 2010). Work by De Soyza et al. (2014) was undertaken to investigate cross-
infection with P. aeruginosa among adult NCFBr patients attending a single centre. A 
total of 56 isolates were selected for analysis; 50 from 40 NCFBr patients, collected 
between 2008 and 2011, and 6 isolates from CF patients to be used a laboratory 
controls. This was undertaken at an adult bronchiectasis service in the north-east of 
England that is separate from the regional CF centre (situated 2 miles away). The 
service was started in 2007 as a weekly specialist clinic, with no Pseudomonas-
specific clinic. 36 patients who regularly attended the bronchiectasis service were 
randomly selected and paired longitudinal isolates were included from 10 patients 
with a mean of 16 months between isolates (2 – 35 months). Single isolates were also 
chosen from 4 NCFBr patients who did not attend the clinic and who had not been 
hospitalised to act as potential patient controls. Two genotyping methods were used 
in this study: AT genotyping (described in chapter 2) and variable number tandem 
repeat (VNTR) analysis based on the number of DNA repeats at specified sites across 
the genome at nine variable loci and comparison to a VNTR database.  
De Soyza et al. (2014) found that the vast majority of the 36 NCFBr patients 
harboured their own strains of P. aeruginosa. Four patients, 2 patients attending the 
clinic and 2 from the non-hospitalised control group, had distinct variants of clone C, 
which is found environmentally worldwide (Römling et al. 2005). Three pairs of 
patients from the remaining 34 attending the adult NCFBr service were found to 
harbour P. aeruginosa isolates which shared very similar profiles. For one pair of 
patients the similarity was confirmed by PFGE of SpeI-digested genomic DNA; the 
profile was unusual and the fact that the two patients shared a strain most likely 
reflects inter-patient transmission. Mapping of the NCFBr isolates among a wider 
population structure of P. aeruginosa isolates, based on AT genotype, demonstrated 
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that the NCFBr isolates were widely distributed and AT analysis found several 
matches with known clone types in the AT database. Data from the longitudinally 
paired isolates were compared and showed that in 9 of the 10 patients the first and 
second isolates were indistinguishable by both AT and VNTR, which confirms 
persistence of the initial strain. Longitudinal isolates from the final patient were 
identified as identical by VNTR typing but not by AT type. 
The key findings of this study were a lack of dominant clones of P. aeruginosa 
among the NCFBr population, with many patients harbouring “unique” strains, and 
little evidence of cross-infection among patients. Isolates from the NCFBr population 
were widely distributed, with little to no distinct clustering. Clone C was found in 6% 
of the NCFBr patients but is found widely in the environment; differences at several 
loci in the VNTR profiles of these isolates suggests that the isolates were 
independently acquired, as opposed to inter-patient transmission. Standard 
infection control and prevention measures are less stringent in NCFBr clinics than in 
CF clinics (De Soyza et al. 2014) and so the apparent absence of cross-infection by P. 
aeruginosa is unlikely to be due to the standards of infection control practice in 
NCFBr clinics.  
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3.2 Aims 
The aims of this chapter are to: 
1. Use AT genotyping to investigate the maintenance of P. aeruginosa 
strains in chronic lung infections in NCFBr patients over periods of 
up to 84 months; 
2. Compare four digit AT codes to those in databases from previous 
studies to place NCFBr P. aeruginosa isolates in the context of the 
wider P. aeruginosa population. 
3.3 Results 
3.3.1 Panel of isolates 
A collection of 48 isolates from 20 patients (table 3.1) regularly attending an 
adult bronchiectasis centre, separate from the regional CF centre, in the north east 
of England were selected based on the number of sequential isolates available for 
each patient, and the period of time between the collection of the early and late 
isolates. The minimum time period between collection of the early and late isolates 
was 12 months, although the period between collection of early and intermediate 
isolates was less than 12 months in some cases. The mean period between early and 
late isolate was 40 months (range 17 – 84). A total of 40 isolates were subjected to 
AT genotyping as part of this study, and the remaining 8 isolates (marked with an 
asterisk in table 3.1) included were previously analysed by (De Soyza et al. 2014). 
3.3.2 Array Tube hexadecimal codes 
The captured AT images were read and converted as described in chapter 2 
(appendix, table A3) and it was found that in 15 out of 20 patients, all isolates from 
each patient had the same hexadecimal code (figure 3.2). Patient 11 had a total of 4 
isolates with 3 different AT codes; the early and first intermediate isolates shared the 
same code but the second intermediate and late isolates both had vastly different AT 
codes. Patients 14 and 22 had no intermediate isolates and the early and late isolates 
had very different AT codes in both patients. Patient 30 had an early isolate, two 
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intermediate isolates and a late isolate; the early and late isolates shared an AT code 
and both the intermediate isolates shared a different AT code. The two codes varied 
only in the presence or absence of the fliCa genomic island. Patient 32 had only early 
and late isolates and the AT codes for the two isolates were very different.  
3.3.3 Array Tube accessory genome markers 
As well as the 17 core genome single nucleotide polymorphisms (SNPs) that 
determine the genotype of isolates, the AT has markers for 41 genomic islands and 
variable genes, including the PS21 marker for LES, which represent the accessory 
genome. The hybridisation at markers for genomic islands and variable genes shows 
presence or absence of the element in a particular isolate and the results were 
determined as described in chapter 2 (appendix, table A4). However, isolates sharing 
a core genotype may have variation in their accessory genomes.  Figures 3.3a and 
3.3b show AT images for isolates B21 and B22, both taken from patient 11. Both 
isolates share genotype C40A (clone C) but also share the same hybridisation pattern 
across the variable genes and genomic islands present on the AT chip. Conversely, 
figures 3.4a and 3.4b show AT images for isolates B79 and B113, both taken from 
patient 18, which also share a genotype (B420) but have variations in hybridisation 
at some of the genomic islands and variable genes present on the AT chip. Faint 
hybridisation is present at the markers for three genomic islands (C47, fla-island-1, 
and 47D7-1) and one variable gene (PA2185) in isolate B79 but no hybridisation is 
seen for these loci in isolate B113.   
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Table 3.1: Summary of isolates used in the longitudinal study. The table shows isolates 
used, their collection dates, and the time between the early isolate and subsequent 
isolates. Asterisk indicates that the isolate was included in data from De Soyza et al. (2014).  
Patient Isolate Date collected AT code Months since  
early isolate   
8 B1 Jul-08 0C1A     
8 B3 Nov-08 0C1A 4 * 
8 B7 Oct-14 0C1A 75   
9 B10 Oct-11 D421     
9 B16 Nov-13 D421 25   
10 B17 Jul-11 741E     
10 B20 May-13 741E 22   
11 B21 Jul-08 C40A     
11 B22 Jan-09 C40A 6 * 
11 B24 Jul-11 AC2E 36 * 
11 B35 Oct-14 3C2A 75   
12 B36 Jul-11 F42A     
12 B38 May-13 F42A 22   
13 B40 Oct-07 3C52     
13 B45 Nov-11 3C52 49   
14 B46 Oct-12 3C28     
14 B49 Oct-14 D421 24   
15 B50 Mar-11 AC2A     
15 B62 Sep-14 AC2A 42   
16 B63 Jul-11 F469     
16 B71 Jul-14 F469 36   
17 B72 Jun-08 239A     
17 B74 Jul-11 239A 42 * 
17 B77 Sep-13 239A 63   
18 B79 Oct-07 B420     
18 B84 Oct-08 B420 12 * 
18 B90 Jul-11 B420 45 * 
18 B113 Oct-14 B420 84   
19 B114 Apr-12 0C4A     
19 B126 Feb-14 0C4A 22   
20 B127 Oct-13 6852     
20 B139 Oct-14 6852 12   
21 B141 Jul-11 D421     
21 B150 Apr-14 D421 33   
22 B151 Nov-10 1BAE     
22 B152 Apr-12 2C12 17   
23 B156 Mar-09 059A     
23 B162 Sep-14 059A 66   
25 B164 Mar-12 CC60     
25 B169 Oct-14 CC60 31   
29 B185 Sep-11 4C8A     
29 B186 May-13 4C8A 20   
30 B187 Dec-07 682A     
30 B190 Jul-10 682E 31 * 
30 B192 Jul-11 682E 42 * 
30 B194 Sep-13 682A 69   
32 B199 Oct-11 F429     
32 B202 Aug-13 0C2E 22   
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Figure 3.2: Timelines of infection for all 20 patients included in the longitudinal study. The 
timelines show all isolates included in the longitudinal study, approximately when they were 
collected and the AT code assigned to them following genotyping. The colour of the arrow 
indicates number of loci in the 16 digit binary code that vary from the earliest isolate 
collected from that patient.  
 
 
Number of loci which are different from the 
genotype of the earliest isolate. 
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Figures 3.3a & 3.3b: AT images for isolates B21 and B22 from patient 11. Both isolates are genotype C40A (clone C) and also share the same hybridisation 
pattern at the markers which represent the accessory genome.  
 
 
Figure 3.3a: AT image for isolate B21. Figure 3.3b: AT image for isolate B22. 
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Figures 3.4a & 3.4b:  AT images for isolates B79 and B113 from patient 18.  Both isolates are genotype B420 but they do not share identical hybridisation 
patterns at the markers representing the accessory genome. Isolate B79 shows hybridisation for the markers for C471, fla-island-13, and 47D7-14 genomic 
islands and PA21852 variable gene. 
1 
3 2 4 
Figure 3.4a: AT image for isolate B79. Figure 3.4b: AT image for isolate B113. 
1 
3 2 4 
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3.3.4 Presence of highly prevalent Pseudomonas aeruginosa clones 
Analysis of the four digit AT codes found that several strains had matches with 
known clones in the AT database (Wiehlmann et al. 2007). Patients 9, 14, and 21 
harboured clone A which is represented by strain PA14 and is highly abundant 
throughout Europe. Patient 11 initially harboured clone C, although the two later 
isolates from this patient were of differing strain types: one unidentified clone and 
clone U.  
Figure 3.5 shows a comparison between the prevalence of 40 common clones 
of P. aeruginosa, as identified by Wiehlmann et al. (2007), in a compiled database of 
AT data from 1175 isolates from previous studies (Wiehlmann et al. 2007; Cramer et 
al. 2012; Shankar et al. 2012; Hall et al. 2013; Hall et al. 2014) and AT data from 61 
NCFBr isolates from this study (n = 24) and work by De Soyza et al. (2014) (n = 37). 
The isolates in the compiled dataset span a period of more than 70 years, with the 
earliest isolate having been collected in 1943,  and have been collected from 
countries around the world; including Germany, Japan, the UK, and the USA. The 
isolates in the compiled dataset come from a wide range of sources: animal, 
environmental, and clinical isolates from several sources including; chronic CF lung 
infections, chronic non-CF lung infections (i.e. COPD), acute lung infections, keratitis, 
and bacteraemia. The NCFBr dataset was compiled from AT data collected in this 
study and data from De Soyza et al. (2014). In order to reduce sampling bias, isolates 
from a patient which shared the same genotype were only included once per patient. 
For example, all four isolates collected from patient 18 (table 3.1) share the same 
genotype, B420, and so this AT code was only included as one entry for this patient 
in the dataset. 
In the compiled dataset 45.36% (533) of the isolates had AT codes that did 
not correspond to any of the 40 common clones (figure 3.5) previously identified by 
Wiehlmann et al. (2007); in the NCFBr dataset 57.38% (35) isolates did not have AT 
codes corresponding to any of the common clone types. In both datasets the most 
prevalent of the identified clones were clone A (D421) and clone C (C40A).  The 
prevalence of clone C (7.06%) was significantly higher than that of clone A (4.60%) in 
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the compiled dataset (P = 0.0134) but these two clones were present at the same 
prevalence in the NCFBr dataset (both 6.56%). Despite the apparent differences in 
percentage prevalence of each clone between the two datasets, a Fisher’s exact test 
showed that the differences in prevalence were not statistically significant (P = 
>0.05). Further statistical analysis revealed that the differences in prevalence 
between the two datasets for any of the clone types were not statistically significant 
(P = >0.05), possibly due to the small size of the NCFBr dataset in comparison to the 
compiled dataset from multiple geographical, clinical and environmental sources. 
There were also some clone types that were common in the compiled dataset 
(>1% prevalence) but were not found to be present in any of the NCFBr data. Clones 
B (2.81%, n = 33), F (1.62%, n = 19), H (1.28%, n = 15), P (1.28%, n = 15), and V (2.55%, 
n = 30) are among the most common clone types found in the general population of 
P. aeruginosa (figure 3.5) but they were not identified in data from this study or from 
De Soyza et al. (2014). Clones B, F, H, and V were identified from a wide range of 
sources (e.g. acute infections, environmental, CF, chronic obstructive pulmonary 
disease (COPD), and keratitis) and were found to be widespread across northern 
Europe and the USA. Clone P was isolated almost exclusively from CF patients in 
Germany, with three UK CF isolates and one environmental isolate from Belgium 
(Wiehlmann et al. 2007; Cramer et al. 2012; Shankar et al. 2012; Hall et al. 2013; Hall 
et al. 2014).
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Figure 3.5:  A comparison of the prevalence of common clonal strains of P. aeruginosa, as identified by Wiehlmann et al. (2007), in a compiled dataset (blue) 
from Wiehlmann et al. (2007); Cramer et al. (2012); Shankar et al. (2012); Hall et al. (2013); Hall et al. (2014), and data from this study combined with further 
NCFBr data from De Soyza et al. (2014) (orange).  The compiled database contains AT data for 1175 isolates from environmental, CF, and non-CF sources. The 
combined data from this study (n = 24) and from De Soyza et al. (2014) (n = 37) is made up of AT data from 61 isolates, with isolates being excluded when the 
same genotype was present more than once in an individual patient to reduce bias.  Although there are several genotypes for which the proportional 
representation within the given population seems to differ, the P values determined by Fisher’s exact test showed that the differences are not statistically 
significant (P = >0.05). 
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3.3.5 Population structure of non-cystic fibrosis bronchiectasis Pseudomonas 
aeruginosa isolates 
The population of NCFBr isolates, from this study and De Soyza et al. (2014), 
was analysed along with the wider population of P. aeruginosa isolates from the 
compiled dataset (Wiehlmann et al. 2007; Cramer et al. 2012; Shankar et al. 2012; 
Hall et al. 2013; Hall et al. 2014) using the eBURST algorithm (http://eburst.mlst.net) 
to determine the distribution of isolates from NCFBr patients amongst the wider P. 
aeruginosa population. The eBURST algorithm identifies mutually exclusive groups of 
related genotypes within a population. Details of how the algorithm was used to map 
the genotypes of these isolates can be found in chapter 2. Figure 3.6a shows the 
distribution of AT genotypes of NCFBr isolates from this longitudinal study alone 
among the wider population of isolates taken from environmental and other clinical 
sources. Figure 3.6b shows the distribution of AT genotypes combining NCFBr isolate 
data obtained in this study and from the earlier De Soyza et al. (2014) to provide a 
fuller representation of the population structure of P. aeruginosa isolates from NCFBr 
patients. Each node represents a defined strain type (ST) and lines between nodes 
represent a single locus difference between two nodes. The size of each node 
indicates the relative abundance of that particular genotype within the population. 
The eBURST diagram consists of one large main cluster of nodes, with the remaining 
smaller clusters (consisting 2 – 5 nodes) and single nodes distributed radially. All but 
8 of the 40 common clones described by Wiehlmann et al. (2007) are found in the 
main cluster of isolates (figure 3.7). As well as being well distributed among the main 
cluster of nodes, several genotypes from NCFBr isolates are located individually or as 
part of smaller clusters away from the main group (figures 3.6a & 3.6b). Hence, NCFBr 
isolates are widely distributed amongst the general population of P. aeruginosa. 
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Figure 3.6a: eBURST diagram showing the distribution of P. aeruginosa genotypes identified in this study among the general population. eBURSTv3 
(http://eburst.mlst.net), developed and hosted by Imperial College London (Feil et al. 2004; Spratt et al. 2004), was used.  
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Figure 3.6b: eBURST diagram showing the distribution of P. aeruginosa genotypes identified in this study and by De Soyza et al. (2014) among the general 
population. eBURSTv3 (http://eburst.mlst.net), developed and hosted by Imperial College London (Feil et al. 2004; Spratt et al. 2004), was used.  
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Figure 3.7: eBURST diagram showing the distribution of the 40 common P. aeruginosa clones as described by Wiehlmann et al. (2007). eBURSTv3 
(http://eburst.mlst/net), developed and hosted by Imperial College London (Feil et al. 2004; Spratt et al. 2004), was used. 
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3.3.6 Poor hybridisation at exoS and exoU variable gene markers 
It had been noted previously that one of the more serious limitations of the 
AT system is poor hybridisation at some markers on the chip (Hall 2015, personal 
communication), leaving interpretation of the results open to ambiguity. In 
particular, hybridisation was frequently poor at the markers for exoS and exoU 
variable genes. Figures 3.8a and 3.8b are AT images from isolates B164 and B169 
(table 3.1) respectively. When the AT images were read initially, B164 was assigned 
the code CC60 and B169 was assigned the code CC62; the difference in codes was 
due to the variance in exoS hybridisation. In figure 3.8b there appears to be faint 
hybridisation at the exoS marker although there is no hybridisation at either exoS or 
exoU in figure 3.8a. A PCR assay was carried out using specific primer sets (table 2.1) 
to determine the presence or absence of both variable genes. Gel electrophoresis 
was performed on the PCR products and the results are shown in figure 3.9. Both 
B164 and B169 were confirmed negative for both exoS and exoU, despite the original 
decision that B169 was positive for exoS, which resulted in the two isolates appearing 
to be of differing strain types. Similarly, isolates B1 and B7 were originally assigned 
different AT codes (0C1C and 0C1A respectively). Figure 3.10a and 3.10b are AT 
images for isolates B1 and B7 (table 3.1), in which there appears to be no 
hybridisation at either exoS or exoU markers in figure 3.10a and faint hybridisation 
at exoS marker in figure 3.10b. A PCR assay was also carried out on these isolates and 
showed that both B1 and B7 were positive for exoS (figure 3.11). There were 8 other 
isolates for which PCR assays were needed to determine the presence or absence of 
the exoS and exoU variable genes (figures 3.12a & 3.12b). 
3.3.7 Transmissible strains of Pseudomonas aeruginosa in non-cystic fibrosis 
bronchiectasis patients 
As part of the initial PCR screening of the panel of isolates (chapter 2.2), four 
isolates taken from patient 10 tested positive for MID1, indicating that they were the 
Midlands 1 strain of P. aeruginosa (figure 3.13). Two of these isolates were 
subsequently selected as a pair of longitudinal isolates to undergo AT genotyping 
(isolates B17 and B20). However, both isolates were assigned AT code 741E, which is 
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not consistent with the previously defined AT code for the Midlands 1 strain, 2C1A 
(Wiehlmann et al. 2007).  Hence, these were in fact false PCR-positives.
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Figures 3.8a & 3.8b: AT images for isolates B164 and B169 from patient 25. Highlighted are hybridisation markers for the exoS and exoU variable genes.  
In figure 3.8a there is no clear hybridisation at either variable gene. However, in figure 3.8b there appears to be faint hybridisation at exoS.  
Figure 3.8a: AT image for isolate B164 Figure 3.8b: AT image for isolate B169 
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Figure 3.9: PCR assay using primers to detect exoS and exoU variable genes performed on patient 25 isolates to confirm hexadecimal AT code with PAO1 and 
PA14 serving as positive controls respectively. Both B164 and B169 showed no amplification of either region. Gel electrophoresis performed on 1.5% agarose 
gel at 50 V for approximately 2 h. Marker: 1 KB+ DNA ladder (Invitrogen).  
118 bp 134 bp 
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Figures 3.10a & 3.10b: AT images for isolates B1 and B7 from patient 8. Highlighted are the hybridisation markers for the exoS and exoU variable genes. There 
is no visible hybridisation at either exoS or exoU markers in figure 3.10a. There is faint hybridisation at the exoS marker in figure 3.10b. 
  
Figure 3.10a: AT image for isolate B1 Figure 3.10b: AT image for isolate B7 
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Figure 3.11: PCR assay using primers to detect exoS and exoU variable genes performed on isolates from patient 8 to confirm hexadecimal AT code with PAO1 
and PA14 serving as positive controls respectively. Both B1 and B7 appear show strong amplification of exoS regions and no amplification of exoU region. Gel 
electrophoresis performed on 1.5% agarose gel at 50 V for approximately 2 h. Marker: 1 KB+ DNA ladder (Invitrogen). 
 
.
118 bp 134 bp 
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Figure 3.12a: PCR assay to determine presence of exoS variable gene in P. aeruginosa 
isolates. PAO1 was used as a positive control. Isolate X was assayed in the same run as other 
isolates but is not part of this study. Marker: 1 KB+ DNA ladder (Invitrogen).  
 
 
Figure 3.12b: PCR assay to determine presence of exoU variable gene in P. aeruginosa 
isolates. PA14 was used as a positive control. Isolate X was assayed in the same run as other 
isolates but is not part of this study. Marker: 1 KB+ DNA ladder (Invitrogen). 
 
118 bp 
134 bp 
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Figure 3.13: Multiplex PCR assay using primers to determine presence of MES and Midlands 1 epidemic strain of P. aeruginosa. All 4 isolates tested come 
from patient 10 and appear to be positive for MID1. Gel electrophoresis performed on 1% agarose gel at 90 V for approximately 1 h. Marker: 1 KB+ DNA 
ladder (Invitrogen). 
649 bp 
308 bp 
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3.4 Discussion 
3.4.1 Maintenance of Pseudomonas aeruginosa strains in non-cystic fibrosis 
bronchiectasis patients 
There have previously been very few studies investigating populations of P. 
aeruginosa among NCFBr patients. In fact, there have been very few long-term 
studies investigating the progression of NCFBr as a disease. Studies that have been 
performed (Wilson et al. 1997; Loebinger et al. 2009), though often not published in 
recent years, implicate P. aeruginosa chronic infection in an increase in morbidity 
and mortality. In early studies P. aeruginosa infection was shown to lead to increased 
disease progression, with a more rapid decline in lung function (Evans et al. 1996; 
Wilson et al. 1998), although the role of P. aeruginosa as a source or marker of  
disease progression was unclear. The study by Loebinger et al. (2009) examined a 
large number of variables in disease progression, and those that were determined 
not to be independently predictive were discarded to provide a multivariate 
modelling strategy to draw mechanistic conclusions from, as opposed to a predictive 
tool for individual patients. By this method Loebinger et al. (2009) suggested that P. 
aeruginosa infection in NCFBr patients was more likely to impact on survival than to 
act as a marker of severity of disease. It is, therefore, important to understand the 
population of P. aeruginosa within NCFBr patients in order to better understand 
disease progression, given that there are many known mutations associated with 
chronic infection in CF patients (Smith et al. 2006; Amiel et al. 2010; Bjarnsholt et al. 
2010; Manos et al. 2013). 
A small longitudinal study of isolates from NCFBr patients was undertaken by 
De Soyza et al. (2014) as a part of a study investigating the occurrence of cross-
infection in NCFBr patients from a single adult clinic. Aside from this, there has been 
no further study into the maintenance of strains of P. aeruginosa in chronically 
infected NCFBr patients. This work builds upon the data from De Soyza et al. (2014) 
to provide evidence of maintenance of clonal strains of P. aeruginosa in NCFBr 
patients.  
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In 15 of the 20 patients from whom isolates were collected for this study, the 
same strain of P. aeruginosa was maintained over a mean (range) period of 40 
months (12 – 84 months), indicating that for the majority of patients infection with 
the same strain can be maintained for considerable periods of time. Two of these 
patients, 9 and 21 (table 3.1), were chronically infected with P. aeruginosa clone A 
(D421). Isolates from patients 9 (B10 and B16) were not only categorised as the same 
clonal type of P. aeruginosa by analysis of the SNPs and variable genes on the AT chip, 
but they also shared an identical hybridisation pattern for the markers used to 
represent the accessory genome (genomic islands and further variable genes). 
Isolates B141 and B150 from patient 21 shared AT codes but varied in hybridisation 
at the variable gene and genomic island markers. The early and late isolates for 
patient 21 (B141 and B150 respectively) were collected 33 months apart. Although 
the strain type appears to have been maintained, the data suggest that the accessory 
genome of the strain has undergone some changes. The late isolate has lost a 
genomic island and a variable gene that was present in the early isolate but also 
appears to have gained a genomic island not present in the early isolate. These 
changes in the accessory genome are most likely evidence of the occurrence of 
horizontal gene transfer between P. aeruingosa strains within the lungs of the 
patient. The early isolate (B141) was positive for both pyoverdine receptor types 3 
and B variable genes (figure 2.2) whereas the late isolate (B150) is only positive for 
pyoverdine receptor type B (Stover et al. 2000; de Chial et al. 2003). The late isolate 
also exhibits no hybridisation at the fla-2 orfA and fla-2 orfJ genomic island markers, 
which indicates a loss of the genomic island essential for glycosylation of flagellin 
(Arora et al. 2004) and shows hybridisation at the C47 marker, which indicates the 
presence of a strain-specific gene island into a tRNAGly gene (Larbig et al. 2002).   
These apparent changes in the accessory genome could be explained in a 
number of different ways.  It is possible that the infecting strain population has 
changed due to environmental factors driving adaptation and evolution of the P. 
aeruginosa populations, as has been described in a number of CF studies (Thomas et 
al. 2000; Ciofu et al. 2005; Smith et al. 2006; Fothergill et al. 2010a). This may be due 
to new regimens of treatment, changes in patient lifestyle, other members of the 
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microbial community, host responses or other factors influencing the conditions 
present in the lung environment in which the bacteria thrive.  However, it has been 
reported in CF that during chronic infections, P. aeruginosa populations diversify 
both phenotypically and genomically (Mowat et al. 2011; Workentine et al. 2013; 
Williams et al. 2015).  It has been shown that genomic instability, in particular the 
transfer of genetic material between strains, can lead to misleading results when 
various genotyping methods are used (Fothergill et al. 2010a; Worby et al. 2014). 
These observations also reflect the intra-population diversity that occurs in CF, with 
accessory genome variations very common. It has been demonstrated in CF patients 
that multiple divergent lineages of P. aeruginosa can co-exist within a single 
chronically infected patient. Work by Williams et al. (2015) sought to investigate the 
diversity of P. aeruginosa isolates within CF patients using whole genome sequencing 
of 40 isolates from 9 patients. Initially, one patient was found to have two divergent 
lineages (A and B) sharing a common ancestor. Lineage A was characterised by 55 
shared SNPs, whilst lineage B shared 24 SNPs. A difference of 79 SNPs separated the 
co-existing lineages, however only 42 SNPs separated the most recent common 
ancestor (MRCA) from the earliest known LES (LESB58), used as a reference genome. 
In addition to this patient, two divergent lineages were found to be present in a 
further 6 of the 8 remaining patients, indicating that the plasticity of the P. 
aeruginosa genome may regularly allow for in-patient diversity of chronic strains 
(Williams et al. 2015). Hence, the observations in this study could reflect the fact that, 
as in CF, P. aeruginosa populations in the NCFBr lung can diversify and exhibit 
genomic instability.  Due to the analysis of only a single isolate per patient, per time 
point in this study it is not possible to confirm this explanation of accessory genome 
variation from the data obtained. 
One other patient (14) was also infected with P. aeruginosa clone A (D421), 
although in this case clone A was only present in the late isolate collected 24 months 
after the early isolate, and varied from the early isolate by 6 SNPs in the AT binary 
code. The hybridisation of variable genes and genomic islands in this isolate (B49) 
were notably different to those of any of the other four isolates with the D421 AT 
code, indicating that these isolates were likely not shared among the patients and 
87 
 
were acquired environmentally, which is unsurprising given the prevalence of clone 
A in the environment among the general population of P. aeruginosa (figure 3.14). 
3.4.2 Pseudomonas aeruginosa strains from non-cystic fibrosis bronchiectasis 
patients in the context of the wider CF population 
There have been many attempts to elucidate the population structure of P. 
aeruginosa in an attempt to better understand the acquisition of bacterial infection 
and the pathogenicity of strains found in clinical isolates although there is a general 
consensus that clinical isolates of P. aeruginosa are generally indistinguishable 
genotypically, chemotaxically, and functionally from environmental isolates (Pirnay 
et al. 2002). It was noted by Römling et al. (1994) that the major clone (C) identified 
in CF patients (28%) was also present at a high frequency in aquatic environments 
(21%). By use of outer membrane lipoprotein gene sequences (oprI, oprL, and oprD), 
DNA fingerprinting, serotyping, and pyoverdine type Pirnay et al. (2002) concluded 
that P. aeruginosa has an epidemic population structure, similar to that of Neisseria 
meningitidis (Feil et al. 2001), comprised of a number of widespread clones 
originating from a larger number of unrelated genotypes. These clones are abundant 
and widespread throughout the natural environment, with no discernible correlation 
between habitat or geographical location and clone type, and are therefore expected 
to be prevalent in clinical isolates. Investigation into the population structure of P. 
aeruginosa was later revisited by this group in 2009, using a wide range of traits to 
analyse a network of relationships between 328 unrelated P. aeruginosa isolates. 
This work confirmed the nonclonal epidemic population structure; providing a view 
of a superficially clonal structure in which frequent recombination occurs and 
successful epidemic clones occasionally arise (Pirnay et al. 2009).  
Further work carried out by Cramer et al. (2012) also confirmed this 
population structure among a large database of P. aeruginosa isolates from CF 
centres, aquatic environments, patients with ventilator associated pneumonia (VAP), 
keratitis, or patients with COPD. There was no evidence of a widespread 
transmissible clone among CF patients, and the five most common clones found in 
CF patients were found to be among the ten most common clones found in the 
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environment and in VAP, COPD, and keratitis (Cramer et al. 2012).  Conversely it has 
been demonstrated that certain genetic characteristics are implicated in the 
adaptation of P. aeruginosa to cause corneal infections (Stewart et al. 2011; Shankar 
et al. 2012). A set of 63 isolates underwent AT genotyping and were analysed by 
Stewart et al. (2011). Using eBURSTv3 it was shown that the majority of keratitis 
isolates were represented in a closely related sub-group of P. aeruginosa. Twitching 
motility, due to type IV pili, in P. aeruginosa is associated with keratitis infection and 
46% of isolates with the most common serotype found in keratitis (O11) were found 
to carry a distinctive pilA which encodes the pilin of type IV pili. This indicates that 
keratitis isolates are associated with specific characteristics and, therefore, that a 
subpopulation of P. aeruginosa is adapted to cause corneal infection (Stewart et al. 
2011). Work by Shankar et al. (2012) also investigated clustering of P. aeruginosa 
isolates from keratitis infections. A total of 123 isolates were collected over two 
different time periods (2003 – 2004 and 2009 – 2010) and analysed using the AT 
genotyping system. When compared to a database of isolates from a non-ocular 
origin it was discovered that 71% of the UK keratitis isolates clustered together, with 
no major evidence for variations in the distribution of the clone types between the 
two collections. The “core keratitis cluster” appeared to be related to the P. 
aeruginosa eccB clonal complex which is associated with an adaptation to survive in 
water, suggesting that adaptation to an aquatic environmental habitat is a key factor 
in the ability of P. aeruginosa isolates to cause ocular infections (Shankar et al. 2012). 
There appeared to be no such clustering or associations within this collection 
of NCFBr isolates. The eBURST diagrams in figures 3.6b and 3.7 show the distribution 
of genotypes found in NCFBr isolates and 40 common clone types (Wiehlmann et al. 
2007) respectively among the general population of P. aeruginosa isolates from a 
compiled dataset (Wiehlmann et al. 2007; Cramer et al. 2012; Shankar et al. 2012; 
Hall et al. 2013; Hall et al. 2014; De Soyza et al. 2014). Comparison of the two 
diagrams shows that the distribution of NCFBr isolates is similar to that of the 
abundant and widely distributed clones described by Wiehlmann et al. (2007), 
indicating that there are no widespread epidemic clones present in the NCFBr 
population, much like the population of CF isolates. Figure 3.14 shows the sources 
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from which genotypes found in this study have previously been isolated. Many 
genotypes have been isolated from multiple sources, both clinical and 
environmental, although genotypes 059A, 0C4A, and AC2E have only previously been 
isolated in patients with CF (figure 3.14). The 16 most common of the 40 clones 
described by Wiehlmann et al. (2007) (those with a frequency of ≥1% in the compiled 
dataset) were generally isolated from a wide range of sources, with a broad 
geographical spread.  
Some isolates with novel genotypes (meaning they had not previously been 
described in the compiled dataset) were also present in this NCFBr data. Six 
genotypes (3C28, 6852, CC60, 4C8A, 682A, and 682E) from isolates in five patients 
had no matches with isolates previously identified by the AT genotyping method. 
Genotypes 6852 and CC60 are represented in figure 3.6b as single nodes, distributed 
radially away from the main cluster of genotypes whereas the remaining novel 
genotypes are present in the main cluster. Genotype 3C28 is only present in the early 
isolate of patient 14. The late isolate from this patient was collected 24 months later 
and was identified as clone A (D421). It is possible that patient 14 acquired a unique 
strain of P. aeruginosa (i.e. ST 3C28) independently from the environment which was 
subsequently replaced by the common clone A. It is also possible that this patient 
was continuously co-infected with both strains, but by sampling only one isolate per 
patient per time point we are unable to determine the exactitudes of this patient’s 
infection. 
Clone P (6C2A) was almost exclusively found in CF patients from Germany and 
the UK, with one isolate being collected from an environmental water source in 
Belgium (Wiehlmann et al. 2007; Cramer et al. 2012; Shankar et al. 2012; Hall et al. 
2013; Hall et al. 2014) but was not found to be present in the NCFBr data. Isolates of 
this clone type were collected from CF patients at clinics in Hannover, Jena, and 
Frankfurt between 1996 and 2001 (Wiehlmann et al. 2007), and from CF patients in 
Liverpool, UK (Hall et al. 2013). Although there is no evidence of clustering of P. 
aeruginosa isolates from CF patients, the limited sources from which this clone has 
been previously isolated is interesting. It is possible that it does not fall within the 
“core keratitis cluster” as described by Shankar et al. (2012) and so is not adapted to 
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cause ocular infection, and therefore is not recovered from keratitis patients. There 
may also be sampling bias in the compiled dataset, in that many of the isolates were 
collected in order to study P. aeruginosa populations within CF patients or clinics and 
so the clone appears to be recovered more frequently from CF patients than the 
environment. In the case of this study, isolates were collected from patients 
attending only one bronchiectasis service which is geographically separate from the 
regional CF centre. It is possible that in a study including a wider range of 
bronchiectasis services, including some which share facilities with a CF service, that 
this clone would also be recovered from NCFBr patients.  
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Figure 3.14: Sources of genotypes identified in this study that have previously been identified in the compiled dataset (Wiehlmann et al. 2007; Cramer et al. 
2012; Shankar et al. 2012; Hall et al. 2014). Genotypes which showed no match with the compiled dataset were not included. 
0
10
20
30
40
50
60
70
80
90
N
u
m
b
er
 o
f 
is
o
la
te
s
AT Code
CF Acute infection Environment COPD Keratitis Animal infection
92 
 
3.4.3 Epidemic strains of P. aeruginosa in NCFBr patients 
Transmissible (epidemic) strains of P. aeruginosa have been a major concern 
in CF units, and they can have severe consequences in terms of morbidity and 
mortality. After the initial description of the LES by Cheng et al. (1996) further work 
was carried out to investigate the possibility of superinfection by transmissible 
strains of P. aeruginosa. Four adult patients who had previously been colonised with 
unique strains of P. aeruginosa were studied after transferring from either a local 
paediatric CF centre or a distant hospital CF clinic to the regional adult centre 
(McCallum et al. 2001). Longitudinal monitoring of sputum samples from these 
patients revealed that after inpatient stays they had become superinfected with the 
strain referred to as AH (LES). In two of the four patients, after a number of months 
only strain AH was cultured from sputum samples. In the case of the remaining two 
patients other strains that had previously been isolated from sputum samples were 
also present alongside strain AH (McCallum et al. 2001). Once it had been established 
that superinfection by LES was a threat among mixed populations of P. aeruginosa-
positive individuals it became important to discover the effects of infection with an 
epidemic strain on patient health and survival. It was shown by Al-Aloul et al. (2004) 
that a group of CF patients infected with the LES experienced a greater deterioration 
in pulmonary function and nutritional state than paired LES-negative patients. 
Chronic infection with LES also led to an increased treatment burden on the affected 
patients. Given that LES tends to be multiresistant to antipseudomonal antibiotics 
this increased burden is important as it has been shown that the repeated use of 
antibiotics to which the strain is susceptible are nephrotoxic and cause renal damage 
in CF patients (Al-Aloul et al. 2002). Antibiotic resistance tends to increase in both 
LES and other strains of P. aeruginosa over time in chronically infected patients, 
although the LES has been found to exhibit significantly higher levels of resistance in 
collected isolates (Ashish et al. 2012). 
Very little is known about cross infection in relation to NCFBr patients 
infected with P. aeruginosa.  In this cohort of patients, no known UK CF transmissible 
strains were found. As part of initial screening, all isolates were assayed by PCR for 
LES, Midlands 1 (Scott & Pitt 2004), and Manchester epidemic strain (Jones et al. 
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2001) (table 2.1) and all 4 isolates collected from patient 10 tested positive for MID1, 
the marker for the Midlands 1 transmissible strain (figure 3.13). However, the 
Midlands 1 strain isolates assayed as part of work by Smart (2007) correspond to AT 
code 0C1A whereas isolates B17 and B20 were assigned code 741E. The MID1 
primers were designed using suppression subtractive hybridisation (SSH) by Smart et 
al. (2006) as a diagnostic test for use in CF centres to rapidly identify patients with 
epidemic strains of P. aeruginosa. Through the use of SSH, sequences from the 
accessory genome of various P. aeruginosa strains were compared to identify 
sequences unique to the Midlands 1 strain. The MID1 primers (table 2.1) target a 
bacteriophage-related site-specific recombinase (Smart, Walshaw, et al. 2006). The 
observations presented here suggest that the selection process used was not 100% 
effective at ensuring that the target sequence was specific for the Midlands 1 strain.  
This is the first reported example of a false PCR-positive for the Midlands 1 strain and 
it suggests that there are other strains of P. aeruginosa that share this accessory 
genome region. Work by Fothergill et al. (2010) investigated anomalous results of 
PCR assays to detect LES isolates from CF patients. The diagnostic PCR for LES uses 
two primer sets (table 2.1): PS21 and LESF9. Originally the PS21 marker was tested 
alone as a marker for LES-positive isolates, but false positives were recognised (Lewis 
et al. 2005; Smart, Walshaw, et al. 2006) and so the test was expanded to include the 
LESF9 marker (Smart et al. 2006a; Fothergill et al. 2008). Fothergill et al. (2010) 
identified four false positives and 11 false negatives for the PS21 marker from a panel 
of 24 isolates. Analysis also revealed 10 false positives and one false negative for the 
LESF9 marker (Fothergill, White, et al. 2010). There were also three false positives for 
both PS21 and LESF9 markers. The large size of the P. aeruginosa genome and, in 
particular, the plasticity of its accessory genome means that it is likely that 
bacteriophage-related sequences are shared among more than one strain of the 
bacteria, leading to false positives in the diagnostic PCR.   The data presented here 
further confirms the need for using more than one typing method in order to 
unequivocally identify strains.  
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3.5 Conclusions 
The main conclusions that can be drawn from this study are: 
1. In the majority of NCFBr patients with chronic P. aeruginosa 
infections, infecting strains of P. aeruginosa are maintained; 
2. Strains of P. aeruginosa isolated from NCFBr patients are widely 
distributed in much the same way as the general population. 
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Chapter Four 
Use of genome sequencing to study the 
diversity of Pseudomonas aeruginosa 
isolates from non-cystic fibrosis 
bronchiectasis patients 
4.1 Introduction 
4.1.1 Diversity of Pseudomonas aeruginosa isolates in cystic fibrosis patients 
There have been many studies undertaken into the genetic diversity of P. 
aeruginosa isolates in cystic fibrosis (CF) patients, using many different methods (Hall et 
al. 2013), in order to establish the prevalence of certain strains of P. aeruginosa (Cramer 
et al. 2012), investigate the methods by which the bacterial population adapts from an 
environmental habitat to the lungs (Marvig et al. 2014), and the effects of selective 
pressures, such as the administration of intravenous antibiotics, on P. aeruginosa 
populations (Fothergill et al. 2010a). The diversity of P. aeruginosa populations can be 
studied at different levels, such as within-patient, inter-patient, and both nationwide 
and globally (Freschi et al. 2015), and using techniques of varying degrees of depth. 
During chronic infection P. aeruginosa exhibits both adaptation and 
diversification, and the mechanisms underlying many of the chronic-stage adaptations, 
such as the switch to a mucoid phenotype and a loss of motility (Govan & Deretic 1996; 
Goodman et al. 2004), have been well established. The acquisition of mutations in 
important regulatory genes can happen rapidly following initial infection in the CF lung 
environment (Wilder et al. 2009; Rau et al. 2010). The conditions experienced by 
bacterial populations living within the CF lung environment are the drivers of these 
mutations, which can confer a selective advantage in niche environments. Mutation 
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commonly occurs in the gene encoding the quorum sensing regulator LasR. In 
comparison with wild type strains lasR mutants exhibit a significant metabolic shift with 
decreased oxygen consumption and increased nitrate utilisation, both of which are 
predicted to offer increased fitness in the nutrient conditions provided in CF lungs 
(Hoffman et al. 2010). This shift by the lasR mutants also conferred increased resistance 
to tobramycin and ciprofloxacin, both of which are commonly used in CF care. Selection 
for resistance in these mutants in vitro did not require previous antibiotic treatment. 
Increases in antibiotic resistance among strains of P. aeruginosa have been previously 
reported, particularly among the Liverpool Epidemic Strain (LES) (Salunkhe et al. 2005; 
Ashish et al. 2012) and among hypermutator strains that are commonly found in CF 
patients (López-Causapé et al. 2013). To further investigate the genotypic changes 
experienced by P. aeruginosa isolates inhabiting the CF lung the genomes of 12 isolates, 
including 4 environmental isolates, underwent whole genome sequencing and 
comparative genomic analysis (Stewart et al. 2014). Paired nonmucoid and mucoid 
isolates from three separate patients were compared. Analysis revealed that two of 
these three pairs were derived from the same strain and that the third pair was not, 
suggesting that this patient may be suffering either a multi-strain infection or undergoing 
a strain succession event (Stewart et al. 2014). One of the related pairs of isolates was 
found to be near-isogenic but it was noted that the mucoid strain had a smaller genome 
than that of its nonmucoid progenitor. Significant evidence for genome shrinkage during 
bacterial adaptation to a host has previously been observed (Toft & Andersson 2010) 
and it is possible that shrinkage occurred in the case of this pair of isolates. Notably the 
mucoid isolate is lacking the filamentous phage PF1 and the exoY gene, due to a 65 kbp 
deletion relative to its putative parental strain (Stewart et al. 2014). The core genomes 
of 55 isolates, including the 12 sequenced isolates, were also analysed using a core 
genome threshold of 55 and sequence identity of 90%. Only one isolate of these 55 was 
found to be closely related to taxonomic outlier PA7 (Roy et al. 2010) and the remainder 
fell into one of two major subgroups of P. aeruginosa known as group 1 and group 2 
(Stewart et al. 2014). Group 1 was the larger of these two groups and contains notable 
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strains DK2, PAO1, LESB58, and PAK. Group 2 is significantly less populous than group 1 
and contains PA14. Isolates from all sources, including CF sputum, were found to be well 
represented in both groups but at present it is unclear whether group 1 isolates are 
naturally more abundant than group 2 isolates or if a bias has been introduced due to 
selection of strains for sequencing projects (Stewart et al. 2014). 
Much of the previous work undertaken to investigate changes in P. aeruginosa 
populations in CF patients has been designed to reveal the genetic changes over the 
course of a longitudinal study, meaning that often only single isolates are taken per 
patient and analysed at the cost of sampling depth. Evidence from phenotypic studies 
has suggested that there is widespread heterogeneity among isolates from individual 
patients (Mowat et al. 2011; Workentine et al. 2013) and so extensive sampling for 
whole genome sequencing was undertaken to further understanding of the diversity of 
P. aeruginosa isolates from CF patients. A total of 360 isolates were collected from 9 
patients attending an adult CF centre in Liverpool, UK to undergo whole genome 
sequencing in order to ascertain the diversity among 40 isolates per patient sputum 
sample. The patients were all known to have been LES positive for a number of years 
prior to the study (Williams et al. 2015). Isolates from all nine patients were analysed, 
revealing that 7 of the 9 patients harboured coexisting, divergent lineages of the LES. 
These divergent lineages were typically found to be more closely related to lineages 
found in other patients than to each other. Other studies have also highlighted within-
population variation for P. aeruginosa during CF infections (Darch et al. 2015; Diaz 
Caballero et al. 2015; Jorth et al. 2015). There are obvious clinically-relevant 
consequences to this. It has been shown that conventional antimicrobial susceptibility 
tests, which rely on a single isolate to represent infection, are not accurate predictors of 
response to therapy (Smith et al. 2003) and this may be in part due to the apparent 
diversity of isolates within chronically infected patients (Williams et al. 2015). 
A study carried out in a Danish CF centre (Marvig et al. 2014) sought to further 
understanding of how P. aeruginosa evolves during long-term infection in human hosts 
by sequencing whole genomes of 474 isolates collected from the airways of 34 children 
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and young adults with CF (aged between 1.4 and 26.3 years). The collection of isolates 
was intended to give insight into the longitudinal progression of the early stages of P. 
aeruginosa infection and so the initial and several subsequent isolates from each patient 
were selected for sequencing. From these 474 isolates 53 genetically distinct clonal 
groups were identified. Genomes from isolates with the same clone type differed on 
average by 122 single nucleotide polymorphisms (SNPs) (median: 9 SNPs, range: 0 – 1 
333 SNPs). Genomes from isolates in different clonal complexes differed by >10 000 
SNPs. 10 clone types were identified that were present in multiple patients. In 19 of 
these patients the genomes of the isolates were found to be separated by at least 50 
SNPs and, taking into account the average mutation rate of P. aeruginosa within patients 
(2.6 SNPs/year) (Marvig et al. 2013), it was concluded that the presence of the same 
clone type in these patients was unlikely to be due to recent or direct transmission 
between the patients. Alternatively, the presence of these genetically distant clonal 
isolates may be due to transmission from a patient not included in this study or as a 
result of independent acquisition of a prevalent clone from the environment (Marvig et 
al. 2014). In a few cases (5 patients) the difference between clonal isolates from different 
patients were only a few SNPs (range = 0 – 29) which suggested the occurrence of recent 
interpatient transmission events. Information on patient visits was retrieved and 
confirmed that in all cases of suspected patient-to-patient transmission there were 
overlaps in the patients’ time spent in the hospital. Heterogeneity of P. aeruginosa 
within patients can mislead attempts to elucidate the direction and source of 
transmission (Worby et al. 2014), although it is suspected in this case that the clone types 
were transmitted from the older patients, in whom the clones were identified first, to 
the younger patients.  
The diversity of P. aeruginosa isolates among CF patients varies worldwide. Many 
different studies, covering centres across various countries, have drawn conclusions 
about the precautions necessary for infection control within their respective CF centres. 
In one study in the UK the majority of patients were found to harbour their own unique 
strains of P. aeruginosa although around one fifth of those sampled carried one of two 
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epidemic strains (LES and Midlands 1) (Scott & Pitt 2004). A third common genotype 
previously identified in Germany (Dinesh et al. 2003), clone C, was also widespread in 
UK CF centres. The LES accounted for 11% of isolates in this study and was found to be 
present in 48% of centres surveyed. The Midlands 1 strain was also highly prevalent and 
accounted for 10% isolates, being found in 29% of centres. The findings were unexpected 
but provided strong evidence of cross-infection both within and between UK CF centres 
(Martin et al. 2013). More recently whole genome sequencing has been used to further 
understanding of the LES. The genomes of seven LES (UK) and LESlike (Canada) isolates 
were sequenced in order to undertake comparative genomic analysis (Jeukens et al. 
2014).In six of the seven isolates at least one large deletion (40 – 50 kbp) was revealed 
in comparison to the LESB58 reference genome. These deletions were shown to 
correspond to prophages which have been previously shown to increase the 
competitiveness of LESB58 in chronic lung infections (Jeukens et al. 2014). A further 308 
non-synonymous polymorphisms were identified, of which 28 were found to be 
associated with virulence determinants and 52 with regulatory proteins. The majority of 
the regulatory mutations were shown to be isolate-specific and 29% were predicted to 
have a high functional impact implicating polymorphism in regulatory genes in variations 
in phenotype between LES isolates (Jeukens et al. 2014). 
Two separate studies were carried out in different provinces in Canada (Ontario 
and British Columbia) and arrived at differing conclusions regarding the risk of 
interpatient transmission. In Ontario 22% of 446 patients were found to be infected with 
one of two transmissible strains. One strain (LES) was found to be present in 15% of 
patients and the second strain, not previously identified as epidemic, was found in 7% 
of patients; 3 patients (0.6%) were found to harbour both of these strains (Aaron et al. 
2010). Conversely, in British Columbia there were 157 genotypes identified from isolates 
collected and 123 of these were unique to individual patients. Only 34 types were shared 
by two or more patients and these were proved to be epidemiologically linked only in 
the case of 10 pairs of siblings and one unrelated pair of patients. It was concluded that 
the risk of transmission of P. aeruginosa between CF patients in British Columbia was 
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low (Speert et al. 2002). However, Canada is a vast country and both provinces are large 
(Ontario: >1 M km2; British Columbia: >900 K km2) and sparsely populated, and 
separated by a distance of over 1000 km meaning that differences in CF patient 
experience are not completely unexpected. 
Patients in Australia underwent a large-scale study to investigate P. aeruginosa 
populations across the country. More than 60% of patients sampled were found to 
harbour a strain of P. aeruginosa indistinguishable from those found in at least one other 
patient. Small areas of clustering were found among populations in small centres but 
AUST-01 and AUST-02 strains were found to be highly prevalent across all centres; all 18 
centres surveyed were found to have either one or both of these strains present (Kidd 
et al. 2013). Greater than 40% of patients were found to be affected by either AUST-01 
or AUST-02. Those harbouring AUST-01 attended healthcare facilities more frequently 
than those patients infected with unique strains of P. aeruginosa which indicates that 
certain genotypes are causing widespread cross-infection in centres across Australia 
(Kidd et al. 2013). In the Netherlands a large study of two centres, serving 45% of the 
Dutch CF population, revealed the prevalence of two P. aeruginosa sequence types 
(ST406 and ST497) which were found in 15% and 5% respectively of the 265 patients 
from whom P. aeruginosa was cultured (van Mansfeld et al. 2009). Neither of these 
sequence types were genetically linked to previously described epidemic strains. Of the 
patients surveyed, 60% were found to harbour a strain of P. aeruginosa also found in at 
least two other patients (van Mansfeld et al. 2009).  
In Belgium 163 P. aeruginosa genotypes were found from 213 patients across all 
7 Belgian CF centres; 75% of these patients harboured only one genotype and 80% of 
patients maintained the same genotype over a 1 year period. Limited clustering of 
isolates was discovered and therefore it is unlikely that cross-infection is a common 
occurrence among Belgian CF patients (Van daele et al. 2006). There was also no strong 
evidence of nationwide cross-infection in New Zealand. DNA fingerprinting of 496 P. 
aeruginosa isolates from 102 patients revealed only one cluster of related isolates that 
was significantly more prevalent than expected in one centre. This cluster involved 
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isolates from 9 patients, 7 of whom attended the same centre. These 7 patients from 
the same centre were also revealed to have had more interpatient contact with one 
another than other patients, unconnected with the cluster, in the same centre. Analysis 
showed that this clustering was likely due to healthcare-related transmission (Schmid et 
al. 2008). Some previously-identified transmissible strains from the UK and Australia 
were identified among patients who had previously lived in or visited these countries, 
although there was no evidence of transmission from these patients to others (Schmid 
et al. 2008). 
Patient care standards for CF centres vary around the world and so, therefore, 
does the population structure of P. aeruginosa among CF patients. In areas where 
transmission within and between centres is a common occurrence (UK, Australia, 
Ontario) it is necessary to implement segregation of patients based not only on their 
Pseudomonas status, but also based on the strain identified from sputum samples. 
However these measures can be costly and time-consuming to implement so areas 
where inter-patient transmission is not a major health risk to CF patients it may be more 
prudent to continue with current segregation measures.  
The relatedness of CF P. aeruginosa isolates from within patients, within centres, 
and between centres has been well studied; although further depth of study can always 
be implemented. Inter-relatedness of P. aeruginosa isolates in non-CF bronchiectasis 
(NCFBr), along with many aspects of the disease, remains underfunded and 
understudied. 
4.1.2 Diversity of Pseudomonas aeruginosa isolates in non-cystic fibrosis 
bronchiectasis patients 
Much of the research into P. aeruginosa populations has been carried out with 
regards to CF patients, with little being done to resolve the population biology of 
infection within other chronic lung diseases. Some work has been previously carried out 
to investigate P. aeruginosa infections in chronic obstructive pulmonary disease (COPD). 
P. aeruginosa infection is more likely to be associated with advanced COPD and is 
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associated with the symptoms of exacerbation, although infections in COPD follow one 
of two possible patterns: (1) short-term colonisation followed by clearance or (2) long-
term persistence. Persistence of a strain of P. aeruginosa in COPD is associated with the 
development of serum antibody response but this response, in turn, is not associated 
with clearance of the infection (Rakhimova et al. 2009). In patients where the infection 
persists P. aeruginosa is found to diversify, leading to co-existing isolates with varying 
morphotypes and antibiotic susceptibilities(Martínez-Solano et al. 2008). Work by 
Martínez-Solano et al.(2008) showed that chronic isolates from COPD patients had 
similar phenotypic profiles to those from chronic CF infections, i.e. an increased 
mutation rate, increased antibiotic resistance, reduced cytotoxicity, reduced motility, 
and greater biofilm production. On the basis of these results it was suggested that P. 
aeruginosa may cause chronic infections in COPD in much the same manner as in CF. 
However, the data collected over a 10 year period by Rakhimova et al.(2009) showed 
that a much lower percentage (17.9%) of the COPD population became chronically 
infected with P. aeruginosa, versus 60% of CF patients (Cramer et al. 2012) and that the 
majority of patients experienced short-term or sporadic infection with strains which 
were sequentially replaced. Although the mechanisms of chronic infection in both COPD 
and CF may be similar, due to the discrepancies in the rates of chronic infection it is 
unlikely that the general population of P. aeruginosa isolates from COPD reflects the 
population structure of CF isolates.  
Epidemiological studies have been carried out into P. aeruginosa populations in 
NCFBr, though often on a smaller scale than those undertaken in CF research. PCR 
fingerprinting was been used to investigate the epidemiology of 64 P. aeruginosa 
isolates collected from 17 patients over the course of a longitudinal study. Nine patients 
were found to have maintained the initially acquired strain of P. aeruginosa over a period 
of between 2 and 38 months. Two patients carried a single major strain which, over a 
period of between 4 and 18 months, acquired minor variations in genotype. Five patients 
lost their initially acquired strain within the first year of the study and underwent strain 
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replacement over a period of 2 – 22 months. One patient was found to be harbouring 
two distinct strains of P. aeruginosa at once (Pujana et al. 1999).  
The main conclusions of the previous chapter, in which the maintenance of P. 
aeruginosa strains in NCFBr patients was investigated through the use of the array tube 
(AT) genotyping system, were that the majority of NCFBr patients with chronic P. 
aeruginosa infections maintained the same strain type over an extended period of time. 
It was also shown using the AT genotyping data that the strains of P. aeruginosa isolated 
from NCFBr patients are widely distributed in a similar population structure to that of 
the general population of P. aeruginosa strains. The AT genotyping system rapidly 
provides information on both the core and accessory genomes of P. aeruginosa isolates; 
however this information is still limited. Many of the adaptations of P. aeruginosa to the 
lung environment are provided by mutations in genes which cannot be detected by the 
AT system and so the use of whole genome sequencing in this chapter allows 
investigation of the diversity of P. aeruginosa isolates in far greater depth.  
4.2 Aims 
The aims of this chapter are to: 
1. Use whole genome sequencing to investigate the diversity and 
population structure of P. aeruginosa isolates from NCFBr patients 
attending bronchiectasis services throughout England and Wales; 
2. Use preliminary genomic analysis of whole genome sequences to 
investigate the heterogeneity of P. aeruginosa populations within 
chronically infected individuals with NCFBr. 
4.3 Results 
4.3.1 Panel of isolates 
A collection of 191 isolates from 94 patients (appendix, table A5) attending 16 
adult bronchiectasis centres throughout England and Wales were selected based on a 
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number of criteria to undergo whole genome sequencing using the Illumina HiSeq 
platform (figure 4.1). A total of 86 isolates were chosen from individual patients across 
all 16 centres to investigate diversity of P. aeruginosa isolates from centres around the 
country. Additionally, two isolates were included that were positive for both LESF9 and 
PS21 (table 2.1) by PCR assay and so were of particular interest. The remaining 102 
isolates were selected from patients from whom multiple isolates had been collected on 
a single visit. Eighteen of the 88 isolates from individual patients were from patients who 
had multiple isolates collected on a single visit and so these were also included in the 
dataset of patient with multiple isolates collected in a single visit. These 18 isolates were 
combined with 58 others to give a total of 76 isolates collected from 20 patients (mean 
isolates per patient: 3.8; median: 3) at 10 of the 16 adult bronchiectasis centres were 
compared to investigate within-patient diversity of P. aeruginosa isolates in NCFBr 
patients. Three patients from Liverpool were chosen to undergo closer investigation of 
within-patient diversity of P. aeruginosa and so 15 isolates per patient were picked from 
direct patient sample plates to be sequenced and compared. One isolate (A138, patient 
149) did not produce long enough reads to be of a high enough quality and so was 
excluded. The reads for a second isolate (B191, patient 30) could not be assembled, 
although the cause of this is yet to be confirmed, and so it was also excluded leaving a 
total of 189 assembled genomes for comparison. 
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Figure 4.1: Flow diagram illustrating the selection process for P. aeruginosa isolates used in this 
study. The total number of isolates with complete genome sequences used in analysis was 189. 
A total of 191 isolates were selected for sequencing but two were excluded due to poor quality 
reads and issues with genome assembly. There is some overlap between the 86 isolates selected 
from individual patients and the 76 isolates selected as multiple isolates from 20 patients and 
this is explained in more detail in section 4.3.1. 
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4.3.1.1 Multiple isolates from three patients to investigate within patient diversity of 
Pseudomonas aeruginosa 
In order to investigate the possible heterogeneity of multiple isolates taken from 
NCFBr patients further, isolates were picked from direct patient sample plates of three 
patients attending the Liverpool adult bronchiectasis service. Patient 147 is known to 
have been Pseudomonas-positive since at least 2004 and patient 148 since at least 2010. 
The direct sample plate from patient 149 from which isolates were collected is the first 
example of this patient culturing P. aeruginosa (2015). A summary of the isolates from 
these patients is shown in table 4.1 along with the observed phenotype of the isolate 
when grown on Columbia agar (Oxoid) and the ST assigned to each isolate. Isolates 
collected from patient 147 were observed to have one of two phenotypes, broadly 
described as “white” and “mucoid-1”, with white isolates growing in small, flat, white 
colonies and mucoid-1 isolates growing in larger colonies with typical mucoid 
appearance (figure 4.2). Isolates from patient 148 were also observed to have one of 
two phenotypes, broadly described here as “mucoid-2” and “brown”. The mucoid-2 
isolates exhibited blue-green pigmentation and had a typical mucoid appearance. 
Isolates exhibiting the brown phenotype grew in small, brown colonies (figure 4.3). Only 
one phenotype was observed for isolates from patient 149, also described as “brown” 
and matching the description above (figure 4.4). The intention of recording observed 
phenotypes was to compare variations in phenotype with possible genomic variation 
between isolates. All 15 isolates from patient 147 were assigned ST17 and cluster closely 
together on the phylogenetic tree (figure 4.6), along with four isolates from patient 148 
and two isolates from patients in other centres. ST17 has been previously identified as 
clone C and so multiple patients with isolates with this ST are unlikely to have 
participated in patient-to-patient transmission as it is far more likely that the 
environmentally abundant strain was acquired independently by these patients.  
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Table 4.1: Summary of multiple isolates collected from three patients attending the adult 
bronchiectasis service in Liverpool. A total of 15 isolates were randomly selected per patient 
but inadequate read lengths for the genome of one isolate from patient 149 meant that the 
genome was unable to be assembled and so this isolate has been excluded.  
Isolate Patient Phenotype ST 
A46 
147 
Mucoid-1 17 
A48 Mucoid-1 17 
A52 Mucoid-1 17 
A53 White 17 
A54 Mucoid-1 17 
A55 White 17 
A56 White 17 
A58 White 17 
A60 White 17 
A70 Mucoid-1 17 
A71 Mucoid-1 17 
A72 Mucoid-1 17 
A73 Mucoid-1 17 
A75 Mucoid-1 17 
A76 Mucoid-1 17 
A77 
148 
Brown 175 
A78 Mucoid-2 17 
A80 Brown 175 
A81 Mucoid-2 17 
A82 Brown 17 
A85 Brown 175 
A86 Brown 175 
A90 Mucoid-2 175 
A91 Brown 175 
A92 Mucoid-2 175 
A95 Brown 175 
A97 Brown 175 
A100 Mucoid-2 17 
A106 Brown 175 
A107 Brown 175 
A119 
149 
Brown 667 
A122 Brown 667 
A123 Brown 667 
A126 Brown 667 
A130 Brown 667 
A134 Brown 667 
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Isolate Patient Phenotype ST 
A137 
149 
Brown 667 
A141 Brown 667 
A144 Brown 667 
A147 Brown 667 
A148 Brown 667 
A151 Brown 667 
A154 Brown 667 
A156 Brown 667 
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Figure 4.2: Photographs of streak plates of isolates from patient 147 exhibiting differing 
phenotypes. A single colony exhibiting each of the phenotypes (described as “white” and 
“mucoid-1”) was picked using an inoculating loop and streaked onto Columbia agar (Oxoid) and 
grown overnight at 37°C. 
 
Figure 4.3: Photographs of streak plates of isolates from patient 148 exhibiting differing 
phenotypes. A single colony exhibiting each of the phenotypes (described as “mucoid-2” and 
“brown”) was picked using an inoculating loop and streaked onto Columbia agar (Oxoid) and 
grown overnight at 37°C.  
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Figure 4.4: Photograph of streak plate of an isolate from patient 149 exhibiting the observed 
phenotype. A single colony, described as “brown” phenotype, was picked using an inoculating 
loop and streaked onto Columbia agar (Oxoid) and grown overnight at 37°C.  
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Figure 4.5: Map of Great Britain showing the locations of the 16 adult bronchiectasis centres 
from which isolates in this study were collected.  
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Figure 4.6: Phylogenetic tree showing two main clades of P. aeruginosa. Group 1 (labelled blue) 
includes PAO1, the LES, and clone C isolates. Group 2 (labelled pink) includes lab strain PA14. 
The locations of PAO1, LESB58, PA14, and PA7 are indicated by red boxes. Tree labelled using 
iTOL software (Letunic & Bork 2007; Letunic & Bork 2011).  
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Figure 4.7: Phylogenetic tree of 522 genomes of P. aeruginosa isolates. Highlighted in purple are 
NCFBr isolates from this study. A further 329 isolates from work by Kos et al.(2015) are included, 
alongside the genomes of PAO1 (Stover et al. 2000), PA14 (Lee et al. 2006), LESB58 (Winstanley 
et al. 2009), and PA7 (Roy et al. 2010). Tree labelled using iTOL software (Letunic & Bork 2007; 
Letunic & Bork 2011). 
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4.3.4 Distribution of non-cystic fibrosis bronchiectasis isolates among the general 
population 
Figure 4.7 shows a core genome SNP phylogeny based on all 189 isolates from 
this study, labelled in purple, distributed on a tree of P. aeruginosa isolates which 
includes an additional 329 genomes from research into the P. aeruginosa resistome by 
Kos et al.(2015), the genomes of laboratory strains PAO1 and PA14 (Stover et al. 2000; 
Lee et al. 2006), LESB58 (Winstanley et al. 2009), and the taxonomic outlier PA7 (Roy et 
al. 2010). Small groups of NCFBr isolate genomes appear to cluster together, but 
generally they are widely distributed across the tree. Figure 4.6 shows two main clades 
of isolates generally known as group 1, including PAO1, LES, and clone C, and group 2, 
which includes PA14. P. aeruginosa strain PA7 is described as a taxonomic outlier (Roy 
et al. 2010) and is shown as such in figure 4.6 as it falls within neither of the two main 
clades. 
4.3.5 Distribution and population structure of isolates from non-cystic fibrosis 
bronchiectasis patients in England and Wales 
Figure 4.8a shows the distribution of the 88 isolates selected from individual 
patients at bronchiectasis centres in England and Wales, colour-coded by centre. The 
isolates from all centres are widely distributed throughout the tree and there is little 
evidence of extensive clustering of isolates from the same centre. This suggests that 
transmission between patients in the same centre does not occur regularly, though the 
sample sizes for each centre are relatively small. In nine of the 16 centres there are 
examples of pairs of isolates clustering next to one another on the tree, though it is likely 
that this is due to independent acquisition of strains from the environment, as opposed 
to transmission events. Isolates from 12 of the 16 centres were present in both the group 
1 and group 2 clades (figure 4.6) which indicates a large amount of genetic diversity. 
Isolates from four centres (Reading, Cardiff, Norfolk & Norwich, and Sunderland) were 
found to only be present in the group 1 clade, which also includes PAO1, LES, and clone 
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C. Given that the group 1 clade is much larger than the group 2 clade (figure 4.6) it is 
unsurprising that some centres have isolates only from this group. There was only one 
isolate from an individual patient available from the Cardiff centre, so although this 
isolate can be compared in its relatedness to isolates from other centres it is not possible 
to investigate the diversity of isolates within this centre. 
A small number of isolates cluster together as part of a distinct branch in group 
2 (figure 4.8.b). Isolates B199 (Newcastle) and C119 (Hull) appear closest together in this 
part of the tree, and are apparently more closely related than C119 and C124 despite 
both isolates being collected from patients in Hull. The remainder of the isolates that are 
part of this group are from patient 149 (Liverpool). Isolate B113 (Newcastle) does not 
appear as part of either of the main clades or as part of a cluster (figure 4.8b) and is the 
closest of the NCFBr isolates to the taxonomic outlier PA7. However, further analysis of 
B113 in comparison with PA7 with read mapping and genome analysis toolkit (GATK) 
revealed that the two are not closely related, with a total difference of 262 039 SNPs and 
18 305 indels between the two genomes. 
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Figure 4.8a: Phylogenetic tree showing the distribution of isolates from individual patients at 16 adult bronchiectasis centres in England and Wales. 
Tree labelled using iTOL software (Letunic & Bork 2007; Letunic & Bork 2011). 
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Figure 4.8b: Enhanced view of a section of the phylogenetic tree of NCFBr isolates showing 
isolate B113 (Newcastle) and taxonomic outlier PA7, which do not fall within either the group 1 
or group 2 clades, and isolates which form a distinct group as part of group 2. Tree labelled using 
iTOL software (Letunic & Bork 2007; Letunic & Bork 2011). 
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4.3.6 Evidence for multiple Pseudomonas aeruginosa strain types within non-cystic 
fibrosis bronchiectasis patients 
As shown in figure 4.9 there is far greater evidence of clustering among isolates 
taken from the same patient in a single visit than among isolates merely collected from 
the same centre. The isolates shown in figure 4.9 were collected from 23 patients at 13 
bronchiectasis centres in England and Wales during a single visit and should therefore 
be somewhat representative of the population of P. aeruginosa within a given patient at 
a single point in time. All isolates taken from a patient in a single visit clustered together 
for the majority of the 23 patients (table 4.2). 
 Table 4.2: Patients from whom all available isolates cluster together in figure 4.9. 
Patient No. of isolates Group Centre 
Maximum branch 
length 
79 5 2 Dorset County Hospital 0 
147 15 1 Liverpool 0 
45 3 1 Papworth 0 
37 3 1 Sheffield 0 
65 5 1 Norfolk & Norwich 0 
102 3 1 Colchester 0 
149 14 1 Liverpool 0 
86 2 1 Swansea 0 
62 6 1 London Chest Hospital 8.96 X 10-4 
40 3 1 Sheffield 8.99 x 10-4 
50 3 1 Papworth 9.03 x 10-4 
3 3 1 Liverpool 9.07 X 10-4 
101 3 1 Colchester 9.09 x 10-4 
55 3 1 Papworth 9.17 x 10-4 
81 3 1 Dorset County Hospital 9.29 x 10-4 
87 3 1 Swansea 1.78 x 10-3 
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Figure 4.9: Phylogenetic tree showing the distribution of multiple isolates taken from patients in a single visit from 13 centres (not visually 
represented). Tree labelled using iTOL software (Letunic & Bork 2007; Letunic & Bork 2011). 
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Multiple isolates collected from 7 patients did not cluster together (figure 4.9). A 
total of five isolates were collected from patient 92 (Hull) and these are dispersed across 
the tree. Three of the isolates are part of the group 1 clade; two of these are closely 
related (branch length: 0) but the third (C129) is separate and is more closely related to 
three isolates from a patient from Swansea (patient 87). The remaining two isolates from 
patient 92 are part of the PA14 clonal complex in group 2. Six isolates were collected 
from patient 42 (Sheffield) and five of these cluster closely together; three of these have 
a branch length of 0 and two are slightly further away from these on a branch with a 
length of 1.75 x 10-3. The remaining isolate from patient 42 is located much further away 
on the tree and is in fact more closely related to an isolate from another patient at 
Sheffield (patient 41). A total of seven isolates were collected from patient 72 (Chertsey, 
Surrey); six of these cluster relatively closely together in group 2, alongside an isolate 
from a patient from the London Chest Hospital (patient 63). The final isolate from patient 
72 is very distant from these first six isolates and is part of the group 1 clade; isolate C78 
clusters with two isolates from two different patients from Swansea. Three isolates were 
collected from patient 84 (Swansea); two of these isolates are closely related and a part 
of group 1, though do not appear next to one another on the phylogenetic tree. The 
remaining isolate is part of the PA14 clonal complex in group 2. Of the three isolates 
collected from patient 73 (Chertsey, Surrey) two cluster closely together, although not 
next to one another, in group 1 and the third falls in group 2, most closely related to a 
single isolate from another patient from the same centre (patient 71). All four isolates 
collected from patient 85 (Swansea) are found in the group 1 clade; three are closely 
related and found next to one another, the final isolate is distantly related to these and 
is most closely related to an isolate from another patient at the same centre and an 
isolate from a patient from the Chertsey, Surrey centre. 
Patient 148 was one of three patients from Liverpool from whom 15 isolates 
were selected from a direct culture plate. Isolates from patients 147 and 149 cluster by 
patient; all 15 isolates from patient 147 cluster together as part of group 1; all isolates 
from patient 149 cluster together as part of group 2. Eleven isolates from patient 148 
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cluster together in group 1, away from most of the other isolates collected from NCFBr 
patients and the remaining four isolates cluster near the isolates from patient 147. 
4.3.7 Multilocus sequence typing of isolates 
Multilocus sequence typing (MLST) data was extracted from the assembled 
genomes of all 189 isolates and the most commonly identified MLST types are listed in 
table 4.3. Thirty-one isolates could not be assigned a sequence type (ST) (appendix, table 
A5). The online MLST database (http://pubmlst.org) was used to identify commonly 
found STs and clonal complexes. 
Table 4.3: Summary of the most abundant STs among the isolates sequenced, and the number 
of centres each of these STs was identified in. Full list of isolates and STs can be found in the 
appendix, table A5. 
ST No. of isolates No. of centres 
17 22 3 
253 21 9 
667 14 1 
175 11 1 
179 10 4 
252 7 4 
620 6 2 
27 5 3 
244 5 1 
260 5 3 
274 5 1 
395 5 3 
108 4 2 
871 4 2 
840 3 2 
 
The LES has previously been identified as ST146 (http://pubmlst.org) and there 
are two isolates of the 189 that were shown to have this ST. Isolates A36 and A163 (both 
from a patient in Liverpool) were both found to be positive for LESF9 and PS21 markers 
by PCR assay (table 2.1) as part of general screening of all isolates. Due to the occurrence 
of occasional false positives for isolates with either of the LES markers (Fothergill et al. 
2010a), isolates suspected to be LES positive were subjected to further testing to confirm 
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their status. This included a PCR assay for pyoverdine receptor (table 2.1). Isolate A36 
was confirmed as LES as it was pyoverdine receptor type III positive (the rarest of the 
three types). Isolate A163 was collected late in the work and so following the initial 
positive result for both LES markers was submitted for whole genome sequencing as 
means of confirmation. Both LES isolates (A36 and A163) were compared to LESB58 (high 
quality, relevant reference genome) using GATK which revealed that both LES isolates 
were closely related to LESB58. Isolate A36 differed from LESB58 by 109 SNPs and 22 
indels, and isolate A163 differed from LESB58 by 113 SNPs and 25 indels. A36 and A163 
shared 95 of these SNPs, whilst 14 were unique to A36 and 18 to A163. 
Isolates from patients 79 and 101 cluster closely together despite being collected 
from patients in Dorset and Colchester respectively. These isolates also cluster with a 
number of isolates from other patients at 7 other centres and PA14 (figure 4.10). All 
isolates on the highlighted branch of the tree in figure 4.10 have the ST253 assigned by 
MLST of their genomes. 
Clone C is commonly found in the environment and is associated with ST17, as 
well as with ST142 and ST14 (Curran et al. 2004). A total of 22 isolates, from 5 patients 
at 3 centres, were found to be ST17 (figure 4.11). All 15 isolates collected from patient 
147 (Liverpool) were found to be ST17. Four isolates from patient 148, also from 
Liverpool, were found to be ST17 but due to the prevalence of clone C in the 
environment it is more probable that these patients acquired strains of P. aeruginosa 
independently rather than this being an example of a transmission event. The remaining 
11 isolates from patient 148 are all ST175 which has been identified on numerous 
occasions from patients in France and Spain (http://pubmlst.org). 
All 14 isolates collected from patient 149 (Liverpool) were shown to be ST667 
which has not been previously identified in the PubMLST database (http://pubmlst.org). 
The isolates cluster together as part of group 2 but are only distantly related to PA14 
(figure 4.9). Figure 4.12 shows the other isolates from this study which cluster most 
closely to the isolates from patient 149, along with the STs assigned to them by MLST. 
Although the leaves appear relatively close to one another on the tree the branch 
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lengths indicate that the isolates are not closely related and are more likely to cluster 
together due to genetic differences from the majority of other isolates on the tree. 
Isolates C88 (Chertsey, Surrey) and C124 (Hull) were assigned STs 1251 and 1753 
respectively and occupy their own branches on the tree. Despite not being assigned a 
ST, isolate C119 (Hull) clusters closely with isolate B199 (Newcastle) which was 
designated ST1182.  
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Figure 4.10: Enlarged section of phylogenetic tree showing branch of isolates with ST253. Tree 
labelled using iTOL software (Letunic & Bork 2007; Letunic & Bork 2011). 
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Figure 4.11: Enlarged section of phylogenetic tree showing branch of isolates with ST17. Tree 
labelled using iTOL software (Letunic & Bork 2007; Letunic & Bork 2011). 
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Figure 4.12: Enlarged section of phylogenetic tree showing the isolates with ST667 and its closest 
relatives. Tree labelled using iTOL software (Letunic & Bork 2007; Letunic & Bork 2011)
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Figure 4.13: Enlarged section of phylogenetic tree showing isolates assigned ST179 and those 
closely related to these isolates that were unable to be assigned a ST. Tree labelled using iTOL 
software (Letunic & Bork 2007; Letunic & Bork 2011).  
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4.4 Discussion 
4.4.1 Diversity of Pseudomonas aeruginosa isolates from adult bronchiectasis centres 
in England and Wales 
Little is known about the population structure of P. aeruginosa isolates from 
NCFBr patients. Work has been previously undertaken to investigate the wider 
population of P. aeruginosa isolates from patient infections across the UK, including 
those in CF patients. Combinations of sequenced-based typing techniques have been 
used to attempt to elucidate the population structure of P. aeruginosa. It is generally 
agreed that P. aeruginosa has a non-clonal population structure punctuated by closely 
related genotypes or clonal complexes (Pirnay et al. 2002; Pirnay et al. 2009; Curran et 
al. 2004). Large-scale studies of population structure can be subject to bias, in that many 
databases include over-sampling of isolates from highly studied regions or clinical 
manifestations of P. aeruginosa (i.e. CF isolates) and so this is important to take into 
consideration when making statements about the abundance or relatedness of strains. 
In broad terms, strains of P. aeruginosa can be divided into three genetically distinct 
groups: group 1, containing PAO1, LESB58, and clone C strains; group 2, containing PA14 
clonal complex; and group 3, containing the taxonomic outlier PA7 (Stewart et al. 2014; 
Freschi et al. 2015). Work by the International Pseudomonas aeruginosa Consortium 
(IPC) suggests that group 1 strains are naturally more abundant than strains falling in 
group 2 (Freschi et al. 2015) and this is reflected in the results of this work (figure 4.4). 
Due to the clinical origin of isolates from this study and much of the IPC cohort (Freschi 
et al. 2015) it is possible that sampling bias implies that the abundance of group 1 
isolates is naturally higher, especially given that conflicting evidence has been provided 
using the AT typing method by Wiehlmann et al.(2007).  
Using the STs assigned to isolates and the P. aeruginosa MLST database 
(http://pubmlst.org) it is possible to investigate the occurrence of commonly reported 
strains within the NCFBr population in England and Wales. Within each of the two groups 
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there are several previously reported STs that have often been identified in multiple 
countries around the world, and from varying sources. In general the NCFBr isolates in 
group 1 do not form closely related clusters. Two STs with multiple isolates from 
bronchiectasis centres around the UK were identified. A group of closely related isolates 
were identified though closer examination of the phylogenetic tree in figure 4.8a. This 
group consisted of 13 isolates, 10 of which had been assigned ST179; the remaining three 
isolates could not be assigned a ST. Isolates previously assigned this ST in the P. 
aeruginosa MLST database (http://pubmlst.org) have been collected mainly from 
Canada and Australia but also from the UK and Spain, and mainly from sputum samples. 
The isolates in this closely related group (figure 4.13) were collected from five different 
centres, with the majority (eight) coming from the Swansea centre. These eight isolates 
were collected from four different patients. The second closely related group of isolates 
were assigned ST17 which has been previously associated with clone C isolates (Curran 
et al. 2004). A total of 21 isolates were assigned ST17; 19 of these were isolated from 
patients in Liverpool, and 15 were from one patient. The two remaining isolates were 
collected from Reading and West Wales General hospital (figure 4.11). There have been 
several other STs associated with clone C strains of P. aeruginosa but none of these were 
identified among these NCFBr isolates (Curran et al. 2004). 
Investigation of closely related isolates in group 2 (figure 4.10) reveals two main 
clusters of closely related isolates which share a common ancestor, although one of 
these groups is only populated with isolates from work by Kos et al.(2015). All NCFBr 
isolates from the second group of closely related isolates were assigned ST253 which has 
been previously identified as belonging to the PA14 clonal complex. Isolates assigned 
ST253 have been found extensively throughout the environment and in human 
infections in countries around the world, including the UK, France, Spain, Australia, and 
Brazil (http://pubmlst.org). Another group of isolates was identified on a branch located 
distantly from the PA14 clonal complex, though still as part of the group 2 clade. All 
isolates from patient 149 were a part of this group having been assigned ST667. Four 
other isolates were also located on this branch (figure 4.12) one of which was unable to 
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be assigned a ST. Although the isolates in this group appear on one branch of the tree 
they are not closely related to one another. None of the three STs assigned to these 
isolates were found to be particularly common in the PubMLST database; ST1251 was 
previously identified in an isolate from a bronchial lavage in Spain, ST1753 had previously 
been identified in a water isolate from France, and ST1182 was previously found in water 
isolates from Australia and France, and in isolates from unnamed sources in China and 
France (http://pubmlst.org).  
The most common STs among NCFBr isolates are listed in table 4.2. Five isolates 
from three patients attending the Sheffield bronchiectasis centre were assigned ST244 
which has previously been identified across Europe, Asia, Australia, Africa, and South 
America from a wide range of clinical and environmental sources (http://pubmlst.org). 
A clade of isolates assigned ST395 were identified among the isolates collected by Kos et 
al. (2015) and five isolates from three patients, attending three geographically separate 
bronchiectasis centres were assigned this ST. Previously ST395 has been associated with 
water sources (Slekovec et al. 2012) and it was suggested by Kos et al.(2015) that its 
prevalence among clinical isolates implied that P. aeruginosa was easily acquired from 
the environment in many diseases. There were, however, STs previously acknowledged 
as being distributed worldwide and that were well represented among the clinical 
isolates analysed by Kos et al.(2015) that were not assigned to any of the 189 NCFBr 
isolates sequenced as part of this work. ST235 (serotype O:11)and ST111 (serotype O:12) 
were commonly identified in work undertaken by Maatallah et al.(2011) and Woodford 
et al. (2011) and have previously been described worldwide (http://pubmlst.org) but 
were not identified among the NCFBr isolates. The widespread origins of isolates sharing 
the most common STs identified among these NCFBr isolates, and their distribution 
among the other isolates on the phylogenetic tree, implies that the population structure 
of P. aeruginosa among NCFBr patients is nonclonal. 
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4.4.1.1 Transmissible strains of Pseudomonas aeruginosa in non-cystic fibrosis 
bronchiectasis patients from England and Wales 
Further work by Pirnay et al. (2009) into the population structure of P. aeruginosa 
led to the conclusion that the nonclonal structure of the population is generally 
punctuated by outbreaks of epidemic strains that are common in both the environment 
and in clinical isolates. Various transmissible “epidemic” strains of P. aeruginosa have 
been identified in the CF population in the UK (Scott & Pitt 2004) but the prevalence of 
these strains among patients with NCFBr has not previously been investigated. Two 
isolates from a patient attending the Liverpool bronchiectasis service were confirmed to 
be LES positive. The LES was not found to be present in any other centres in England and 
Wales and no other known UK epidemic strains (Midlands 1 or Manchester epidemic 
strain) were identified among any patients. The two LES isolates recovered (A36 and 
A163) were found to be closely related to one another but the strain is obviously not 
widespread among NCFBr patients attending the Liverpool centre given its presence in 
only one of 56 patients (appendix, table A1) surveyed from Liverpool. In total, the LES 
accounted for fewer than 0.5% of the 408 NCFBr patient isolates sampled from 16 
centres which is significantly lower than the prevalence of LES recorded among CF 
patients in the UK (P = >0.0001) (Scott & Pitt 2004). The low frequency of LES and 
absence of other known epidemic strains indicates that transmissible strains of P. 
aeruginosa are not as great a cause for concern among NCFBr patients as in patients 
with CF, although the prognostic implications of LES infections previously studied in CF 
(Al-Aloul et al. 2003) should not be ignored in NCFBr patients.  
4.4.2 Diversity of Pseudomonas aeruginosa isolates from individual non-cystic fibrosis 
bronchiectasis patients 
In the field of diagnostic microbiology it has been commonplace to use diagnostic 
results from single bacterial isolates from patient samples to inform the appropriate 
method of treatment and prognosis. However, more recently it has become apparent 
than in the case of chronic lung infections, predominantly in CF, that a single isolate is 
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unlikely to be representative of the true nature of the infection. It has been noted that 
different areas of the lung are likely to have different oxygen levels, available nutrients, 
and varying microflora, and this may lead to large variations in both the phenotypic and 
genotypic characteristics of isolates collected from patients (Jorth et al. 2015).  
Sample sizes were small for many of the NCFBr patients from whom multiple 
isolates were collected (mean isolates per patient: 5.2, median: 3) and so may still not 
necessarily reflect the true diversity of the P. aeruginosa populations within the lungs of 
individual patients. In the majority of patients (16 of 23) isolates collected in a single visit 
were closely related, clustering together on the phylogenetic tree (figure 4.9) and 
sharing a single ST. Of the seven patients whose isolates were not closely related, four 
had isolates present in both group 1 and group 2 clades indicating a large amount of 
genetic diversity between these isolates. Seven isolates were collected from patient 72 
(Chertsey, Surrey) and six of these clustered closely together as part of the group 2 clade 
in the phylogenetic tree (figure 4.9). Five of these isolates were assigned ST620 and the 
remaining member of this cluster of isolates (C83) was unable to be assigned a ST. The 
final isolate collected from patient 72 falls into the group 1 clade and was assigned 
ST840. Both ST620 and ST840 were relatively uncommon in the PubMLST database 
(http://pubmlst.org) and both have previously been identified in veterinary isolates from 
Australia. Only one previous example of ST840 was recorded as an Australian canine 
wound isolate, however this ST has also been assigned to two isolates from two patients 
attending the Swansea bronchiectasis centre. Aside from these, the majority of STs 
assigned to isolates which did not cluster together were STs that were relatively common 
in the PubMLST database, many having been identified worldwide, which may indicate 
that NCFBr patients are capable of harbouring more than one environmentally-acquired 
strain of P. aeruginosa at any given time.  
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4.4.2.1 Diversity of multiple Pseudomonas aeruginosa isolates from three non-cystic 
fibrosis bronchiectasis patients attending the Liverpool bronchiectasis service 
Preliminary genomic analysis carried out on multiple isolates from three patients 
attending the Liverpool bronchiectasis service was carried out to investigate the diversity 
of P. aeruginosa isolates within NCFBr patients. Upon initial selection of the isolates 
details of the colony morphology were recorded (table 4.1). Variations in the colony 
morphology of isolates was then compared alongside the ST assigned to each isolate by 
MLST, The variation in colony morphology between these isolates did not seem to be 
influenced by the relatedness of the isolates as all 15 isolates from patient 147 were 
assigned ST17 and had a branch length of 0 (figure 4.14). Four isolates collected from 
patient 148 were also assigned ST17 and the remaining 11 isolates were assigned ST175. 
ST17 has previously been associated with clone C strains of P. aeruginosa and so it is 
unlikely that the presence of isolates in two patients with this ST is due to interpatient 
transmission; the high prevalence of clone C in the environment implicates independent 
acquisition of the strain by both patients. Isolates previously assigned ST175 have mainly 
been recovered from blood isolates from France and Spain, as well as from other human 
infections in both of these countries (http://pubmlst.org). Although ST17 and ST175 are 
both part of the group 1 clade (figure 4.6) they are only very distantly related, falling 
virtually as far away from one another as possible on the phylogenetic tree. All 14 
isolates from patient 149 cluster in the group 2 clade (figure 4.6) and were assigned 
ST667. This ST has not previously been identified in the PubMLST database 
(http://pubmlst.org). No other isolates collected from NCFBr patients clustered closely 
with the 14 isolates from patient 149. Given the versatility of P. aeruginosa and its 
adaptability it is likely that this strain is environmental and has been acquired 
independently by the patient. Further examination of the genomes of these isolates 
would allow us to compare it to chronic lung infection isolates and investigate the 
presence of mutations and adaptations associated with chronic lung infection isolates.  
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Figure 4.14: Phylogenetic tree showing the distribution of multiple isolates taken from 3 patients 
in a single attending the Liverpool bronchiectasis service. Tree labelled using iTOL software 
(Letunic & Bork 2007; Letunic & Bork 2011).  
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4.5 Conclusions 
The main conclusions that can be drawn from this study are: 
1. In bronchiectasis centres throughout England and Wales there is little 
evidence of geographical clustering or transmissible epidemic strains of 
P. aeruginosa; 
2. In the majority of NCFBr patients there is only one infecting strain of P. 
aeruginosa at a given time, though there is evidence for multiple strain 
infections in some cases. 
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Chapter Five 
General Discussion 
 
The previous chapters have discussed in detail the current understanding of non-
cystic fibrosis bronchiectasis (NCFBr) as a disease and the implications of P. aeruginosa 
infections in patients suffering the condition. It is clear that there is a fundamental lack 
of focused research into NCFBr both in terms of the disease itself and the microbial 
infections associated with it, particularly when compared with cystic fibrosis (CF). 
Bronchiectasis has been considered in recent years to be easily treatable and of 
little clinical significance, possibly due to a belief that the disease would gradually fall 
into decline in developing countries alongside other pulmonary diseases, such as 
tuberculosis (TB) (Chalmers 2015). There are several known causes of bronchiectasis 
including: CF; childhood infection, most commonly pneumonia leading to post-infective 
bronchiectasis; and particle inhalation (NHS Choices 2015). It is estimated, however, that 
in 25 – 50% of NCFBr cases a cause is never identified and this is known as idiopathic 
bronchiectasis (http://www.blf.org.uk/page/bronchiectasis). Conversely, CF is an easily 
defined disease due to its genetic aetiology and has rightfully garnered public and 
scientific attention due to the significantly reduced quality of life and life expectancy 
experienced by sufferers. In the UK more than 10 000 people are affected by CF 
(http://www.cysticfibrosis.org.uk/about-cf). However, in just nine centres in the UK 
there are 5000 patients undergoing regular follow-up treatment for NCFBr (De Soyza et 
al. 2013) suggesting a much higher prevalence than CF, and higher incidence than 
previously believed. In CF patients chronic lung infection with P. aeruginosa is the 
leading cause of morbidity and mortality (Fothergill et al. 2010a) and many studies have 
demonstrated an association between chronic P. aeruginosa infection and increased 
mortality, lowered lung function, and worsened quality of life in NCFBr patients (Evans 
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et al. 1996; Davies et al. 2006; King et al. 2007; Loebinger et al. 2009). However it has 
not been conclusively shown that P. aeruginosa is the cause of a worsening prognosis in 
NCFBr patients instead of merely a marker of existing disease severity (Chalmers 2015). 
The uncertainty surrounding the role of P. aeruginosa in NCFBr has been the basis for 
this study.  
The main focus of this work has been to reveal more information about the 
population structure of P. aeruginosa in NCFBr patients in a manner similar to work that 
has already been undertaken with regards to CF. Once colonised with P. aeruginosa CF 
patients generally carry the infection for life and often maintain the same strain of the 
bacteria throughout the course of infection (Şener et al. 2001; Leone et al. 2008) 
although more recently it has been acknowledged that transmissible “epidemic” strains 
can superinfect patients and displace the established strain (McCallum et al. 2001). 
Previously there has only been a very small amount of work undertaken to investigate 
the maintenance of strains of P. aeruginosa in the lungs of NCFBr patients and the 
possibility of transmissible strains. The work undertaken by De Soyza et al. (2014) 
investigated the incidence of transmission of P. aeruginosa between NCFBr patients in a 
single centre, as well as including paired longitudinal isolates from 10 patients. The 
majority of patients were shown to harbour unique strains of P. aeruginosa and both 
isolates from nine of the 10 patients with paired isolates were found to be 
indistinguishable by both array tube (AT) and variable number tandem repeat (VNTR) 
typing. The work described in chapter three aimed to build on the previous research by 
De Soyza et al. (2014) through the use of AT genotyping of longitudinal NCFBr isolates. 
In the majority of the 20 patients from whom isolates were collected the strain type was 
maintained for the period spanned by this study. Use of the AT system allows for rapid 
identification of isolates and provides information regarding the accessory genome. 
Assigning each isolate a four digit AT code also allows for the use of the eBURST 
algorithm (Feil et al. 2004; Spratt et al. 2004) to examine the distribution and population 
structure of P. aeruginosa isolates from NCFBr patients. There was shown to be no 
clustering of isolates collected from NCFBr patients and the strains identified were 
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widely distributed throughout the general population, although common clones were 
found to be more prevalent. This is in line with work carried out previously which has 
defined the population structure of P. aeruginosa as nonclonal though punctuated by 
closely related clonal complexes, such as clone C (Pirnay et al. 2002; Pirnay et al. 2009; 
Curran et al. 2004). The main limitation of the AT system is its lack of depth. The 
immobilised oligonucleotides in the AT chip only represent a very limited number of 
sequences from the large and versatile genome of P. aeruginosa and the dichotomy of 
PAO1- vs. non-PAO1-type sequences necessary for analysis of the AT data does not 
accurately portray the diversity of P. aeruginosa genotypes. Whilst some information 
regarding the accessory genome of isolates can be shown, it mainly concerns the 
presence or absence of mobile genetic elements and cannot provide information 
regarding single nucleotide polymorphisms (SNPs) or indels which can differentiate 
closely related isolates. With the ever-decreasing cost of whole genome sequencing it is 
likely that the AT system will cease to be used in research in favour of the increased the 
depth of information acquired by whole genome sequencing.   
The work undertaken in chapter three focused only on patients from one 
bronchiectasis centre in the north-east of England, and so to achieve a broader 
understanding of the population of P. aeruginosa among NCFBr patients the work 
described in chapter four included isolates from 16 bronchiectasis services in England 
and Wales. Whole genome sequencing provides a much greater depth of study and has 
previously been used in studies of P. aeruginosa to investigate virulence mechanisms, 
including antibiotic resistance genes and virulence factors (Lee et al. 2006; Boyle et al. 
2012); the relatedness of isolates and possible transmission events (Snyder et al. 2013; 
Jeukens et al. 2014; Quick et al. 2014); and the evolution of infectious bacterial strains 
(Wong et al. 2012; Dettman et al. 2013; Marvig et al. 2014). The collection of isolates 
from this study were compiled into a phylogenetic tree with isolates from work by Kos 
et al. (2015) in order to place them in the context of the general P. aeruginosa 
population. Similarly to the results in chapter three, the NCFBr isolates were not found 
to cluster extensively and were distributed throughout the phylogenetic tree. The results 
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reflected work by Stewart et al. (2014) and Freschi et al. (2015) which showed two 
distinct subgroups of P. aeruginosa within the population, termed group 1 and group 2, 
with a third sparsely populated group containing taxonomic outlier PA7 (Roy et al. 2010). 
Strains from group 1, including PAO1, clone C strains, LESB58, and PAK, have been 
suggested to be naturally more abundant than strains from group 2, which includes 
PA14. However, it has also been suggested that this apparent disparity between group 
1 and group 2 isolates may be introduced due to selection bias, given that the data used 
to compile these phylogenetic trees are largely from clinical sources (Freschi et al. 2015). 
The International Pseudomonas aeruginosa Consortium (IPC) aims to compile a database 
of over 1000 P. aeruginosa genomes to allow easily accessible and user-friendly 
comparisons of genomic data and so as the number of environmental isolates in the 
dataset increases there may be a shift in the abundance of group 2 isolates. Chapter four 
also included work undertaken to investigate the possible heterogeneity of multiple 
isolates taken from NCFBr patients in a single visit to a bronchiectasis centre. In the 
majority of patients all isolates taken in a single visit were found to cluster closely 
together and shared a single sequence type (ST) assigned by multilocus sequence typing 
(MLST), indicating that typically NCFBr patients do not experience multi-strain infections 
of P. aeruginosa. Further analysis of the STs assigned to isolates showed that many were 
strains commonly identified worldwide, both in the environment and in clinical isolates, 
demonstrating that there are not strains directly associated with NCFBr pulmonary 
infections. The sample sizes for multiple isolates from NCFBr patients were small (mean 
isolates per patient: 5.2, median: 3) and so any further research to confirm that these 
results are typical would be better served by larger sample sizes. It has been shown in 
CF patients that coexisting, divergent strains of P. aeruginosa can infect the lungs 
(Williams et al. 2015) but sample sizes of 40 isolates per sputum sample from each 
patient were used in this work and so further investigation into heterogeneity of P. 
aeruginosa infections in NCFBr patients would be better served on this scale. On a 
smaller scale, it would be beneficial to further investigate the isolates collected from 
patients 147 and 149 (patients attending Liverpool bronchiectasis service) from whom a 
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larger number of isolates were collected from a single visit. In the case of both patients 
all isolates clustered closely together on the larger phylogenetic tree but construction of 
a core genome from the isolates from each patient would allow for a higher resolution 
investigation of relatedness between the isolates. Patient 147 has been known to have 
been colonised with P. aeruginosa for >10 years, whereas the isolates collected from 
patient 149 are the first Pseudomonas-positive culture from this patient. Given the 
known diversification of P. aeruginosa within the lungs of CF patients over time (Williams 
et al. 2015) it would be expected that there would be greater heterogeneity between 
the isolates collected from patient 147 than in patient 149. Further analysis of these 
isolates would allow for a greater comparison between the behaviour of P. aeruginosa 
in the lungs of CF patients vs. NCFBr.  
 There was also very little evidence of transmissible strains of P. aeruginosa 
among NCFBr patients. After the emergence of epidemic strains of P. aeruginosa among 
CF patients work was undertaken to investigate the prevalence of these strains in the 
UK. The Liverpool Epidemic Strain (LES) was found to account for 11% of the patient 
isolates collected from CF sufferers in the UK (Scott & Pitt 2004). Among this cohort of 
NCFBr patients only one patient was found to be infected with the LES. The patient was 
attending the Liverpool bronchiectasis service and no other epidemic strains were 
identified in this or any other centre. Although the lungs of NCFBr and CF patients 
provide similar conditions for bacterial growth the disparity between the prevalence of 
transmissible strains among CF patients and NCFBr patients may imply that there are 
subtle differences in the host environment which mean that these epidemic strains are 
more suited to life in the CF lung as opposed to in the lungs of those suffering other 
chronic lung conditions. Further work should continue to be undertaken using larger 
sample sizes across UK centres to investigate evidence of transmissible strains of P. 
aeruginosa among the NCFBr population, as only a small sample of the predicted NCFBr 
patients in the UK have been included in this work.  
The genomic analysis undertaken in this work has largely been preliminary, and 
has not fully explored the fine detail offered by the availability of whole genomes. With 
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regards to CF there have been large amounts of work undertaken to investigate the 
specific mutations acquired by P. aeruginosa in chronic lung infections, including 
changes in lasR, mucA, and mutS, (Marvig et al. 2013; Jeukens et al. 2014; Marvig et al. 
2014) and so further investigation into the presence of similar mutations in isolates from 
NCFBr patients would allow a more direct comparison between infections in both 
diseases. Although the isolates collected from NCFBr patients have been compared 
alongside a panel of other P. aeruginosa isolates (Kos et al. 2015) it is also important to 
understand their place within the larger, general P. aeruginosa population. Further work 
to place NCFBr isolates in the context of the wider population would allow any common 
strains among NCFBr patients to be identified and observed with regards to patient 
health. 
It is only recently that the world’s first national guidelines for the diagnosis and 
treatment of NCFBr were developed in the UK by the British Thoracic Society (BTS) 
(Pasteur et al. 2010) and so the amount of research being undertaken to better 
understand the disease and its implications on both patients and health services is 
gradually increasing. It is hoped by many that the development of cheaper, quicker, and 
more user-friendly sequencing platforms will allow whole genome sequencing to play a 
role in the future of diagnostic microbiology (Török & Peacock 2012) as well as bringing 
greater depth to clinical research. As well as striving to develop a better understanding 
of NCFBr as a disease, research must continue to progress into the implications of 
bacterial infections in chronic lung conditions.  
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Appendix 
Table A1: Complete list of all isolates, and accompanying information, collected as part of this study. 
Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient info. 
Notes 
Liverpool COPD 
09/10/201
4 1 A1 N N N C4AA Y     
Liverpool COPD 
16/10/201
4 2 A2 N N N EC29 Y     
Liverpool 4B 
10/10/201
4 3 A3 N N N 049A Y   Spreading 
Liverpool 4B 
10/10/201
4 3 A4 N N N   Y   Smooth 
Liverpool 4B 
10/10/201
4 3 A5 N N N   Y   Rough 
Liverpool GP 
09/10/201
4 4 A6 N N N C408       
Liverpool GP 
10/10/201
4 5 A7 N N N 2CAA       
Liverpool GP 
09/11/201
4 6 A8 N N N         
Liverpool GP 
09/11/201
4 7 A9 N N N         
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Liverpool GP 
11/11/201
4 33 
A1
3 N N N         
Liverpool GP 
13/11/201
4 34 
A1
1 N N N         
Liverpool CPOCCU 
14/11/201
4 35 
A1
2 N N N   Y   Smooth 
Liverpool CPOCCU 
14/11/201
4 35 
A1
0 N N N       Rough 
Liverpool 6Y 
16/12/201
4 116 
A1
4 N N N       
Pip/Tazo 
Sens 
Liverpool GP 
18/12/201
4 117 
A1
5 N N N         
Liverpool GP 
31/12/201
4 118 
A1
6 N N N         
Liverpool Link 6Z 
16/12/201
4 119 
A1
7 N N N       Small 
Liverpool Link 6Z 
16/12/201
4 119 
A1
8 N N N       Large 
Liverpool COPD 
16/12/201
4 120 
A1
9 N N N 6C2A Y     
Liverpool 6Y 
15/12/201
4 121 
A2
0 N N N       
Pip/Tazo 
Res 
Liverpool GP 
11/11/201
4 122 
A2
1 N N N         
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Liverpool Link 6Z 
13/01/201
5 123 
A2
2 N N N         
Liverpool GP 
20/01/201
5 124 
A2
3 N N N         
Liverpool COPD 
13/01/201
5 125 
A2
4 N N N         
Liverpool Link 6Z 
22/01/201
5 126 
A2
5 N N N         
Liverpool 6X 
22/01/201
5 127 
A2
6 N N N         
Liverpool GP 
26/01/201
5 128 
A2
7 N N N         
Liverpool GP 
26/01/201
5 129 
A2
8 N N N         
Liverpool GP 
26/01/201
5 130 
A2
9 N N N         
Liverpool AMAU 
02/02/201
5 131 
A3
0 N N N         
Liverpool GP Aintree 
08/02/201
5 132 
A3
1 N N N         
Liverpool GP Aintree 
09/02/201
5 133 
A3
2 N N N         
Liverpool GP Aintree 
12/02/201
5 134 
A3
3 N N N         
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Liverpool GP Aintree 
16/02/201
5 135 
A3
4 N N N         
Liverpool CTC 
19/02/201
5 136 
A3
5 N N N         
Liverpool GP 
17/02/201
5 137 
A3
6 Y N N   Y     
Liverpool GP 
18/02/201
5 138 
A3
7 N N N         
Liverpool GP Aintree 
19/02/201
5 139 
A3
8 N N N         
Liverpool Aintree OP 
18/02/201
5 140 
A3
9 N N N         
Liverpool GP Aintree 
13/02/201
5 141 
A4
0 N N N         
Liverpool Ward 23 (Aintree) 
25/02/201
5 142 
A4
1 N N N         
Liverpool Ward 23 (Aintree) 
27/02/201
5 143 
A4
2 N N N         
Liverpool 
Aintree Outpatient 
Unit 
04/03/201
5 144 
A4
3 N N N         
Liverpool COPD 
05/03/201
5 145 
A4
4 N N N         
Liverpool GP Aintree 
07/03/201
5 146 
A4
5 N N N         
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Liverpool Link 6Z 
07/04/201
5 147 
A4
6 N N N   Y 
Earliest 
known: 2004 Mucoid 
Liverpool Link 6Z 
07/04/201
5 147 
A4
7 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A4
8 N N N   Y   Mucoid 
Liverpool Link 6Z 
07/04/201
5 147 
A4
9 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A5
0 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A5
1 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A5
2 N N N   Y   Mucoid 
Liverpool Link 6Z 
07/04/201
5 147 
A5
3 N N N   Y   White 
Liverpool Link 6Z 
07/04/201
5 147 
A5
4 N N N   Y   Mucoid 
Liverpool Link 6Z 
07/04/201
5 147 
A5
5 N N N   Y   White 
Liverpool Link 6Z 
07/04/201
5 147 
A5
6 N N N   Y   White 
Liverpool Link 6Z 
07/04/201
5 147 
A5
7 N N N         
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Liverpool Link 6Z 
07/04/201
5 147 
A5
8 N N N   Y   White 
Liverpool Link 6Z 
07/04/201
5 147 
A5
9 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A6
0 N N N   Y   White 
Liverpool Link 6Z 
07/04/201
5 147 
A6
1 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A6
2 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A6
3 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A6
4 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A6
5 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A6
6 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A6
7 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A6
8 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A6
9 N N N         
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Liverpool Link 6Z 
07/04/201
5 147 
A7
0 N N N   Y   Mucoid 
Liverpool Link 6Z 
07/04/201
5 147 
A7
1 N N N   Y   Mucoid 
Liverpool Link 6Z 
07/04/201
5 147 
A7
2 N N N   Y   Mucoid 
Liverpool Link 6Z 
07/04/201
5 147 
A7
3 N N N   Y   Mucoid 
Liverpool Link 6Z 
07/04/201
5 147 
A7
4 N N N         
Liverpool Link 6Z 
07/04/201
5 147 
A7
5 N N N   Y   Mucoid 
Liverpool Link 6Z 
07/04/201
5 147 
A7
6 N N N   Y   Mucoid 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A7
7 N N N   Y 
Earliest 
known: 2010 Brown 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A7
8 N N N   Y   Mucoid 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A7
9 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A8
0 N N N   Y   Brown 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A8
1 N N N   Y   Mucoid 
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A8
2 N N N   Y   Brown 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A8
3 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A8
4 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A8
5 N N N   Y   Brown 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A8
6 N N N   Y   Brown 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A8
7 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A8
8 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A8
9 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A9
0 N N N   Y   Mucoid 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A9
1 N N N   Y   Brown 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A9
2 N N N   Y   Mucoid 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A9
3 N N N         
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A9
4 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A9
5 N N N   Y   Brown 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A9
6 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A9
7 N N N   Y   Brown 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A9
8 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A9
9 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
00 N N N   Y   Mucoid 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
01 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
02 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
03 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
04 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
05 N N N         
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
06 N N N   Y   Brown 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
07 N N N   Y   Brown 
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
08 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
09 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
10 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
11 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
12 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
13 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
14 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
15 N N N         
Liverpool 
BGH Alexandra 
Wing 
07/04/201
5 148 
A1
16 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
17 N N N     
Earliest 
known: 2015   
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
18 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
19 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
20 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
21 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
22 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
23 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
24 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
25 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
26 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
27 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
28 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
29 N N N         
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(PCR) 
AT 
Type 
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patient 
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Notes 
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
30 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
31 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
32 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
33 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
34 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
35 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
36 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
37 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
38 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
39 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
40 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
41 N N N   Y     
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AT 
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Notes 
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
42 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
43 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
44 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
45 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
46 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
47 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
48 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
49 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
50 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
51 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
52 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
53 N N N         
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AT 
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Notes 
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
54 N N N   Y     
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
55 N N N         
Liverpool  LHCH Maple Suite 
15/05/201
5 149 
A1
56 N N N   Y     
Liverpool GP (Aintree) 
17/04/201
5 150 
A1
57 N N N         
Liverpool GP (Aintree) 
07/05/201
5 152 
A1
58 N N N         
Liverpool 22 (Aintree) 
09/05/201
5 153 
A1
59 N N N         
Liverpool GP (Aintree) 
14/05/201
5 154 
A1
60 N N N         
Liverpool 6Y 
15/05/201
5 155 
A1
61 N N N         
Liverpool Link 6Z 
15/05/201
5 156 
A1
62 N N N         
Liverpool 6Y 
19/05/201
5 137 
A1
63 Y N N   Y     
Liverpool 6Y 
19/05/201
5 158 
A1
64 N N N         
Newcastle   
01/07/200
8 8 B1 N N N 0C1A   10   
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(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
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patient 
info. 
Notes 
Newcastle   
01/11/200
8 8 B3 N N N 0C1A Y 10   
Newcastle   
23/10/201
4 8 B7 N N N 0C1A   10   
Newcastle   
26/10/201
1 9 
B1
0 N N N D421   New patient 
Non-
mucoid 
Newcastle   
18/12/201
1 9 
B1
2 N N N     New patient   
Newcastle   
24/05/201
3 9 
B1
5 N N N     New patient   
Newcastle   
25/11/201
3 9 
B1
6 N N N D421 Y New patient   
Newcastle   
14/07/201
1 10 
B1
7 N N N 741E   26 
Non-
mucoid 
Newcastle   
21/03/201
2 10 
B1
8 N N N     26 
Non-
mucoid 
Newcastle   
19/09/201
2 10 
B1
9 N N N     26   
Newcastle   
24/05/201
3 10 
B2
0 N N N 741E   26   
Newcastle   
22/07/200
8 11 
B2
1 N N N C40A   11   
Newcastle   
01/01/200
9 11 
B2
2 N N N C40A   11   
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AT 
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Notes 
Newcastle   
27/07/201
1 11 
B2
4 N N N AC2E   11 Mucoid 
Newcastle   
03/09/201
4 11 
B3
4 N N N   Y 11   
Newcastle   
23/10/201
4 11 
B3
5 N N N 3C2A   11   
Newcastle   
20/07/201
1 12 
B3
6 N N N F42A   31 
Non-
mucoid 
Newcastle   
18/01/201
2 12 
B3
7 N N N   Y 31   
Newcastle   
24/05/201
3 12 
B3
8 N N N F42A   31 Mucoid 
Newcastle   
01/10/200
7 13 
B4
0 N N N 3C52   New patient Mucoid 
Newcastle   
04/11/201
1 13 
B4
5 N N N 3C52   New patient   
Newcastle   
12/10/201
2 14 
B4
6 N N N 3C28   New patient   
Newcastle   
23/10/201
4 14 
B4
9 N N N D421   New patient   
Newcastle   
01/03/201
1 15 
B5
0 N N N AC2A   24   
Newcastle   
06/11/201
2 15 
B5
8 N N N     24 Mucoid 
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MA15 
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AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Newcastle   
03/09/201
4 15 
B6
2 N N N AC2A Y 24   
Newcastle   
09/07/201
1 16 
B6
3 N N N F469   New patient Mucoid 
Newcastle   
11/07/201
4 16 
B7
1 N N N F469   New patient   
Newcastle   
01/06/200
8 17 
B7
2 N N N 239A   35   
Newcastle   
27/07/201
1 17 
B7
4 N N N 239A   35   
Newcastle   
20/08/201
2 17 
B7
5 N N N     35   
Newcastle   
04/09/201
3 17 
B7
7 N N N 239A   35   
Newcastle   
01/10/200
7 18 
B7
9 N N N B420   8 Mucoid 
Newcastle   
01/10/200
7 18 
B8
0 N N N     8   
Newcastle   
01/12/200
7 18 
B8
1 N N N     8   
Newcastle   
01/08/200
8 18 
B8
2 N N N     8   
Newcastle   
01/10/200
8 18 
B8
4 N N N B420   8   
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(PCR) 
AT 
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patient 
info. 
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Newcastle   
01/05/201
0 18 
B8
5 N N N     8   
Newcastle   
01/11/201
0 18 
B8
7 N N N     8   
Newcastle   
25/07/201
1 18 
B9
0 N N N B420   8 
Non-
mucoid 
Newcastle   
22/03/201
3 18 
B9
9 N N N     8   
Newcastle   
22/03/201
3 18 
B1
00 N N N     8   
Newcastle   
23/10/201
4 18 
B1
12 N N N     8   
Newcastle   
23/10/201
4 18 
B1
13 N N N B420 Y 8   
Newcastle   
11/04/201
2 19 
B1
14 N N N 0C4A Y New patient 
Non-
mucoid 
Newcastle   
18/02/201
4 19 
B1
25 N N N     New patient   
Newcastle   
19/02/201
4 19 
B1
26 N N N 0C4A   New patient   
Newcastle   
09/10/201
3 20 
B1
27 N N N 6852   New patient   
Newcastle   
19/02/201
4 20 
B1
32 N N N     New patient   
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AT 
Type 
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Original 
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info. 
Notes 
Newcastle   
22/10/201
4 20 
B1
39 N N N 6852   New patient Mucoid 
Newcastle   
12/07/201
1 21 
B1
41 N N N D421   New patient Mucoid 
Newcastle   
06/03/201
2 21 
B1
45 N N N     New patient Mucoid 
Newcastle   
03/04/201
4 21 
B1
50 N N N D421   New patient   
Newcastle   
01/11/201
0 22 
B1
51 N N N 1BAE   17   
Newcastle   
18/04/201
2 22 
B1
52 N N N 2C12   17 Mucoid 
Newcastle   
01/03/200
9 23 
B1
56 N N N 059A   New patient   
Newcastle   
03/09/201
4 23 
B1
62 N N N 059A   New patient   
Newcastle   
29/11/201
2 24 
B1
63 N N N     New patient   
Newcastle   
20/03/201
2 25 
B1
64 N N N CC60   New patient Mucoid 
Newcastle   
23/10/201
4 25 
B1
69 N N N CC62   New patient   
Newcastle   
10/06/201
4 26 
B1
70 N N N     New patient   
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AT 
Type 
Sequenced 
Original 
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info. 
Notes 
Newcastle   
29/08/201
4 26 
B1
74 N N N     New patient   
Newcastle   
08/07/200
8 27 
B1
79 N N N     New patient   
Newcastle   
07/11/201
3 28 
B1
83 N N N     New patient   
Newcastle   
29/11/201
4 28 
B1
84 N N N     New patient   
Newcastle   
23/09/201
1 29 
B1
85 N N N 4C8A   New patient Mucoid 
Newcastle   
24/05/201
3 29 
B1
86 N N N 4C8A   New patient Mucoid 
Newcastle   
01/12/200
7 30 
B1
87 N N N 682A   14   
Newcastle   
01/07/201
0 30 
B1
90 N N N 682E   14   
Newcastle   
05/07/201
1 30 
B1
91 N N N   Y 14   
Newcastle   
05/07/201
1 30 
B1
92       682E   14   
Newcastle   
04/09/201
3 30 
B1
94 N N N 682A   14   
Newcastle   
14/03/201
2 31 
B1
96 N N N     New patient   
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AT 
Type 
Sequenced 
Original 
patient 
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Notes 
Newcastle   
04/09/201
3 31 
B1
98 N N N     New patient   
Newcastle   
18/10/201
1 32 
B1
99 N N N F429 Y New patient   
Newcastle   
23/08/201
3 32 
B2
02 N N N 0C2E   New patient   
Sheffield 4 
14/10/200
9 36 C1 N N N         
Sheffield 4 
14/10/200
9 36 C2 N N N   Y     
Sheffield 4 
25/02/201
0 37 C3 N N N   Y     
Sheffield 4 
25/02/201
0 37 C4 N N N   Y     
Sheffield 4 
25/02/201
0 37 C5 N N N   Y     
Sheffield 4 
03/03/201
0 38 C6 N N N   Y     
Sheffield 4 
23/03/201
0 39 C7 N N N   Y     
Sheffield 4 
16/04/201
0 40 C8 N N N   Y     
Sheffield 4 
16/04/201
0 40 C9 N N N   Y     
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AT 
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Sequenced 
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patient 
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Notes 
Sheffield 4 
16/04/201
0 40 C10 N N N   Y     
Sheffield 4 
19/08/201
0 41 C11 N N N   Y     
Sheffield 4 
20/08/201
0 42 C12 N N N   Y     
Sheffield 4 
20/08/201
0 42 C13 N N N   Y     
Sheffield 4 
20/08/201
0 42 C14 N N N   Y     
Sheffield 4 
20/08/201
0 42 C15 N N N   Y     
Sheffield 4 
20/08/201
0 42 C16 N N N   Y     
Sheffield 4 
20/08/201
0 42 C17 N N N   Y     
Sheffield 4 
15/04/201
1 43 C18 N N N   Y     
Sheffield 4 
01/07/201
1 44 C19 N N N         
Sheffield 4 
01/07/201
1 44 C20 N N N   Y     
Papworth 6 
14/04/200
9 45 C21 N N N   Y     
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Sequenced 
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patient 
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Notes 
Papworth 6 
14/04/200
9 45 C22 N N N   Y     
Papworth 6 
14/04/200
9 45 C23 N N N   Y     
Papworth 6 
20/05/200
9 46 C24 N N N         
Papworth 6 
20/05/200
9 46 C25 N N N   Y     
Papworth 6 
01/06/200
9 47 C26 N N N         
Papworth 6 
01/06/200
9 47 C27 N N N         
Papworth 6 
03/06/200
9 48 C28 N N N         
Papworth 6 
03/06/200
9 48 C29 N N N   Y     
Papworth 6 
04/06/200
9 49 C30 N N N   Y     
Papworth 6 
25/08/200
9 50 C31 N N N   Y     
Papworth 6 
25/08/200
9 50 C32 N N N   Y     
Papworth 6 
25/08/200
9 50 C33 N N N   Y     
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patient 
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Notes 
Papworth 6 
30/12/200
9 51 C34 N N N         
Papworth 6 
30/12/200
9 51 C35 N N N         
Papworth 6 
21/05/201
0 52 C36 N N N   Y     
Papworth 6 
21/05/201
0 52 C37 N N N         
Papworth 6 
30/06/201
0 53 C38 N N N         
Papworth 6 
30/06/201
0 53 C39 N N N         
Papworth 6 
30/06/201
0 53 C40 N N N         
Papworth 6 
12/07/201
0 54 C41 N N N         
Papworth 6 
12/07/201
0 54 C42 N N N   Y     
Papworth 6 
28/07/201
0 55 C43 N N N   Y     
Papworth 6 
28/07/201
0 55 C44 N N N   Y     
Papworth 6 
28/07/201
0 55 C45 N N N   Y     
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info. 
Notes 
Papworth 6 
24/08/201
0 56 C46 N N N         
Papworth 6 
02/02/201
1 57 C47 N N N         
Papworth 6 
02/02/201
1 57 C48 N N N         
Papworth 6 
22/02/201
1 58 C49 N N N   Y     
Papworth 6 
22/02/201
1 58 C50 N N N         
Papworth 6 
23/02/201
1 59 C51 Y N N 4C12 Y     
Papworth 6 
16/03/201
1 60 C52 N N N         
Papworth 6 
16/03/201
1 60 C53 N N N         
Papworth 6 
15/06/201
1 61 C54 N N N   Y     
London Chest 
Hospital 9 
26/06/200
9 62 C55 N N N   Y     
London Chest 
Hospital 9 
26/06/200
9 62 C56 N N N   Y     
London Chest 
Hospital 9 
26/06/200
9 62 C57 N N N   Y     
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AT 
Type 
Sequenced 
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Notes 
London Chest 
Hospital 9 
26/06/200
9 62 C58 N N N   Y     
London Chest 
Hospital 9 
26/06/200
9 62 C59 N N N   Y     
London Chest 
Hospital 9 
26/06/200
9 62 C60 N N N   Y     
London Chest 
Hospital 9 
17/11/200
9 63 C61 N N N   Y     
Norfolk & Norwich 10 
02/09/200
9 64 C62 N N N         
Norfolk & Norwich 10 
02/09/200
9 64 C63 N N N   Y     
Norfolk & Norwich 10 
25/11/200
9 65 C64 N N N   Y     
Norfolk & Norwich 10 
25/11/200
9 65 C65 N N N   Y     
Norfolk & Norwich 10 
25/11/200
9 65 C66 N N N   Y     
Norfolk & Norwich 10 
25/11/200
9 65 C67 N N N   Y     
Norfolk & Norwich 10 
25/11/200
9 65 C68 N N N   Y     
Norfolk & Norwich 10 
12/05/201
0 66 C69 N N N   Y     
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(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Reading 11 
04/09/200
9 67 C70 N N N         
Reading 11 
04/09/200
9 67 C71 N N N   Y     
Reading 11 
05/11/201
0 68 C72 N N N         
Reading 11 
05/11/201
0 68 C73 N N N   Y     
Reading 11 
03/12/201
0 69 C74 N N N   Y     
Reading 11 
03/12/201
0 69 C75 N N N         
Chertsey, Surrey 15 
12/05/200
9 70 C76 N N N   Y     
Chertsey, Surrey 15 
03/07/200
9 71 C77 N N N   Y     
Chertsey, Surrey 15 
14/07/200
9 72 C78 N N N   Y     
Chertsey, Surrey 15 
14/07/200
9 72 C79 N N N   Y     
Chertsey, Surrey 15 
14/07/200
9 72 C80 N N N   Y     
Chertsey, Surrey 15 
14/07/200
9 72 C81 N N N   Y     
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Chertsey, Surrey 15 
14/07/200
9 72 C82 N N N   Y     
Chertsey, Surrey 15 
14/07/200
9 72 C83 N N N   Y     
Chertsey, Surrey 15 
14/07/200
9 72 C84 N N N   Y     
Chertsey, Surrey 15 
06/08/200
9 73 C85 N N N   Y     
Chertsey, Surrey 15 
06/08/200
9 73 C86 N N N   Y     
Chertsey, Surrey 15 
06/08/200
9 73 C87 N N N   Y     
Chertsey, Surrey 15 
15/12/200
9 74 C88 N N N   Y     
Chertsey, Surrey 15 
25/03/201
0 75 C89 N N N   Y     
Chertsey, Surrey 15 
25/03/201
0 75 C90 N N N         
Chertsey, Surrey 15 
13/01/201
1 76 C91 N N N   Y     
Chertsey, Surrey 15 
01/02/201
1 77 C92 N N N   Y     
Dorset County 
Hospital 16 
05/06/200
9 78 C93 N N N         
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AT 
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Sequenced 
Original 
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Notes 
Dorset County 
Hospital 16 
03/07/200
9 78 C94 N N N   Y     
Dorset County 
Hospital 16 
29/07/200
9 79 C95 N N N   Y     
Dorset County 
Hospital 16 
29/07/200
9 79 C96 N N N   Y     
Dorset County 
Hospital 16 
29/07/200
9 79 C97 N N N   Y     
Dorset County 
Hospital 16 
29/07/200
9 79 C98 N N N   Y     
Dorset County 
Hospital 16 
29/07/200
9 79 C99 N N N   Y     
Dorset County 
Hospital 16 
13/10/200
9 80 
C10
0 N N N   Y     
Dorset County 
Hospital 16 
21/10/200
9 81 
C10
1 N N N   Y     
Dorset County 
Hospital 16 
21/10/200
9 81 
C10
2 N N N   Y     
Dorset County 
Hospital 16 
21/10/200
9 81 
C10
3 N N N   Y     
Swansea 17 
16/05/200
9 82 
C10
4 N N N   Y     
Swansea 17 
25/07/200
9 83 
C10
5 N N N   Y     
171 
 
Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
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Swansea 17 
11/08/200
9 84 
C10
6 N N N   Y     
Swansea 17 
11/08/200
9 84 
C10
7 N N N   Y     
Swansea 17 
11/08/200
9 84 
C10
8 N N N   Y     
Swansea 17 
11/08/200
9 85 
C10
9 N N N   Y     
Swansea 17 
11/08/200
9 85 
C11
0 N N N   Y     
Swansea 17 
11/08/200
9 85 
C11
1 N N N   Y     
Swansea 17 
11/08/200
9 85 
C11
2 N N N   Y     
Swansea 17 
05/12/200
9 86 
C11
3 N N N         
Swansea 17 
05/12/200
9 86 
C11
4 N N N   Y     
Swansea 17 
05/12/200
9 86 
C11
5 N N N   Y     
Swansea 17 
04/06/201
0 87 
C11
6 N N N   Y     
Swansea 17 
04/06/201
0 87 
C11
7 N N N   Y     
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Notes 
Swansea 17 
04/06/201
0 87 
C11
8 N N N   Y     
Hull 20 
23/01/201
0 88 
C11
9 N N N   Y     
Hull 20 
29/01/201
0 89 
C12
0 N N N   Y     
Hull 20 
29/01/201
0 89 
C12
1 N N N         
Hull 20 
02/04/201
0 90 
C12
2 N N N         
Hull 20 
02/04/201
0 90 
C12
3 N N N   Y     
Hull 20 
08/04/201
0 91 
C12
4 N N N   Y     
Hull 20 
29/04/201
0 92 
C12
5 N N N   Y     
Hull 20 
29/04/201
0 92 
C12
6 N N N   Y     
Hull 20 
29/04/201
0 92 
C12
7 N N N   Y     
Hull 20 
29/04/201
0 92 
C12
8 N N N   Y     
Hull 20 
29/04/201
0 92 
C12
9 N N N   Y     
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Hull 20 
08/05/201
0 93 
C13
0 N N N         
Hull 20 
08/05/201
0 93 
C13
1 N N N   Y     
Hull 20 
28/05/201
0 94 
C13
2 N N N         
Hull 20 
28/05/201
0 94 
C13
3 N N N   Y     
Hull 20 
19/12/201
0 95 
C13
4 N N N   Y     
Sunderland 21 
02/11/200
9 96 
C13
5 N N N   Y     
Sunderland 21 
16/04/201
0 97 
C13
6 N N N         
Sunderland 21 
16/04/201
0 97 
C13
7 N N N   Y     
Sunderland 21 
08/09/201
0 98 
C13
8 N N N         
Sunderland 21 
08/09/201
0 98 
C13
9 N N N   Y     
Sunderland 21 
01/10/201
0 99 
C14
0 N N N         
Sunderland 21 
01/10/201
0 99 
C14
1 N N N   Y     
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Sunderland 21 
11/02/201
1 100 
C14
2 N N N   Y     
Colchester 22 
08/07/201
0 101 
C14
3 N N N   Y     
Colchester 22 
08/07/201
0 101 
C14
4 N N N   Y     
Colchester 22 
08/07/201
0 101 
C14
5 N N N   Y     
Colchester 23 
25/06/201
0 102 
C14
6 N N N   Y     
Colchester 23 
25/06/201
0 102 
C14
7 N N N   Y     
Colchester 23 
25/06/201
0 102 
C14
8 N N N   Y     
Colchester 23 
22/03/201
1 103 
C14
9 N N N   Y     
Portsmouth 25 
27/08/201
0 104 
C15
0 N N N   Y     
Portsmouth 25 
03/03/201
1 105 
C15
1 N N N   Y     
Portsmouth 25 
03/03/201
1 105 
C15
2 N N N         
Portsmouth 25 
07/04/201
1 106 
C15
3 N N N   Y     
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
Portsmouth 25 
07/04/201
1 106 
C15
4 N N N         
Cardiff 26 
04/12/201
0 107 
C15
5 N N N   Y     
West Wales G. 
Hospital 28 
16/11/201
0 108 
C15
6 N N N   Y     
West Wales G. 
Hospital 28 
03/12/201
0 109 
C15
7 N N N         
West Wales G. 
Hospital 28 
03/12/201
0 109 
C15
8 N N N   Y     
West Wales G. 
Hospital 28 
09/12/201
0 110 
C15
9 N N N   Y     
West Wales G. 
Hospital 28 
09/12/201
0 111 
C16
0 N N N   Y     
West Wales G. 
Hospital 28 
03/03/201
1 112 
C16
1 N N N   Y     
West Wales G. 
Hospital 28 
03/03/201
1 112 
C16
2 N N N         
West Wales G. 
Hospital 28 
03/03/201
1 112 
C16
3 N N N         
West Wales G. 
Hospital 29 
08/12/201
0 113 
C16
4 N N N   Y     
West Wales G. 
Hospital 29 
08/12/201
0 113 
C16
5 N N N         
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Centre Location 
Date 
collected 
P
at
ie
n
t 
Is
o
la
te
 
LES 
(PCR) 
MID1 
(PCR) 
MA15 
(PCR) 
AT 
Type 
Sequenced 
Original 
patient 
info. 
Notes 
West Wales G. 
Hospital 29 
21/04/201
1 114 
C16
6 N N N         
West Wales G. 
Hospital 29 
21/04/201
1 114 
C16
7 N N N   Y     
West Wales G. 
Hospital 29 
21/12/201
0 115 
C16
8 N N N   Y     
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Table A2: List of probe sequences used in the Array Tube system. Adapted from supplementary information from Wiehlmann et al. (2007). 
Probe name Reference 5'-3'-Sequence (probe) 
oriC PAO PAO1- Sequence, Stover et al. (updated 2006) GAAGCCCAGCAATTGCGTGTTTC 
oriC non-PAO UCBPP-PA14, complete genome, Lee et al. (2006) GAAGCCCAGCAACTGCGTGTTTC 
oprL (1) PAO PAO1- Sequence, Stover et al. (updated 2006) GGTGCTGCAGGGTGTTTCGCCGG 
oprL (1) non-PAO UCBPP-PA14, complete genome, Lee et al. (2006) GGTGCTGCAGGGCGTTTCGCCGG 
oprL (2) PAO PAO1- Sequence, Stover et al. (updated 2006) GTGCTGCAGGGTGTTTCGCCG 
oprL (2) non-PAO UCBPP-PA14, complete genome, Lee et al. (2006) GCTGCAGGGCGTTTCGCCG 
fliCa (1) PAK PAK, Totten and Lory (1990), flagellin type a2, Giske et al. (2006)  CAAGATCGCCGCAGCGGTCAAC 
fliCa (1) non-PAK ATCC15691, Spangenberg et al. (1998), flagellin type a1, Giske et al. (2006) CAAGATCGCCGCTGCGGTCAAC 
fliCa (2) PAK PAK, Totten and Lory (1990), flagellin type a2, Giske et al. (2006)  CAAGATCGCCGCAGCGGTCAACGAC 
fliCa (2) non-PAK ATCC15691, Spangenberg et al. (1998), flagellin type a1, Giske et al. (2006) CAAGATCGCCGCTGCGGTCAACGAC 
alkB2 PAO PAO1- Sequence, Stover et al. (updated 2006) CCTCGCCCTGTTCCCACCGCTCTGG 
alkB2 non-PAO ATCC 15691, Morales et al. (2004) CTCGCCCTGTTCCCGCCGCTCTGG 
citS-1 PAO PAO1- Sequence, Stover et al. (updated 2006) TCGAGCAACTGGCAGAGAAATCCG 
citS-1 non-PAO UCBPP-PA14, complete genome, Lee et al. (2006)  CGAGCAACTGGCGGAGAAATCCG 
citS-2 PAO PAO1- Sequence, Stover et al. (updated 2006) GCGGAAAACTTCCTGCACATGATGTT 
citS-2 non-PAO Kiewitz and Tummler. J Bacteriol. (2000) 182:3125-35.  GCGGAAAACTTCCTCCACATGATGTT 
oprI (1) PAO PAO1- Sequence, Stover et al. (updated 2006) AGCTCAGCAGACTGCTGACGAGG 
oprI (1) non-PAO UCBPP-PA14, complete genome, Lee et al. (2006)  AGCTCAGCAGACCGCTGACGAG 
oprI (2) PAO PAO1- Sequence, Stover et al. (updated 2006) GCTCAGCAGACTGCTGACGAGGCTAACG 
oprI (2) non-PAO UCBPP-PA14, complete genome, Lee et al. (2006)  GCTCAGCAGACCGCTGACGAGGCTAAC 
ampC-1 PAO PAO1- Sequence, Stover et al. (updated 2006) ACGGCCGCCGGGTGACGCC 
ampC-1 non-PAO De Champs et al. (2002),  Kiewitz and Tummler. J Bacteriol. (2000) 182:3125-35. ACGGCCGCCAGGTGACGCCG 
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Probe name Reference 5'-3'-Sequence (probe) 
ampC-3 PAO PAO1- Sequence, Stover et al. (updated 2006) CGACCTACGCGCCGGGCAG 
ampC-3 non-PAO De Champs et al. (2002), Kiewitz and Tummler. J Bacteriol. (2000) 182:3125-35. CGACCTATGCGCCGGGCAGC 
ampC-4 PAO PAO1- Sequence, Stover et al. (updated 2006) CGTTCGAACGGCTCATGGAGCAG 
ampC-4 non-PAO De Champs et al. (2002), Kiewitz and Tummler. J Bacteriol. (2000) 182:3125-35. CGTTCGAACGACTCATGGAGCAGC 
ampC-5 PAO PAO1- Sequence, Stover et al. (updated 2006) TGGAGCAGCAAGTGTTCCCGGC 
ampC-5 non-PAO De Champs et al. (2002), Kiewitz and Tummler. J Bacteriol. (2000) 182:3125-35. TGGAGCAGCAACTGTTCCCGGC 
ampC-6 PAO PAO1- Sequence, Stover et al. (updated 2006) GAACAAGACCGGTTCCACCAACGG 
ampC-6 non-PAO UCBPP-PA14, complete genome, Lee et al. (2006)  AACAAGACCGGCTCCACCAACGG 
ampC-7 PAO PAO1- Sequence, Stover et al. (updated 2006) CGACCTGGGCCTGGTGATCCT 
ampC-7 non-PAO De Champs et al. (2002), Kiewitz and Tummler. J Bacteriol. (2000) 182:3125-35. GCGACCTGGGACTGGTGATCCTGG 
fliC a ATCC15691, Spangenberg et al. (1998) GTCGCTGAACGGCACCTACTTCA 
fliC b PAO1- Sequence, Stover et al. (updated 2006) GCCGACCAACTGAACTCCAACTCG 
exoS PAO1- Sequence, Stover et al. (updated 2006) CAGCCCAGTCAGGACGCGCA 
exoU UCBPP-PA14, complete genome, Lee et al. (2006)  CGCCAGTTTGAGAACGGAGTCACC 
fpvA type I PAO1- Sequence, Stover et al. (updated 2006) CCTGAATCCGACCATTCGCGAGTC 
fpvA type IIa de Chial et al. (2003) TCGGACTGTACTCCTACGAAGCAGC 
fpvA type IIb Spencer et al. (2003) CCAATCCCTATCGCTGGAACCGTACC 
fpvA type III de Chial et al. (2003) GCTCGGGACTCGCATTTCGTCC 
fpvB PAO1- Sequence, Stover et al. (updated 2006) GCGTTATTGCTCGGTCTCTCCTCG 
LES LES400 (personal communication C. Winstanley) TGCATAGGAGTCATGCCGACAGCA 
PA0636 PAO1- Sequence, Stover et al. (updated 2006) GCCAATTGGGTCAGCAAGCAACG 
PA0722 PAO1- Sequence, Stover et al. (updated 2006) CGTGTCGCGAACTCGCATGGC 
PA0728 PAO1- Sequence, Stover et al. (updated 2006) CTGGAGCCTGCGAAAGTGGCTC 
PA2185 PAO1- Sequence, Stover et al. (updated 2006) ACGAGGGTGATGGCTGGGAATACG 
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Probe name Reference 5'-3'-Sequence (probe) 
PA2221 PAO1- Sequence, Stover et al. (updated 2006) CAGTTGTCGCCAGGTCTGGAGAATCC 
PA3835 PAO1- Sequence, Stover et al. (updated 2006) CACATCAATGTCAGCCCACGCCA 
fla-island Arora et al. (2001) ACCTGTGTCGCTGGAGGGTATGTT 
orfA Arora et al. (2001) CGCTGGAGGGTATGTTCCGCAAGG 
orfI Arora et al. (2001) CCTGGACCTCTCCAAGGTTCGCCT 
orfJ Arora et al. (2001) GCCATTCCGACGACCAAACAAGGC 
PA0980 PAO1- Sequence, Stover et al. (updated 2006) CGGTATGAAGATGGGTGGTTGGGTCG 
XF1753 UCBPP-PA14, complete genome, Lee et al. (2006)  TGCGAGGACCAGAAACCTTGATGG 
acetyltransferase UCBPP-PA14, complete genome, Lee et al. (2006)  CGAAGCGTAGGGTCTTCGTAGCC 
pKL-1 Klockgether et al. (2004) CACCATGCAAATGCTCGATGGACTGC 
pKL-3 Klockgether et al. (2004) TCTGAACTGCGGCTATCACCTGGA 
TB-C47-1 P.aeruginosa TB, pKLC102 related gene island integrated in tRNA(Lys) PA4541.1 GCAGGCGTCCAAGTTGGAGCTCTCC 
TB-C47-2 P.aeruginosa TB, pKLC102 related gene island integrated in tRNA(Lys) PA4541.1 TCCAACAGGCAGGAGTACAGGGTG 
PAPI-1 pili chaperone UCBPP-PA14, complete genome, Lee et al. (2006)  GGAACACAACGTGGGGCGTGAC 
PAPI-1 luminal binding protein UCBPP-PA14, complete genome, Lee et al. (2006)  CCAGTTGGCACCACCATGCTTGC 
pKLC conserved hypothetical Klockgether et al. (2004) GCCTGCCTACTTGTTCCCAACGC 
pKLC adhesin Klockgether et al. (2004) GGCTGTATTGCCCGCCATTCTCC 
pKLC fatty acid synthase Klockgether et al. (2004) CGACAGACAGAAAGGGTTCTTGCGC 
PAGI-2/3-4 Larbig et al. (2002) GCGCCTTCTCCTCTTTGCAGATGT 
PAGI-2/3-5 Larbig et al. (2002) CAGTATGGTACGGACACGAAGCGC 
PAGI-2/3-6 Larbig et al. (2002) CCATGGTCGGAACAGGCACGATATGC 
C-45 Larbig et al. (2002) CGAGGAGTTTCGGACCCGCTTTGA 
C-46 Larbig et al. (2002) CGAAGTCTGAGGTGTGGACCCGC 
C-47 Larbig et al. (2002) CCACTCGATCATGTTGAGCATCGGCTCC 
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Probe name Reference 5'-3'-Sequence (probe) 
PAGI-2 Larbig et al. (2002) GCATCATTGCGCGTCACATCTGGT 
PAGI-2/3-1 Larbig et al. (2002) GACCGCAAGCAGAAACGGCATGC 
PAGI-3-1 Larbig et al. (2002) CCCGTTGCTCATAACCCGTTCCTG 
PAGI-3-8 Larbig et al. (2002) GGTTAGTCCCTTCTGCCCGCATCG 
tRNA(Pro)- island  1 P.aeruginosa TB, gene island integrated into tRNA(Pro) PA2736.1 GTGTCACGGCCCATGTCTAGCAGC 
tRNA(Pro)- island  2 P.aeruginosa TB, gene island integrated into tRNA(Pro) PA2736.1 AGGCCATGGGCTAGCCGGATGC 
PAGI-1 Liang et al. (2001) TTCTCGGTGTCGAGGGATTCTCGG 
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Table A3: SNP data from AT genotyping for all longitudinal isolates included in chapter 3. 
Patient 
Date 
collected 
AT code oriC oprL alkB2 
citS-
1 
citS-
2 
oprI 
ampC-
1 
ampC-
3 
ampC-
4 
ampC-
5 
ampC-
6 
ampC-
7 
fliCa 
fliCa-
SNP 
exoS exoU 
8 
01/07/2008 0C1A 0 0 0 0 1 1 0 0 0 0 0 1 1 0 1 0 
01/11/2008 0C1A 0 0 0 0 1 1 0 0 0 0 0 1 1 0 1 0 
23/10/2014 0C1A 0 0 0 0 1 1 0 0 0 0 0 1 1 0 1 0 
9 
14/07/2011 D421 1 1 0 1 0 1 0 0 0 0 1 0 0 0 0 1 
24/05/2013 D421 1 1 0 1 0 1 0 0 0 0 1 0 0 0 0 1 
10 
14/07/2011 741E 0 1 1 1 0 1 0 0 0 0 0 1 1 1 1 0 
24/05/2013 741E 0 1 1 1 0 1 0 0 0 0 0 1 1 1 1 0 
11 
22/07/2008 C40A 1 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 
01/01/2009 C40A 1 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 
27/07/2011 AC2E 1 0 1 0 1 1 0 0 0 0 1 0 1 1 1 0 
23/10/2014 3C2A 0 0 1 1 1 1 0 0 0 0 1 0 1 0 1 0 
12 
20/07/2011 F42A 1 1 1 1 0 1 0 0 0 0 1 0 1 0 1 0 
24/05/2013 F42A 1 1 1 1 0 1 0 0 0 0 1 0 1 0 1 0 
13 
01/10/2007 3C52 0 0 1 1 1 1 0 0 0 1 0 1 0 0 1 0 
04/11/2011 3C52 0 0 1 1 1 1 0 0 0 1 0 1 0 0 1 0 
14 
12/10/2012 3C28 0 0 1 1 1 1 0 0 0 0 1 0 1 0 0 0 
23/10/2014 D421 1 1 0 1 0 1 0 0 0 0 1 0 0 0 0 1 
15 
01/03/2011 AC2A 1 0 1 0 1 1 0 0 0 0 1 0 1 0 1 0 
03/09/2014 AC2A 1 0 1 0 1 1 0 0 0 0 1 0 1 0 1 0 
16 
09/07/2011 F469 1 1 1 1 0 1 0 0 0 1 1 0 1 0 0 1 
11/07/2014 F469 1 1 1 1 0 1 0 0 0 1 1 0 1 0 0 1 
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Patient 
Date 
collected 
AT code oriC oprL alkB2 
citS-
1 
citS-
2 
oprI 
ampC-
1 
ampC-
3 
ampC-
4 
ampC-
5 
ampC-
6 
ampC-
7 
fliCa 
fliCa-
SNP 
exoS exoU 
17 
01/06/2008 239A 0 0 1 0 0 0 1 1 1 0 0 1 1 0 1 0 
27/07/2011 239A 0 0 1 0 0 0 1 1 1 0 0 1 1 0 1 0 
04/09/2013 239A 0 0 1 0 0 0 1 1 1 0 0 1 1 0 1 0 
18 
01/10/2007 B420 1 0 1 1 0 1 0 0 0 0 1 0 0 0 0 0 
01/10/2008 B420 1 0 1 1 0 1 0 0 0 0 1 0 0 0 0 0 
25/07/2011 B420 1 0 1 1 0 1 0 0 0 0 1 0 0 0 0 0 
23/10/2014 B420 1 0 1 1 0 1 0 0 0 0 1 0 0 0 0 0 
19 
11/04/2012 0C4A 0 0 0 0 1 1 0 0 0 1 0 0 1 0 1 0 
19/02/2014 0C4A 0 0 0 0 1 1 0 0 0 1 0 0 1 0 1 0 
20 
09/10/2013 6852 0 1 1 0 1 0 0 0 0 1 0 1 0 0 1 0 
22/10/2014 6852 0 1 1 0 1 0 0 0 0 1 0 1 0 0 1 0 
21 
12/07/2011 D421 1 1 0 1 0 1 0 0 0 0 1 0 0 0 0 1 
03/04/2014 D421 1 1 0 1 0 1 0 0 0 0 1 0 0 0 0 1 
22 
01/11/2010 1BAE 0 0 0 1 1 0 1 1 1 0 1 0 1 1 1 0 
18/04/2012 2C12 0 0 1 0 1 1 0 0 0 0 0 1 0 0 1 0 
23 
01/03/2009 059A 0 0 0 0 0 1 0 1 1 0 0 1 1 0 1 0 
03/09/2014 059A 0 0 0 0 0 1 0 1 1 0 0 1 1 0 1 0 
25 
20/03/2012 CC60 1 1 0 0 1 1 0 0 0 1 1 0 0 0 0 0 
23/10/2014 CC60 1 1 0 0 1 1 0 0 0 1 1 0 0 0 0 0 
29 
23/09/2011 4C8A 0 1 0 0 1 1 0 0 1 0 0 0 1 0 1 0 
24/05/2013 4C8A 0 1 0 0 1 1 0 0 1 0 0 0 1 0 1 0 
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Patient 
Date 
collected 
AT code oriC oprL alkB2 
citS-
1 
citS-
2 
oprI 
ampC-
1 
ampC-
3 
ampC-
4 
ampC-
5 
ampC-
6 
ampC-
7 
fliCa 
fliCa-
SNP 
exoS exoU 
30 
01/12/2007 682A 0 1 1 0 1 0 0 0 0 0 1 0 1 0 1 0 
01/07/2010 682E 0 1 1 0 1 0 0 0 0 0 1 0 1 1 1 0 
01/07/2011 682E 0 1 1 0 1 0 0 0 0 0 1 0 1 1 1 0 
04/09/2013 682A 0 1 1 0 1 0 0 0 0 0 1 0 1 0 1 0 
32 
18/10/2011 F429 1 1 1 1 0 1 0 0 0 0 1 0 1 0 0 1 
23/08/2013 0C2E 0 0 0 0 1 1 0 0 0 0 1 0 1 1 1 0 
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Table A4: Accessory genome data from AT genotyping of all isolates in chapter 3. 
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8 
0C1A 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
0C1A 0 1 1 0 0 0 0 0 0 0 1 1 0 0 
0C1A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
9 
D421 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
D421 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
10 
741E 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
741E 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
11 
C40A 0 0 1 0 0 0 0 1 0 1 1 1 0 0 
C40A 0 0 1 0 0 0 0 1 0 1 1 1 0 0 
AC2E 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
3C2A 1 0 1 0 0 0 0 1 1 1 1 0 0 0 
12 
F42A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
F42A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
13 
3C52 0 1 1 0 0 0 1 1 0 0 1 1 0 0 
3C52 0 1 1 0 0 0 1 0 0 0 1 1 0 0 
14 
3C28 1 0 1 0 0 0 0 1 1 1 0 1 0 0 
D421 0 0 1 0 0 0 0 0 0 1 1 0 0 0 
15 
AC2A 0 0 1 0 0 0 0 1 0 1 1 1 0 0 
C40A 0 1 0 0 0 0 1 0 0 0 1 0 0 0 
AC2A 0 1 0 0 0 0 0 0 0 0 1 0 0 0 
16 
F469 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
F469 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
17 
239A 0 0 1 0 0 0 0 1 0 1 1 0 0 0 
239A 0 1 1 0 0 0 0 1 0 1 1 0 0 0 
239A 0 1 1 0 1 0 0 1 0 0 1 0 0 0 
18 
B420 0 1 1 0 0 0 0 0 0 0 0 0 0 0 
B420 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
B420 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
B420 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
19 
0C4A 0 0 0 0 0 0 0 0 0 0 1 1 0 0 
0C4A 0 0 0 0 0 0 0 0 0 0 1 1 0 0 
20 
6852 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
6852 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
21 
D421 0 1 0 0 0 0 0 0 0 0 1 1 0 0 
D421 0 1 1 0 0 0 0 0 0 0 1 1 0 0 
22 
1BAE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
2C12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
23 
059A 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
059A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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25 
CC60 1 0 1 0 0 0 0 1 1 1 0 0 0 0 
CC60 1 1 1 0 0 0 0 1 1 1 0 0 0 0 
29 
4C8A 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
4C8A 0 1 0 0 0 0 0 0 0 0 1 0 0 0 
30 
682A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
682E 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
682A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
32 
F429 0 0 1 0 0 0 0 1 1 1 1 1 0 0 
0C2E 0 0 1 0 0 0 0 0 0 1 1 0 0 0 
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8 
0C1A 0 0 1 1 0 0 1 0 0 1 0 0 1 
0C1A 0 1 0 0 0 0 1 0 1 1 0 0 1 
0C1A 0 0 0 0 0 0 1 0 0 1 0 0 1 
9 
D421 0 0 0 0 0 1 0 0 0 1 0 1 1 
D421 0 0 0 0 0 1 0 0 0 1 0 1 1 
10 
741E 0 0 1 0 0 0 1 0 0 1 0 1 0 
741E 0 0 1 0 0 0 1 0 0 1 0 1 0 
11 
C40A 0 0 1 1 1 0 0 1 0 1 0 1 1 
C40A 0 0 1 1 1 0 0 1 0 1 0 1 1 
AC2E 0 1 1 0 0 0 0 0 1 1 0 0 0 
3C2A 0 0 1 0 0 0 0 1 0 1 0 0 0 
12 
F42A 0 0 0 0 0 1 0 0 0 1 0 1 0 
F42A 0 0 0 0 0 1 0 0 0 1 0 1 0 
13 
3C52 0 0 0 0 0 0 0 0 1 1 0 0 0 
3C52 0 0 0 0 0 0 0 0 1 1 0 0 0 
14 
3C28 0 0 1 0 0 0 0 1 0 1 0 0 0 
D421 1 0 1 0 0 1 0 0 0 1 0 1 1 
15 
AC2A 0 0 1 1 1 0 0 1 1 1 0 1 1 
C40A 1 1 1 0 0 0 0 0 0 1 0 1 1 
AC2A 0 1 1 0 0 0 0 0 0 1 0 0 0 
16 
F469 0 0 0 0 0 0 0 0 0 1 0 1 1 
F469 0 0 0 0 0 0 0 0 0 1 0 1 1 
17 
239A 0 0 1 0 0 1 0 0 0 1 0 1 0 
239A 0 0 1 0 0 1 0 0 0 1 0 1 0 
239A 0 0 1 1 0 1 0 0 0 1 0 1 0 
18 
B420 0 0 0 0 0 0 0 1 0 0 0 1 1 
B420 0 0 0 0 0 0 0 1 0 0 0 1 1 
B420 0 0 0 0 0 0 0 1 0 0 0 1 1 
B420 0 0 0 0 0 0 0 1 0 0 0 1 1 
19 
0C4A 0 0 1 1 1 1 0 0 0 1 0 1 0 
0C4A 0 0 1 1 1 1 0 0 0 1 0 1 0 
20 
6852 0 0 0 0 0 0 0 1 0 1 0 0 0 
6852 0 0 0 0 0 0 0 1 0 1 0 0 0 
21 
D421 1 1 0 0 0 0 0 0 1 1 0 1 1 
D421 1 1 0 0 0 0 0 0 0 1 0 1 1 
22 
1BAE 0 0 0 0 0 0 0 0 1 1 0 1 1 
2C12 0 0 0 0 0 0 0 0 1 1 0 1 1 
23 
059A 0 0 0 0 1 0 1 0 0 1 0 1 0 
059A 0 0 0 0 0 0 1 0 0 1 0 1 0 
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682A 0 0 0 0 0 0 1 0 0 1 0 1 1 
682E 0 0 0 0 0 0 1 0 0 1 0 1 1 
682A 0 0 0 0 0 0 1 0 0 1 0 1 1 
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F429 0 0 0 0 0 0 0 0 1 1 1 1 0 
0C2E 0 0 1 0 0 1 0 0 0 1 0 0 1 
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0C1A 1 1 0 1 1 1 0 1 0 1 1 1 
0C1A 1 1 1 1 1 1 0 1 0 1 1 1 
0C1A 1 0 0 1 1 1 0 1 0 1 1 1 
9 
D421 1 1 0 0 0 0 0 1 0 0 0 0 
D421 1 1 0 0 0 0 0 1 0 0 0 0 
10 
741E 1 0 0 1 1 1 0 0 0 0 1 1 
741E 1 0 0 1 1 1 0 0 0 0 1 1 
11 
C40A 1 1 0 1 1 1 1 1 0 0 1 1 
C40A 1 1 0 1 1 1 1 1 0 0 1 1 
AC2E 1 1 0 1 1 1 0 1 0 1 1 1 
3C2A 1 0 0 0 1 1 0 1 1 0 0 0 
12 
F42A 1 0 1 0 1 1 0 0 0 1 0 1 
F42A 1 0 1 0 1 1 0 0 0 1 0 0 
13 
3C52 1 1 0 1 1 0 1 1 0 1 0 0 
3C52 1 1 0 1 1 0 1 1 0 1 0 0 
14 
3C28 1 1 0 0 1 1 0 1 1 0 0 0 
D421 1 1 0 1 1 0 1 1 0 1 0 0 
15 
AC2A 1 1 0 1 1 1 1 1 0 0 1 1 
C40A 1 1 0 1 1 1 0 1 0 0 1 1 
AC2A 1 1 0 1 1 1 0 1 0 1 1 1 
16 
F469 1 1 0 1 1 0 0 1 0 0 0 1 
F469 1 1 0 0 0 0 0 1 0 0 0 0 
17 
239A 1 1 0 1 1 1 0 1 1 1 1 1 
239A 1 1 0 1 1 1 0 1 1 1 1 1 
239A 1 1 0 1 1 1 1 1 1 1 1 1 
18 
B420 1 0 0 1 1 0 1 0 0 0 0 0 
B420 1 0 0 0 1 0 0 0 0 0 0 0 
B420 1 0 0 0 1 0 0 0 0 0 0 0 
B420 1 0 0 0 0 0 0 0 0 0 0 0 
19 
0C4A 1 0 0 1 1 1 0 1 0 1 0 0 
0C4A 1 0 0 1 1 1 0 1 0 1 0 0 
20 
6852 1 0 0 1 0 0 0 0 0 1 0 0 
6852 1 1 0 1 1 0 1 0 0 1 0 0 
21 
D421 1 1 0 1 1 1 1 1 0 1 0 1 
D421 1 1 0 1 1 0 1 1 0 1 0 0 
22 
1BAE 1 0 0 1 1 0 0 0 0 1 0 0 
2C12 1 1 0 1 1 0 0 0 0 1 1 1 
23 
059A 1 1 0 1 1 1 1 0 0 1 1 0 
059A 1 1 0 1 1 1 0 0 0 1 1 1 
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4C8A 1 1 0 1 1 1 0 1 0 0 1 1 
4C8A 1 1 0 1 1 1 0 1 0 0 1 1 
30 
682A 1 1 0 1 1 1 1 0 0 1 1 1 
682E 0 0 1 1 1 1 0 0 0 1 1 1 
682A 1 0 0 1 1 1 0 0 0 1 1 1 
32 
F429 1 1 0 1 1 1 1 1 0 1 0 0 
0C2E 1 1 1 1 1 1 0 0 0 1 1 1 
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0C1A 0 0 1 0 1 0 
0C1A 0 0 1 0 1 0 
0C1A 0 0 1 0 1 0 
9 
D421 0 1 0 1 0 1 
D421 0 1 0 1 0 1 
10 
741E 0 0 1 0 1 0 
741E 0 0 1 0 1 0 
11 
C40A 1 0 1 0 1 0 
C40A 1 0 1 0 1 0 
AC2E 0 0 1 0 1 0 
3C2A 0 0 1 0 1 0 
12 
F42A 0 0 1 0 1 0 
F42A 0 0 1 0 1 0 
13 
3C52 1 0 0 1 1 0 
3C52 1 0 0 1 1 0 
14 
3C28 0 0 1 0 0 0 
D421 0 1 0 1 0 1 
15 
AC2A 1 0 1 0 1 0 
C40A 0 0 1 0 1 0 
AC2A 0 0 1 0 1 0 
16 
F469 0 0 1 0 0 1 
F469 0 0 1 0 0 1 
17 
239A 0 0 1 0 1 0 
239A 0 0 1 0 1 0 
239A 0 0 1 0 1 0 
18 
B420 0 0 0 1 0 0 
B420 0 0 0 1 0 0 
B420 0 0 0 1 0 0 
B420 0 0 0 1 0 0 
19 
0C4A 0 0 1 0 1 0 
0C4A 0 0 1 0 1 0 
20 
6852 0 0 0 1 1 0 
6852 0 0 0 1 1 0 
21 
D421 0 1 0 1 0 1 
D421 0 1 0 1 0 1 
22 
1BAE 0 0 1 0 1 0 
2C12 1 1 0 1 1 0 
23 
059A 0 0 1 0 1 0 
059A 0 0 1 0 1 0 
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CC60 1 0 0 1 0 0 
CC60 1 0 0 1 0 0 
29 
4C8A 0 0 1 0 1 0 
4C8A 0 0 1 0 1 0 
30 
682A 0 0 1 0 1 0 
682E 0 0 1 0 1 0 
682A 0 0 1 0 1 0 
32 
F429 0 1 1 0 0 1 
0C2E 0 0 1 0 1 0 
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Table A5: All isolates with complete genome sequences from chapter 4, including MLST sequence 
type 
Isolate ID Centre Patient ST 
C155 Cardiff 107 1211 
C76 Chertsey, Surrey 70 253 
C77 Chertsey, Surrey 71 308 
C78 Chertsey, Surrey 72 840 
C79 Chertsey, Surrey 72 620 
C80 Chertsey, Surrey 72 620 
C81 Chertsey, Surrey 72 620 
C82 Chertsey, Surrey 72 620 
C83 Chertsey, Surrey 72 - 
C84 Chertsey, Surrey 72 620 
C85 Chertsey, Surrey 73 - 
C86 Chertsey, Surrey 73 308 
C87 Chertsey, Surrey 73 179 
C88 Chertsey, Surrey 74 1251 
C89 Chertsey, Surrey 75 1239 
C91 Chertsey, Surrey 76 253 
C92 Chertsey, Surrey 77 252 
C143 Colchester 101 253 
C144 Colchester 101 253 
C145 Colchester 101 253 
C146 Colchester 102 395 
C147 Colchester 102 395 
C148 Colchester 102 395 
C149 Colchester 103 108 
C100 Dorset County Hospital 80 612 
C101 Dorset County Hospital 81 - 
C102 Dorset County Hospital 81 - 
C103 Dorset County Hospital 81 - 
C94 Dorset County Hospital 78 395 
C95 Dorset County Hospital 79 253 
C96 Dorset County Hospital 79 253 
C97 Dorset County Hospital 79 253 
C98 Dorset County Hospital 79 253 
C99 Dorset County Hospital 79 253 
C119 Hull 88 - 
C120 Hull 89 - 
C123 Hull 90 27 
C124 Hull 91 1753 
C125 Hull 92 253 
C126 Hull 92 253 
C127 Hull 92 164 
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Isolate ID Centre Patient ST 
C128 Hull 92 164 
C129 Hull 92 871 
C131 Hull 93 253 
C133 Hull 94 253 
C134 Hull 95 253 
A1 Liverpool 1 17 
A12 Liverpool 35 179 
A163 Liverpool 150 146 
A19 Liverpool 120 - 
A2 Liverpool 2 207 
A3 Liverpool 3 252 
A36 Liverpool 137 146 
A4 Liverpool 3 252 
A46 Liverpool 147 17 
A48 Liverpool 147 17 
A5 Liverpool 3 252 
A52 Liverpool 147 17 
A53 Liverpool 147 17 
A54 Liverpool 147 17 
A55 Liverpool 147 17 
A56 Liverpool 147 17 
A58 Liverpool 147 17 
A60 Liverpool 147 17 
A70 Liverpool 147 17 
A71 Liverpool 147 17 
A72 Liverpool 147 17 
A73 Liverpool 147 17 
A75 Liverpool 147 17 
A76 Liverpool 147 17 
A100 Liverpool (BGH) 148 17 
A106 Liverpool (BGH) 148 175 
A107 Liverpool (BGH) 148 175 
A77 Liverpool (BGH) 148 175 
A78 Liverpool (BGH) 148 17 
A80 Liverpool (BGH) 148 175 
A81 Liverpool (BGH) 148 17 
A82 Liverpool (BGH) 148 17 
A85 Liverpool (BGH) 148 175 
A86 Liverpool (BGH) 148 175 
A90 Liverpool (BGH) 148 175 
A91 Liverpool (BGH) 148 175 
A92 Liverpool (BGH) 148 175 
A95 Liverpool (BGH) 148 175 
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Isolate ID Centre Patient ST 
A97 Liverpool (BGH) 148 175 
A119 Liverpool (LHCH) 149 667 
A122 Liverpool (LHCH) 149 667 
A123 Liverpool (LHCH) 149 667 
A126 Liverpool (LHCH) 149 667 
A130 Liverpool (LHCH) 149 667 
A134 Liverpool (LHCH) 149 667 
A137 Liverpool (LHCH) 149 667 
A141 Liverpool (LHCH) 149 667 
A144 Liverpool (LHCH) 149 667 
A147 Liverpool (LHCH) 149 667 
A148 Liverpool (LHCH) 149 667 
A151 Liverpool (LHCH) 149 667 
A154 Liverpool (LHCH) 149 667 
A156 Liverpool (LHCH) 149 667 
C55 London Chest Hospital 62 - 
C56 London Chest Hospital 62 - 
C57 London Chest Hospital 62 - 
C58 London Chest Hospital 62 - 
C59 London Chest Hospital 62 - 
C60 London Chest Hospital 62 - 
C61 London Chest Hospital 63 620 
B113 Newcastle 18 1328 
B114 Newcastle 19 198 
B16 Newcastle 9 253 
B199 Newcastle 32 1182 
B3 Newcastle 8 281 
B34 Newcastle 11 179 
B37 Newcastle 12 - 
B62 Newcastle 15 - 
C63 Norfolk & Norwich 64 27 
C64 Norfolk & Norwich 65 274 
C65 Norfolk & Norwich 65 274 
C66 Norfolk & Norwich 65 274 
C67 Norfolk & Norwich 65 274 
C68 Norfolk & Norwich 65 274 
C69 Norfolk & Norwich 66 - 
C21 Papworth 45 - 
C22 Papworth 45 - 
C23 Papworth 45 - 
C25 Papworth 46 253 
C29 Papworth 48 252 
C30 Papworth 49 252 
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Isolate ID Centre Patient ST 
C31 Papworth 50 - 
C32 Papworth 50 - 
C33 Papworth 50 - 
C36 Papworth 52 253 
C42 Papworth 54 309 
C43 Papworth 55 108 
C44 Papworth 55 108 
C45 Papworth 55 108 
C49 Papworth 58 395 
C51 Papworth 59 683 
C54 Papworth 61 1342 
C150 Portsmouth 104 253 
C151 Portsmouth 105 1244 
C153 Portsmouth 106 155 
C71 Reading 67 968 
C73 Reading 68 17 
C74 Reading 69 1202 
C10 Sheffield 40 244 
C11 Sheffield 41 282 
C12 Sheffield 42 282 
C13 Sheffield 42 27 
C14 Sheffield 42 27 
C15 Sheffield 42 27 
C16 Sheffield 42 - 
C17 Sheffield 42 - 
C18 Sheffield 43 - 
C2 Sheffield 36 253 
C20 Sheffield 44 878 
C3 Sheffield 37 260 
C4 Sheffield 37 - 
C5 Sheffield 37 260 
C6 Sheffield 38 244 
C7 Sheffield 39 244 
C8 Sheffield 40 244 
C9 Sheffield 40 244 
C135 Sunderland 96 160 
C137 Sunderland 97 260 
C139 Sunderland 98 - 
C141 Sunderland 99 - 
C142 Sunderland 100 252 
C104 Swansea 82 179 
C105 Swansea 83 840 
C106 Swansea 84 - 
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Isolate ID Centre Patient ST 
C107 Swansea 84 253 
C108 Swansea 84 179 
C109 Swansea 85 840 
C110 Swansea 85 179 
C111 Swansea 85 179 
C112 Swansea 85 179 
C114 Swansea 86 179 
C115 Swansea 86 179 
C116 Swansea 87 871 
C117 Swansea 87 871 
C118 Swansea 87 871 
C156 West Wales G. Hospital 108 260 
C158 West Wales G. Hospital 109 155 
C159 West Wales G. Hospital 110 260 
C160 West Wales G. Hospital 111 1244 
C161 West Wales G. Hospital 112 110 
C164 West Wales G. Hospital 113 - 
C167 West Wales G. Hospital 114 296 
C168 West Wales G. Hospital 115 17 
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